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Abstract 
 
Patients with pancreatic and prostate cancer have a poor survival rate and new therapeutic 
strategies are needed. Epithelial cell adhesion molecule (EpCAM), suggested as a marker for 
cancer stem cells, is over-expressed on most pancreatic and prostate tumor cells but not on 
normal cells and may be an ideal therapeutic target. The anti-tumor efficiency of bispecific 
EpCAMxCD3 antibody linking tumor cells and T lymphocytes was evaluated. Furthermore, it 
was tested whether the combination of bsAb EpCAMxCD3 with lymphocytes over-
expressing the death ligand TRAIL, inducing apoptosis in cancer cell but not on normal cells, 
would be effective. In NOD/SCID mice, EpCAMxCD3 had a  long serum half‐life  (t1/2 ∼ 7 days). Co-transplanted pre-activated lymphocytes and EpCAMxCD3 effectively retarded the 
tumor growth of BxPc-3 pancreatic and PC-3 prostate xenografts. TRAIL-over-expressing 
lymphocytes strongly enhanced the efficacy of very low doses of EpCAMxCD3 and retarded 
the tumor growth. Furthermore, TRAIL-over-expressing lymphocytes enhanced 
EpCAMxCD3 treatment in a BxPc-3 xenograft model with developed tumors. Tumor growth 
retardation was associated with a reduced tumor cell proliferation and with a reduced blood 
vessel density. In 3D in vitro tumor reconstructs, TRAIL-over-expressing lymphocytes 
dramatically increased the expression of apoptosis-related proteins, compared to pre-activate 
lymphocytes and EpCAMxCD3. For mimicking a pancreatic cancer microenvironment in 
vitro, we used a three-dimensional tumor reconstruct system, in which lymphocytes were co-
cultured with tumor cells and fibroblasts in a collagen matrix. In this in vivo–like system, 
EpCAMxCD3 potently stimulated production of the effector cytokines IFN-γ and TNF-α by 
extracorporally pre-activated lymphocytes. Moreover, compared with a bivalent anti-CD3 
antibody, EpCAMxCD3 more efficiently activated the production of TNF-α and IFN-γ by 
non-stimulated peripheral blood mononuclear cells. Most excitingly, we demonstrate for the 
first time that EpCAMxCD3 induces prolonged contacts between lymphocytes and tumor 
cells, which may be the main reason for the observed anti-tumor effects. In addition, 
EpCAMxCD3 stimulated the expression of multiple chemokines in 3D tumor reconstructs. 
Those chemokines could potentially contribute to the increased infiltration of the tumor 
tissues with CD68+ and F4/80+ macrophages. Conclusively the combination of TRAIL-
transduced lymphocytes and the bispecific antibody EpCAMxCD3 was very efficient in 
pancreatic and prostate xenograft models in vivo and in vitro. This combination of gene 
therapy with immunotherapy may open a way to improve the immune response and treatment 
outcome in patients with pancreatic, prostate cancer and most likely other tumor entities. 
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Summary 
 
The aim of this project was to test the efficacy of a novel therapeutic approach for cancer 
therapy. This approach combines immunotherapy with bispecific antibody (bsAb) 
EpCAMxCD3 and gene therapy with TRAIL. The potential efficacy of this approach was 
tested in experimental models of pancreatic and prostate carcinoma. Specific aims were i) to 
construct a lentiviral vector suitable for the transduction of human lymphocytes and the over-
expression of TRAIL. The next aim was ii) to establish and to evaluate suitable xenograft 
models for the study of the chosen approach, iii) to test the efficacy and the anti-tumor 
potential of TRAIL-over-expressing lymphocytes and bsAb EpCAMxCD3 in vivo and iv) to 
elucidate the functional mechanisms underlying observed anti-tumor effects of TRAIL-over-
expressing lymphocytes and bsAb EpCAMxCD3 in vivo and in vitro.  
In conclusion, this is the first study, which shows the effective lentiviral transduction of 
human lymphocytes with the death ligand TRAIL. The vector pV3TP2A effectively 
transduced human lymphocytes to over-express TRAIL. The majority of these TRAIL-over-
expressing lymphocytes were CD8+ T cells and retained their cytotoxic functions, their 
migratory and proliferative properties after the transduction. Furthermore, this study showed 
that EpCAMxCD3 possesses a potent anti-tumor activity in vivo. In NOD/SCID mice, 
EpCAMxCD3 had a long serum half-life (t1/2 ∼ 7 days). In two mouse models the 
combination of EpCAMxCD3 with lymphocytes significantly retarded the growth of BxPc-3 
pancreatic and PC-3 prostate cancer xenografts. For mimicking a pancreatic cancer 
microenvironment in vitro a 3D tumor reconstruct system was used, in which lymphocytes 
were co-cultured with EpCAM-expressing tumor cells and fibroblasts in a collagen matrix. In 
this in vivo-like system EpCAMxCD3 potently stimulated the production of the effector 
cytokines IFN-γ and TNF-α by extracorporally pre-activated lymphocytes. Moreover, 
compared with a bivalent anti-CD3 antibody, EpCAMxCD3 more efficiently activated 
production of TNF-α and IFN-γ by non-stimulated PBMCs. We demonstrate for the first time 
that EpCAMxCD3 induces prolonged contacts between lymphocytes and tumor cells, which 
may be one of the main reason for the observed anti-tumor effects. The combination with 
lymphocytes over-expressing the death ligand TRAIL could effectively enhance the anti-
tumor effects of bsAb EpCAMxCD3. The combination with TRAIL-over-expressing 
lymphocytes enabled us to strongly reduce the dose of EpCAMxCD3 necessary for an anti-
tumor effect. This is a great advantage, which could minimize potential side effects of bsAb 
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treatment. EpCAMxCD3 did not alter lymphocyte migration as measured by time-lapse video 
microscopy, which is an important prerequisite for future use in patients. Apoptosis induction 
in tumor cells by TRAIL-over-expressing lymphocytes was confirmed in vitro in 3D tumor 
reconstructs. In cytotoxic killing assays, the anti-tumor effect of TRAIL-over-expressing 
lymphocytes was significantly enhanced by EpCAMxCD3. In 3D gels, lymphocytes were 
effective producers of IFN-γ, TNF-α and chemokines, which could also be detected in vivo 
from tumor lysates. An increased infiltration of the tumor islets with macrophages and 
granulocytes was observed upon treatment with TRAIL-over-expressing lymphocytes and 
EpCAMxCD3. A potential explanation for the demonstrated anti-tumor effect of 
EpCAMxCD3 and TRAIL-over-expressing lymphocytes combination therapy, is an 
enhancement of the observed effects of single treatment, namely the reduced proliferation in 
tumor cells, decreased blood vessels formation, local production of cytokines and 
chemokines, apoptosis and an increased infiltration of tumor tissue with macrophages. 
Conclusively, the combination of TRAIL-over-expressing lymphocytes and the bispecific 
antibody EpCAMxCD3 was very efficient in pancreatic and prostate xenograft models in 
vivo. This combination of gene therapy with immunotherapy could potentially be a possible 
therapeutic option for the clinical application in the future.   
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Zusammenfassung 
 
Ziel dieser Studie war einen neuartigen Therapieansatz für die Krebstherapie zu testen. Dieser 
Ansatz kombiniert die Immuntherapie mit dem bispezifischem Antikörper (bsAk) 
EpCAMxCD3 mit einer Gentherapie mit TRAIL. Die potentielle Wirksamkeit dieser 
Therapie wurde in experimentellen Modellen des Prostata und des Pankreaskarzinoms 
getestet. Konkrete Ziele dabei waren i) die Generierung eines lentiviralen Vektors, der 
geeignet für die Transduktion von humanen Lymphozyten ist und die Überexpression des 
Todesliganden TRAIL ermöglicht, ii) die Etablierung und die Evaluierung eines geeigneten 
Xenograft Models, iii) die Untersuchung der Effektivität und der Anti-Tumor Wirkung 
TRAIL-überexprimierender Lymphozyten mit bsAk EpCAMxCD3 in vivo und in vitro und 
iv) die Analyse des Funktionsmechanismus der beobachteten Anti-Tumor Wirkung von 
TRAIL-überexprimierender Lymphozyten und EpCAMxCD3 in vivo und in vitro. 
Zusammenfassend zeigte diese Studie dass EpCAMxCD3 eine potente Anti-Tumor-Wirkung 
in vivo besitzt. In NOD/SCID Mäusen besaß EpCAMxCD3 eine lange Serum Halbwertszeit 
von ungefähr 7 Tagen. In zwei unabhängigen Mausmodellen reduzierte EpCAMxCD3 
zusammen mit Lymphozyten effizient das Tumorwachstum von pankreatischen BxPc-3 und 
prostata PC-3 Xenografts. Um die Mikroumgebung eines Karzinoms in vitro nachzuahmen, 
wurde ein 3D Tumor Rekonstrukt benutzt in dem Lymphozyten zusammen mit EpCAM-
exprimierenden Tumorzellen in Fibroblasten in einer Kollagenmatrix co-kultiviert wurden. In 
diesem in vivo artigem System stimulierte EpCAMxCD3 die Produktion der Effektorzytokine 
IFN-γ und TNF-α in voraktivierten Lymphozyten. Verglichen mit bivalenten anti-CD3 
Antikörpern, stimulierte EpCAMxCD3 sogar die Produktion von IFN-γ und TNF-α von 
unstimulierten Lymphozyten. Wir demonstrieren hier erstmalig dass EpCAMxCD3 die 
Kontaktzeit zwischen Lymphozyten und Tumorzellen verlängert, was die Grundlage für die 
Anti-Tumor Wirkung sein könnte. Als eine wichtige Vorraussetzung für eine mögliche 
klinische Anwendung hatte EpCAMxCD3 keinen Einfluß auf die Migration von 
Lymphozyten, was mit Time-lapse Video Mikroskopie demonstriert wurde. Die Kombination 
mit Lymphozyten die den Todesliganden TRAIL überexprimierten verstärkte die Anti-
Tumor-Wirkung von EpCAMxCD3 sehr effizient. Schon geringe Dosen von EpCAMxCD3 
genügten um eine Anti-Tumor Wirkung zu erzielen in dieser Kombination mit TRAIL-
überexprimierenden Lymphozyten. Diese Tatsache könnte vorteilhaft sein um mögliche 
Nebeneffekte der Behandlung zu minimieren. Die Induktion von Apoptose in Tumorzellen 
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konnte in 3D Tumor Rekonstrukten in vitro  gezeigt werden. In Versuchen zur Zytotoxizität 
von Lymphozyten auf Tumorzellen wurde die Wirkung von TRAIL-überexprimierendev 
Lymphozyten noch durch EpCAMxCD3 signifikant gesteigert. In 3D Tumor Rekonstrukten 
wurden neben den Zytokinen IFN-γ und TNF-α auch Chemokine produziert, die sowohl in 
vitro als auch in Tumor Lysaten detektiert werden konnten. Diese Chemokine stehen 
höchstwahrscheinlich im Zusammenhang mit der vermehrten Infiltrierung des Tumorgewebes 
mit Makrophagen und Granulozyten nach der Behandlung mit TRAIL-überexprimierenden 
Lymphozyten und mit EpCAMxCD3. Eine mögliche Erklärung für die gezeigte Anti-Tumor 
Wirkung von TRAIL-überexprimierenden Lymphozyten und EpCAMxCD3 ist eine 
Reduktion der Blutgefäße, die lokale Produktion von Zytokinen und Chemokinen mit einer 
vermehrten Einwanderung von Makrophagen in das Tumor Gewebe.  
Zusammenfassend konnte die Kombination aus TRAIL-überexprimierenden Lymphozyten 
und dem bispezifischen Antikörper EpCAMxCD3 erfolgreich für die Therapie 
experimenteller Pankreas und Prostata Tumor Xenografts in vivo getestet werden.  
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Abbreviations 
 
WHO World Health Organization 
% Percent 
°C Degree celsius 
3D three dimensional 
aa Amino acids 
AAV Adeno associated virus 
Ad Adeno virus 
ADCC 
Antibody-dependent cell-mediated 
cytotoxicity 
Apo2/TRAIL 
Tumor nekrosis factor related apoptosis 
inducing ligand 
Bad Pro-apoptotic protein Bad 
Bak Pro-apoptotic protein Bak 
Bax Pro-apoptotic protein Bax 
Bcl-2 Anti-apoptotic protein B cell lymphoma 2 
BCR/Abl 
Fusion protein of the BCR gene and the V-
abl Abelson murine leukemia viral oncogene 
homolog 1 
BiTE Bi-specific T cell engagers 
bsAb Bispecific antibody 
CD19xCD3 
Bispecific antibody dual specific for CD19 
and CD3 
CDC Complement dependent cytotoxicity 
CEA Carcinoembryonic antigen 
cm3 Cubic centimeter 
CML Chronic myelogenous leukemia 
CTL Cytotoxic T lymphocytes 
Db Diabody 
DC Dendritic cell 
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DISC Death-Inducing Signalling Complex 
Dox Doxycycline 
EGF Epithelial Growth Factor 
EGFP Enhanced green fluorescent protein 
EGFR Epithelial Growth Factor Receptor 
ELISA Enzyme-linked immunosorbent assay 
EpCAM Epithelial cell adhesion molecule 
EpCAMxCD3 
Bispecific antibody dual specific for 
EpCAM and CD3 
FACS fluorescence activated cell sorting 
FADD Fas-Associated protein with Death Domain 
FasL Death ligand Fas Ligand 
Fig Figure 
FITC Fluorescin isothyocyanate 
FLIP FLICE-like inhibitory Protein 
g gram 
h hour 
H+E Hematoxylin and eosin 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HEA125 Anti human EpCAM monoclonal antibody 
HER-2 Human Epidermal growth factor Receptor 2 
HIV Human immunodeficiency virus 
HPV Human papilloma virus 
hTERT Human telomerase reverse transcriptase 
i.e. for example 
i.p. Intra peritoneal 
i.v.  Intra venous 
IAP Inhibitors of apoptosis 
IFN-γ Interferon gamma 
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IgG Immunoglobulin G 
IL-x Interleukin 
IRES Internal ribosomal entry site 
Iso Iso-type control 
K-ras Small GTPase 
Kg Kilogram 
Ki-67 Proliferation marker Ki-67 
L Liter 
LPS Lipopolysaccharid 
Lt-α Lymphotoxin alpha 
Lt-β Lymphotoxin beta 
LTR Long terminal repeats 
LV Lentivirus 
M&M Materials and methods 
mAb Monclonal antibody 
MAGE Melanoma associated antigen 
mg/kg Milligram per kilogram 
Min Minutes 
Ml milliliter 
MMAC1/PTEN Tumor suppressor gene MMAC1/PTEN 
MOCK-L Mock transduced lymphocytes 
MOI Multiplicity of infection 
MSC Mesenchymal stem cells 
n Number of animals 
Nf-κB 
nuclear factor kappa-light-chain-enhancer of 
activated B cells 
ng Nanogram 
ng/ml Nanogram per milliliter 
NHL Non-Hodgekin Lymphoma 
NK cell Natural killer cell 
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NKT Natural killer T cell 
nm nanometer 
NOD/ SCID 
Non-obese diabetic/ severe combined 
immunodeficient mice 
NY-ESO-1 
cancer/testis family of human tumour-
associated antigens 
OKT3 Anti CD3 monoclonal antibody 
OPG Osteoprotegerin 
P16/INK4A/retinoblastoma protein 
Pathway for tumor suppressor gene p16/ 
INK4A and retinoblastoma protein 
p21 Tumor suppressor gene p21 
p2A 2A element of porcine teschovirus 
p53 Tumor suppressor gene p53 
p73 Tumor suppressor gene p73 
pAb Polyclonal antibody 
PBMC Peripheral blood mononuclear cell 
PBS Phosphate buffered saline 
PE phycoerythrin 
pg/ml Picogram per milliliter 
PI3/Akt 
Pathway for phosphoinositide 3-kinase and 
protein kinase B Akt 
recTRAIL Recombinant TRAIL 
rpm Rotations per minute 
RV Retrovirus 
s.a. such as 
s.c.  Subcutaneous 
ScFv Single chain variable fragment 
SIN Self-inactivating vector 
SIV Simian immunodeficiency virus 
ssDNA single strand DANN 
ssRNA Single strand RNA 
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t½ Half life 
TCR T cell receptor 
TGF-α Transforming Growth Factor alpha 
TNF-α Tumor necrosis factor alpha 
TNM 
Classification system of malignant 
carcinoma 
TRAIL 
Tumor nekrosis factor related apoptosis 
inducing ligand 
TRAIL-L TRAIL-transduced lymphocytes 
TRAIL-R1/ DR4 
Tumor nekrosis factor related apoptosis 
inducing ligand receptor 1/ death receptor 4 
TRAIL-R2/ DR5 
Tumor nekrosis factor related apoptosis 
inducing ligand receptor 1/ death receptor 5 
TRE Tet responsive element 
TU Transducing units 
TUNEL TdT-mediated dUTP-biotin nick end labeling 
v/v Volume per volume 
VEGF Vacular endothelial growth factor 
WPRE 
Woodchuck hepatitis virus B post-
transcriptional regulatory element 
µg/ml Microgram per milliliter 
µl microliter 
µm Mycrometer 
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1 Introduction 
1.1 Epidemiology of pancreatic and prostate cancer 
1.1.1 Prostate cancer 
 
In 2008, approximately 110.000 men died of prostate cancer in the EU and 350.000 died 
worldwide, thus causing 0.6% of all causes of death (WHO 2008). According to the Robert-
Koch-Institut statistics, 28.53% of all estimated cancer deaths in Germany will be prostate 
cancer, making it the most prevalent tumors in males. With 58.000 newly diagnosed patients 
in 2008, and increasing incidents, prostate cancer remains one of the major public health 
problems in the western world. The rising numbers are caused mainly by demographic 
factors, especially the increasingly elderly population, and the improvement of the diagnostic 
tools (i.e. prostate-specific antigen test). The improvements in the diagnosis and the treatment 
of prostate cancer increased the 5-year survival rate for all prostate cancer patients to almost 
99%. The relative 10-year survival rate is 91% and 76% for 15 years. However, 10-20% of all 
patients are already diagnosed with advanced prostate carcinoma with metastasis and many 
other develop metastasis in spite of clinical intervention.  
The natural history of the prostate carcinoma is not completely understood and the disease 
ranges from aggressive to slow growing tumors [1]. There are several risk factors. The 
strongest factor is age, prostate cancer is rare under the age of 40 and its incidence increases 
exponentially with age. More than 70% of all patients are older than 65 years at the time of 
diagnosis [2]. There is a varying geographical incidence and ethnicity also plays a role in the 
development of the disease, with the highest incidents in African Americans (about twice that 
in white men) and lowest in Asian, American Indians and Hispanic-Latinos [3]. An estimated 
9% of prostate cancer are related to inherited predisposition [4]. Among environmental 
factors, dietary factors like a high intake of saturated fat, mainly animal fat, and low levels of 
dietary selenium, vitamin E and vitamin D, may increase the risk [5, 6]. Prostate cancer is 
thought to arise after a sequence of at least eight genetic mutational events. Early events 
include the loss of tumor suppressor genes such as p53, which is mutated in up to 64% of 
tumors and p21 in up to 55%. The p73 tumor suppressor gene, with significant homology to 
p53, is also mutated in prostate cancer [7]. However, MMAC1/PTEN is the most widely 
mutated suppressor gene in prostate cancer and may contribute to the acquisition of the 
metastatic phenotype [8]. The development of the hormone refractory phenotype appears to 
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be related to the over-expression of mutant p53 and bcl-2 family of proteins as well as 
amplification of the androgen receptor [9].  
Pathologically, 95% of all prostate cancers are adenocarcinomas. Primary carcinoid tumors of 
the prostate, sarcomas, and primary small cell carcinomas are rare. The prostate cancer cell 
cytoplasm may contain large amounts of acid phosphatase and prostate specific antigen 
(PSA), which is used diagnostically. The clinical features of prostate cancer include localized 
prostate cancer, confined within the prostate capsule, locally advanced prostate cancer, where 
the cancer extends outside the prostate capsule, and metastatic prostate cancer most 
commonly graded by the Gleason method and staged by the TNM system [10]. The treatment 
options for the prostate carcinoma vary depending on age, stage of the cancer and medical 
condition of the patient. Management of primary prostate cancer includes the treatment 
modalities of radical prostatectomy, external beam radiotherapy, interstitial radiotherapy and 
watchful waiting. However, the prostate carcinoma is relatively radiation insensitive. The 
tumor has a low growth rate and hence a slow response to radiotherapy. To improve the 
disease control in patients, radiotherapy is combined with adjuvant therapy with gonadotropin 
releasing hormone (GnRH) analogues. The hormonal therapy supports the disease 
management at least in initial stages of the treatment [10]. 
1.1.2 Pancreatic cancer 
 
In 2008, approximately 97.000 people died of pancreatic cancer in the EU and 285.000 
worldwide, this makes statistically 0.5% of all causes of death (WHO 2008). According to the 
Robert-Koch-Institut statistic, 30.73% of all estimated cancer deaths in Germany will be 
pancreatic cancer. This number makes pancreatic cancer the fourth leading cause of cancer 
death. Approximately 13.000 patients were newly diagnosed in the year 2008. The early 
detection is still a clinical challenge and more sensitive detection methods are under 
development. Hence, in more than 50% of the patients advanced pancreatic carcinoma with 
metastasis is diagnosed. The 5-year survival rate of only 5% reflects this diagnosis problem 
and the 5-year survival rate of patients diagnosed with an early metastasis free stage is only 
20%.  
The major risk factors for pancreatic cancer are increasing age, smoking [11], new onset 
diabetes mellitus [12], increased body mass index [11], chronic pancreatitis [13, 14], 
hereditary pancreatitis [15] and an inherited predisposition for pancreatic cancer [16]. Dietary 
factors are also associated with an increased risk like the comsumption of red and processed 
meat and a reduced intake of methionine and folate from food sources [17-19]. The molecular 
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lesions in pancreatic cancers are classified into late and early lesions. Activating mutations in 
K-ras and the PI3/Akt signaling pathway, regulating growth factor mediated signaling 
pathways and cell survival, proliferation and resistance to apoptosis, respectively, are 
commonly found. Several growth factors and their receptors i.e. the epidermal growth factor 
receptor (EGFR), HER-2, EGF and TGF-α are over-expressed by pancreatic cancer cells. 
Genetic lesions in the molecular pathways occur with a varying degree in pancreatic 
carcinomas. The most commonly affected pathways are the pathways of the tumor suppressor 
genes such as p16/INK4A/retinoblastoma protein pathway, p53 transcription factor pathway 
or Smad4/TGFb pathway and a reactivation of the developmental signaling by Notch and 
Hedgehog [19].  
Ductal adenocarcinoma is the most common malignant tumor of the pancreas. The late 
presentation and the aggressive tumor biology of this disease makes an early diagnosis 
difficult and only a minority of 10-15% of patients can undergo potentially curative surgery. 
Another problem is the high resistance of ductal adenocarcinoma to conventional methods of 
cytotoxic treatment and radiotherapy. The most widely used chemotherapeutic for advanced 
pancreatic cancer has been 5-Fluoracil, an inhibitor of thymidylate synthetase or combinations 
with gemcitabine. External beam radiotherapy is routinely used with 5-Fluoracil, but the main 
drawback is the limit of the dosage owing to the close proximity of adjacent radiosensitive 
organs. Patients with advanced pancreatic carcinoma, which are inoperable, are subjected to 
palliative or to adjuvant therapy to improve survival and quality of life, but the median 
survival dates do not offer a good prognosis [19].  
1.2 Novel experimental approaches for the cancer therapy 
 
The evolution of these two cancer diseases and their insensitivity to conventional therapies or 
the late diagnosis urgently increases the need for alternative therapeutic approaches. As 
radiation and chemotherapy often have a limited effect and a substantial toxicity, there is a 
strong need to test new therapeutic approaches or to find supportive treatments for the 
combination with conventional treatments. 
The understanding of the biological abnormalities of cancer has generated a large number of 
studies targeting cancer cells on the cellular and on the molecular level. The tumorigenesis in 
humans has been widely recognized as a multistep process, underlying a stepwise evolution 
from normality via a series of pre-malignant states into an invasive cancer. Cancers are as 
distinct and complex as the cells and tissues of which they are derived, and only distinct 
hallmarks discriminate them from a normal cell. Hanahan et al. and Schreiber et al. suggested 
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seven essential alterations in cell physiology that collectively dictate malignant growth [20, 
21]. Those hallmarks are the self-sufficiency in growth signals, the insensitivity to growth-
inhibitory signals, the evasion of programmed cell death (apoptosis), a limitless replicative 
potential, a sustained angiogenesis, the avoidance of immuno surveillance and tissue invasion 
and metastasis. Each of these physiological changes – novel capabilities acquired during 
tumor development – represents the successful breaching of an anti-cancer defense 
mechanism.  
Based on these “hallmarks” the research on novel therapeutic strategies has several directions 
to target a cancer cell. Central considerations include the inhibition of angiogenesis, cell 
proliferation and migration, the re-sensitization to apoptosis, immunotherapeutic boosting of 
the tumor-specific immunity by vaccines, cytokines and immune modulators or by the 
transfer of tumor-reactive cells In addition, there are gene therapy approaches by the 
restoration of lost genes, the inhibition of over-expressed or dys-regulated genes or the direct 
cancer eradication by introducing suicide-genes, lytic viruses only to mention a few.  
1.3 Gene therapy 
 
Gene therapy is one of the most promising therapeutic strategies for cancer. Gene therapy - 
the introduction of one or more foreign genes into an organism - has the potential to correct 
the genetic changes that were acquired by the tumor cells. Gene therapy approaches differ as 
much as the targeted malignancies. The concept of gene therapy was envisioned in the late 
1970s and early 1980s shortly after the emergence of restriction enzymes and subcloning of 
mammalian genes in plasmids and phages. Today, major gene therapy research areas for 
cancer include tumor suppressor gene therapy, suicide gene therapy, anti-angiogenic and pro-
apoptotic gene therapy, the genetic enhancement of antitumor immune response by strategies 
using dendritic and T cells and by cytokine-based gene transfer strategies and drug resistant 
gene therapy (reviewed in [22]).  
1.3.1 Vectors for gene therapy 
 
Different vectors have been developed for the transfer of genetic information. These vectors 
are nonviral, integrating virus vectors (gammaretrovirus and lentivirus), and non-integrating 
virus vectors (adenovirus, adeno-associated virus, and herpes simplex virus vectors).  
1.3.1.1 Nonviral vector systems 
 
Non-viral vectors deliver genes i.e. in liposomes, by a chemical linking of DNA to carrier 
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molecules, which will bind to a specific receptor, by nanoparticles and cationic 
liposomes/lipoplexes, by transfection or by electroporation [23]. However, the non-viral 
delivery systems have a significantly reduced transfection efficiency as they are hindered by 
numerous extra- and intracellular obstacles.  
1.3.1.2 Viral vector systems 
 
For many applications, the vehicles of choice are the viral vectors. An ideal vector is efficient, 
non-pathogenic, capable of transferring genetic material into a broad range of cells and tissues 
and can maintain expression for an appropriate period of time. Viruses have an innate 
invasive ability to infect cells and to deliver their genes, which makes them highly efficient 
tools for gene therapy. In general, viral vectors are derived from wild-type strains and the 
parts of the viral genome required for replication and pathogenesis are deleted. Thereby, the 
virus is converted into a recombinant vector with insertional space for therapeutical genes and 
regulatory sequences. For the production of viral vectors, these essential genes are expressed 
in trans by the producer cells. Out of the clinical studies for gene therapy until 2009 more than 
64,5% were directed against cancer (Databank in the Journal of Gene Medicine and NIH). 
Out of these 1019 studies, 23% were conducted with adenoviral, 18% with retroviral and only 
0.5% with lentiviral vectors.  
In most virus-based approaches recombinant adenoviruses and adeno-associated viruses have 
been the main vectors. The adenoviral vectors (Adv) are derived from the Adenoviridae 
family, a icosahedral, non-enveloped virus with a broad tropism, which can infect both 
dividing and quiescent cells. This large double stranded DNA virus does not integrate into the 
genome, making it limited to transient, episomal expression. Most adenoviral vectors are 
derived from adenovirus type 5 with deletions of the E1 and E3 region, essential for 
replication. Adv is currently the most widely used gene delivery vector, with a high delivery 
efficiency, a great packaging capacity for therapeutical genes (<30kb), a fast and efficient 
production to high titers, it is non-oncogenic and allows a high expression of the transgene. 
Adenoviral vectors have been successfully applied in the clinical setting, but express 
transgenes only for less than a week. The transgene will not persist because adenovirus-based 
vectors do not integrate into the host genome. Furthermore, adenovirus is immunogenic and 
most people have been exposed to adenovirus at some point in their life [24, 25]. A specially 
engineered adenovirus is the oncolytic adenovirus. These viruses exhibit lytic properties of 
virus replication for the selective infection and lysis of tumor cells [26].  
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The adeno-associated virus (AAV), a ssDNA virus of the Parvoviridae family, is naturally 
replication-deficient and requires the presence of adenovirus to complete its life cycle. AAV 
can infect non-dividing cells and in can integrate into the host genome (<10% of the viruses). 
AAV has a broad host range, low level of immune response and the longevity of gene. There 
are 8 well defined serotypes (serotypes 1 – 5 and 7 – 9) and more than 100 variants with a 
different selective tissue tropism [27]. Disadvantages of the AAV vectors are the small 
packaging limit (<5kb) and adaptive immune responses to their capsids. Although AAV can 
mediate site-selective integrations into the target cell genome, it has not successfully been 
applied to T cells.  
Chromosome-integrating vectors derived from retroviruses or lentiviruses have been most 
useful for long-term gene expression and in lymphocyte –based therapies. These viruses 
integrate into the host-genome, resulting in the permanent expression of the transgene and in a 
low intrinsic immunogenicity.  
The retroviruses (RV), sRNA viruses, are gamma retroviruses from the Orthoretrovirinae 
family, stably integrates into the host genome. Most vectors are derived from murine 
leukaemia virus. The advantages of RV are an easy production with high titers and a stable 
and efficient integration into the host genome. However, the inability to transduce non-
dividing cells and observed insertional mutagenesis with secondary malignancies limits their 
potential use for gene therapy.  
Lentivirus-derived vectors can also integrate into the genome of non-dividing cells and they 
are less susceptible to gene silencing by host restriction factors. The lentiviruses, a ssRNA 
virus, also belongs to the Orthoretrovirinae family. They mediate long-term integration of the 
therapeutic gene, but unlike RV, do not require cellular mitosis to access the host genome for 
integration [28].  
1.3.1.3 The lentiviral vector system  
Lentiviral vectors are derived from human immunodeficiency virus (HIV) [29], but also other 
lentiviruses like the simian immunodeficiency virus (SIV) have been studied. From the viral 
genome, the polyproteins gag, pol and env are required in trans for viral replication and 
packaging. Required in cis are the 5’ and 3’ long terminal repeats (LTR), the integration 
sequences as well as the packaging site ψ, the transport RAN-binding site and finally 
additional sequences involved in reverse transcription. The accessory genes vif, vpr, vpu, nef, 
tat and ref play crucial roles in virus replication. Unlike retrovirus, lentiviruses are capable of 
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transducing quiescent cells [28], although for some cell types (T cells) a progression through 
the cell cycle from G0 to G1b is necessary to complete reverse transcription [30]. To generate 
replication-deficient vectors, deletions in the viral genome were generated. The design of 
lentiviral vectors is based on the separation of cis- and trans-acting sequences. Generally, 
lentiviral particles are generated through transient transfection of three plasmids in the human 
embryonal kidney (HEK) 293T producer cell line. The three plasmids are: (1) a packaging 
plasmid, (2) a transfer/vector plasmid and (3) an envelope-encoding plasmid.  
 
Fig 1 Schematic representation of lentiviral vector production in 293T cells (adapted from www.tronolab.epfl.ch) 
 
The lentiviral particles are divided into 'generations' according to the packaging plasmid 
which was used for virus production (Fig 2). The first-generation packaging construct 
provided the entire gag and pol sequences in trans to enable packaging of the transfer 
construct and contains the viral regulatory genes tat and rev along with the accessory genes 
vif, vpr, vpu and nef. Identification of the HIV genes that are necessary for virulence, but 
disposable for transfer of the genetic cargo, allowed the engineering of multiple-attenuated 
packaging systems [31]. In these second-generation packaging systems, up to four accessory 
genes (vif, vpr, vpu and nef) were removed without negative effects on yield or infection 
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efficiency in most cell types. These minimal packaging systems gained in safety, because any 
replication-competent lentivirus (RCL) that was still generated would be devoid of all 
virulence factors. In the third generation, safety was further improved by engineering split-
genome packaging systems, where the rev gene is expressed from a separate plasmid. Also, 
tat could be removed by placing a strong constitutional promoter in the 5' LTR of the transfer 
vector [32]. 
The transfer plasmid consists of an expression cassette and the HIV cis-acting factors 
necessary for packaging, reverse transcription and integration. Engineering of self-
inactivating (SIN) transfer vectors by deleting the U3 region of the 3' LTR not only further 
minimized the risk of emergence of RCL, but also decreased problems related to promoter 
interference [31, 33]. Nuclear import of the transfer construct was improved by including the 
cPPT and its central termination sequence, together forming a triple helix (TRIP). This 
structure mediates the transport of the preintegration complex through the nuclear pores. 
TRIP/cPPT-containing transfer vectors yield higher virus titers and provide enhanced 
transgene expression in the target cells [34, 35]. Addition of post-transcriptionally active 
elements, such as the woodchuck hepatitis B post-transcriptional regulatory element (WPRE), 
represents another strategy to improve the lentiviral vector design. WPRE may improve gene 
expression by modification of polyadenylation, RNA export or translation [36]. 
The third plasmid required for lentivirus production provides a heterologous envelope. In 
most cases it is the glycoprotein of vesicular stomatitis virus (VSV.G), which allows the 
formation of mixed particles or pseudotypes, displaying the tropism of the virus from which 
the envelope is derived.  
 
Fig 2 Schematic representation of the different LV packaging generations.  
!"#$%$&#'%("!')&*&+#,'&-',*.'/'0&+&'1&#.'2334'5&678'9:;;*'<=9<2>?@A.
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The commonly maintained structures in all LV packaging elements are shown by the cis-acting sequences (the promoter and 
polyadenylation regions that replace the original 5’ and 3’-LTR elements, respectively, as well as the deletion of the 
encapsidation site (Δψ) and the trans-viral helper genes (gag-pol). Depending on the vector generation, the accessory (Acc.) 
and regulatory (Reg. or rev alone) genes are conserved in the packaging constructs.  
 
1.3.2 Gene therapy targeting apoptosis 
 
Cancer is partly caused by the uncontrolled proliferation of malignant cells that harbour 
multiple oncogenic mutations. The increasing understanding of the apoptosis-signaling 
pathway offers many options for the therapeutic intervention in cancer. There are two 
apoptotic pathways characterized - the extrinsic pathway and the intrinsic pathway. The 
extrinsic pathway operates through cell surface death receptors. The intrinsic pathway is 
tightly controlled by the Bcl-2 family of proteins and involves the disruption of mitochondrial 
membrane integrity in response to cellular insults or other danger signals. Both pathways 
converge at the level of effector caspases – proteolytic enzymes that carry out the cell death 
response (Fig 3). These two pathways are localized within a broader superstructure of other 
signaling pathways and molecular targets with links to apoptosis. The main focus of research 
are strategies targeting the extrinsic and/or the intrinsic pathways. These include the targeted 
activation of the extrinsic pathway through pro-apoptotic receptors agonists, inhibition of the 
Bcl-2 family of proteins and the interfaces of extrinsic and intrinsic pathways by caspase 
modulation and IAP inhibition.  
1.3.2.1 The extrinsic and the intrinsic apoptotic pathway 
 
The intrinsic apoptotic pathway is activated by cellular stress (Fig 3). Stress like 
chemotherapy or radiotherapy induces DNA damage and activates the p53 tumour-suppressor 
protein. p53 initiates the intrinsic pathway by upregulating Puma and Noxa, which in turn 
activate Bax and Bak [37, 38]. By contrast, the kinase Akt, which acts downstream of many 
growth factors, inhibits the intrinsic pathway by phosphorylating Bad [39]. Bax and Bak 
permeabilize the outer mitochondrial membrane, resulting in efflux of cytochrome c, which 
binds to the adaptor Apaf‑1 to recruit the initiator procaspase 9 into a signalling complex 
termed the apoptosome. Activated caspase 9 then cleaves and activates the effector caspases 
3, 6 and 7 to trigger apoptosis [40]. The mitochondrial protein Smac/DIABLO augments 
apoptosis by binding inhibitor of apoptosis proteins (IAP) and reversing their grip on several 
caspases [41].  
Introduction 
 26 
The extrinsic apoptotic pathway: cytotoxic immune cells produce pro-apoptotic ligands such 
as Apo2L/TRAIL (Fig 3). The homotrimeric ligand binds to the pro-apoptotic receptors DR4 
and/or DR5 on the surface of a target cell. Ligand binding induces receptor clustering and 
recruitment of the adaptor protein Fas-associated death domain (FADD) and the initiator 
caspases 8 and 10 as pro-caspases, forming a death-inducing signalling complex (DISC). This 
triggers activation of the apical caspases, driving their autocatalytic processing and release 
into the cytoplasm, where they activate the effector caspases 3, 6 and 7. DISC formation is 
modulated by several inhibitory mechanisms, including c‑FLIP, which associates with the 
DISC by interacting with FADD to block initiator caspase activation and decoy receptors, 
which can block ligand binding or directly interfere with receptor activation.  
Although the extrinsic and intrinsic pathways can function separately, they often interact. p53 
mainly stimulates the intrinsic pathway, but it also upregulates some of the pro-apoptotic 
receptors such as DR5 and augments extrinsic signalling [42]. Extrinsic-pathway activation 
leads to caspase 8‑mediated processing of Bid; truncated Bid subsequently stimulates Bax and 
Bak to engage the intrinsic pathway [43, 44]. The effector caspases can then feed back to 
promote further caspase 8 processing.  
 
Introduction 
 27 
 
Fig 3 Key steps in the intrinsic and extrinsic apoptotic signaling pathways (adapted from Ashkenazi et al., 2008 
Nature Reviews [45]) 
 
1.3.2.2 TRAIL as an effector molecule in cancer therapy  
 
Promoting apoptosis involves the signaling through members of the tumor necrosis factor 
(TNF) superfamily. The family members TNF and Fas ligand (FasL) can efficiently induce 
apoptosis in a variety of tumor cells. However, the administration of TNF and FasL is 
associated with extreme toxicity, precluding their development for cancer therapy. Native 
Introduction 
 28 
TNF-related apoptosis-inducing ligand (TRAIL) shares certain similarity to the most related 
members FasL, TNF-α, Lt-α und Lt-β [46]. The TRAIL gene is located on chromosome 3 
and spans approximately 20kb. It is composed of five exons and four introns. The TRAIL 
transcripts are detected in various human tissues, most predominantly in spleen, lung and 
prostate. TRAIL is a type II transmembrane protein and consists of 281 amino acids in the 
human and 291 amino acids in the murine forms, sharing 65% identity [46]. TRAIL has an N-
terminal domain, which is not conserved across the family members, while the C-terminal 
domains show a most significant conservation. TRAIL is the only protein of the TNF family 
that contains cysteine residues, with the capacity to bind and interact with a zinc-ion, which 
allows the interaction of three molecules of TRAIL. After cleavage of the extracellular C-
terminal portion of TRAIL from the cell surface, TRAIL can be released by the cells as a 
soluble molecule [47]. Both forms rapidly induce apoptosis in susceptible cells by the 
extrinsic apoptotic pathway via clustering with their cognate cell surface death receptors 
DR4/TRAIL-R1 and DR5/TRAIL-R2 [48, 49]. Three additional TRAIL receptors exist: 
DcR1/TRAILs-R3 and DcR2/TRAIL-R4 and osteoprotegerin (OPG), incapable of 
transmitting an apoptotic signal [49, 50]. The trimerization of the death receptor is reqired for 
the recruitment of an adaptor protein Fas-associated death domain (FADD) and the formation 
of the death-inducing signal complex (DISC) through recruiting the initiator caspases caspase 
8 and 10 in the extrinsic apoptosis pathway [51]. TRAIL is expressed by a wide variety of 
human tissues, and is expressed on multiple cell types within the immune system such as B 
and T cells [47], mononuclear phagocytes [52], dendritic cells (DCs) [53], and natural killer 
cells (NK cells) [54] and plays a role in shaping and regulating the immune system. TRAIL is 
not expressed by freshly isolated human T cells, B cells, DCs and NK cells [47]. The 
regulation of TRAIL expression in the immune system is cytokine driven. Interferon alpha 
(IFN-α) and interferon gamma (IFN-γ) stimulate TRAIL expression in monocytes and 
dendritic cells [52, 53], IFN-α and IFN-β stimulate TRAIL expression in T lymphocytes and 
NK cells. Interleukins 2, 7 and 15 can also induce NK cell expression of TRAIL [55, 56].  
TRAIL has several functions in vivo. TRAIL contributes to the host immunosurveillance 
against primary tumor development and metastasis (reviewed in [57, 58]). TRAIL has been 
shown to influence viral infections and to contribute to autoimmune diseases. TRAIL can 
boost the host responses to the tumor and change the tumor microenvironment for enhanced 
antigen presentation and tissue infiltration [59, 60]. Although the TRAIL receptors are 
expressed constitutively in a variety of normal tissues [61], TRAIL has the unique 
characteristic to induce apoptosis selectively in tumorigenic or transformed cells [48] without 
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toxicity to normal cells [51, 62]. All above mentioned makes TRAIL an ideal tool in anti-
cancer therapy.  
1.3.2.3 TRAIL delivery in cancer therapy 
 
Based on the characteristic of TRAIL to induce apoptosis selectively in tumorigenic cells, 
many strategies have been developed for the delivery of TRAIL. Many recombinant 
preparations of TRAIL (recTRAIL) have been developed and tested in vivo [48, 63]. Another 
strategy to deliver TRAIL to tumor cells has been the transfer in normal cells as carriers or the 
direct transduction of the tumor cells with viral vector encoding for the TRAIL gene. In 
animal experiments, the treatment with recTRAIL substantially inhibited the growth of a 
variety of human tumors including breast and colon carcinomas [63], gliomas and multiple 
myeloma [64-66] and many other. RecTRAIL was also effective in patient samples [63]. 
However, frequently observed hepatocyte toxicity [67, 68], the required high dose of 
bioactive TRAIL and its short half life in vivo [63] have delayed the entrance into the clinics. 
Although improved recTRAILs are now in phase II clinical trials (reviewed in [69]), the 
pharmacokinetic and pharmacodynamic problems of a systemic delivery and the safety for the 
patient are still a major concern.  
TRAIL is also used by gene therapy. TRAIL can be delivered by normal cells like 
mesenchymal stem cells (MSCs), which have tumor targeting properties, for the targeted 
delivery and local production of TRAIL in tumors [70-73]. Another way to use TRAIL in 
gene therapy is the transduction of the TRAIL coding sequence into the tumor cell directly. 
The vectors encoding TRAIL can be administered directly, locally or systemically. The most 
studied vector have been the adenoviral vectors [74-83] while also other vectors are tested for 
their suitability [84-87]. The delivery of TRAIL by lentiviral vectors for this application has 
rarely been described [88-90]. The intention of this strategy is to kill the tumor cells present at 
the injection site and to generate sufficient apoptotic tumor debris to stimulate a systemic, 
tumor-specific immune response. In this study transduced lymphocytes are used as carrier 
cells for the delivery of TRAIL to pancreatic and prostate cancer cells.  
1.4 Immunotherapy 
 
Immunotherapy is a promising approach for cancer therapy. Immunotherapy in general is the 
treatment of disease by inducing, enhancing or suppressing an immune response. 
Immunotherapies, designed to elicit or amplify an immune response, are classified as 
activating immunotherapies. Immunotherapies, designed to reduce, suppress or direct an 
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existing immune response, as in cases of autoimmunity or allergy, are classified as 
suppressing immunotherapies. A central problem in tumor immunology is that an established 
tumor creates an environment of immune tolerance that promotes tumor growth, protects the 
tumor from immune attack and attenuates the efficacy of immunotherapy. Several 
mechanisms have been described by which tumors can suppress the immune system. It 
includes secretion of cytokines, alterations in antigen-presenting cells, alterations in 
costimulatory and coinhibitory molecules and altered ratios of regulatory T cells to effector T 
cells. These barriers of tolerance have to be overcome in a successful cancer therapy. 
Addiotionally, tumors are a heterogenious mass of cells with numerous subpopulations 
undergoing changes during their proliferation. Also tumor cells can vary in the expression of 
their specific antigens. Since cancers differ in their immunological protection and their 
antigen expression, a immunotherapy against cancer is not universally applicable, but has to 
be adapted to the individual tumor. The observation by William Coley in the 1890s, that soft 
tissue sarcoma in patients having acute bacterial infections would regress, was one of the 
starting points for immunotherapies against cancer. One of the first indications that metastatic 
human cancers could be eliminated using immunological manipulations came from studies of 
the administration of autologous lymphokine-activated killer cells and IL-2 to patient with 
metastatic melanoma, colon cancer or renal-cell cancer [91]. At this time the question whether 
the immune system can recognize and eliminate tumor cells was highly controversial. This 
view has changed and the fact that the immune system is capable of targeting tumors is 
accepted. Cancer immunotherapy approaches concentrate on killing the tumor cells through 
effector cells of the immune system, which include B-cells, producing antibodies, CD8+ CTL, 
CD4+ helper T cells, NK cells and NK T cells. Cancer immunotherapies are either active i.e. 
immunization or passive i.e. adoptive transfer. These approaches target the innate 
immunesytem by inducing humoral immunity or/and the adaptive immune system by 
stimulating cellular immunity [92]. 
The cells of the innate immune system such as NK, γδ T cells or NKT cells have lytic effector 
functions. They can produce activating cytokines like IL-12 which mediate an innate immune 
response and can also initiate an adaptive immune response. Immunotherapy trageting the 
innate immune system also selectively activate these cells of the innate immunity by in vitro 
expansion and activation, by directly providing effector cytokines like TNF-α or IFN-γ, by 
stimulating a local tumor inflammation by the administration of adjuvants like bacterial 
products like LPS or by activating and increasing the number of circulating antigen presenting 
cells like DCs.  
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Immunotherapy stimulating cellular immunity attempts to circumvent the problem of poor 
immunogenicity of tumors by presenting tumor antigens through activated DCs. Therefore the 
stimulus and the antigens are provided to DCs, Tregs which also intervene with T cell 
responses in tumors are depleted, or effector cells such as T cells are transferred. This 
adoptive therapy transfers ex vivo selected and expanded tumor reactive T cells or T cells 
with engineered T cell receptors. 
The activation of B cells is central in humoral immunotherapy. B cells produce antibodies that 
can bind to immunogenic cell surface protein and initiate complement-mediated lysis, bridge 
NK cells or macrophages to the tumor for antibody-dependent cell-mediated cytotoxicity 
(ADCC). Tumor-reactive B cell responses can also be enhanced by cancer vaccines or by 
antigen pulsed DCs. The passive transfer of antibodies has been successfully used in cancer 
therapy. Thus, engineered monoclonal antibodies (mAb) against cancer specific antigens are 
successfully used in the clinics. Examples of an application of antibody therapies in oncology 
are the introduction and approval of mAbs such as trastuzumab (Herceptin, anti-HER2/neu 
receptor), bevacizumab (Avastin, anti-vascular endothelial growth factor (VEGF) antibody), 
of cetuximab (Erbitux, an anti-epidermal growth factor (EGF) antibody), epratuzumab 
(Lymphocide, anti-CD22) and Rutixan (rituximab, anti-CD20). In combination with standard 
chemotherapy, these agents received a significant anti-tumor response in patients with breast 
cancer, metastatic cancers of the colorectum, breast and lungs and in chemotherapy-refractory 
cancers of the colon and rectum, or leukemia. 
Additionally, several new classes of recombinant antibodies such as the bispecific antibodies 
are developed. The application of antibodies in cancer-therapy, include the direct and indirect 
interference with cancerous signaling pathways, angiogenesis, proliferation and the facilitated 
detection of malignant cells. 
1.4.1 Bispecific antibodies in cancer therapy 
 
Bispecific antibodies are artificial molecules (bsAb) carrying a different antigen-binding site 
on each arm (reviewed in [93, 94]). This dual specificity makes them trifunctional molecules. 
The hybridoma technique introduced by Kohler and Milstein in 1975 [95] allowed the 
formation of hybrid cell lines (called hybridomas) by fusing a specific antibody-producing B 
cell with a myeloma (B cell cancer) generating antibodies all of a single specificity 
(monoclonal antibodies). The fusion of two hybridomas yields hybrid-hybridomas or 
quadromas. These quadromas expressing two different heavy and two different light chains 
produce a variety of different antibody species resulting from the random pairing of the heavy 
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and the light chains. From this process, bispecific antibodies are generated, carrying a 
different specificity on each arm [96, 97]. Besides the quadroma technique, other methods 
have been developed to generate different formats of bsAbs (Fig 4). Recombinant bsAb 
formats include the development of chemically linked bsAb [98], BiTE [99], bispecific single 
chain ScFv antibodies [100] and diabodies [101]. The antibodies additionally can be 
chimerized or fully humanized [93]. The dual specificity enable bsAbs completely different 
target strategies such as a) the simultaneous inhibition of two signaling pathways either by 
blocking two receptors or two ligands or a combination of both, b) increased specificity by the 
ability to bind two different antigens simultaneously and c) a retargeting of cells (one binding 
specificity is directed against a target cell, whereas the other binding site is used to recruit a 
toxic activity or moiety). 
 
Fig 4 Schematic representation of therapeutic antibodies 
 
The application of bsAbs in cancer therapy takes advantage of the feature that one arm of the 
antibody can bind to a tumor-associated antigen on cancer cells and the other to abundant 
molecules i.e. on immune cells. This feature brings tumor and immune cells in a close 
contact, triggers immune cell activation and can redirect immune cells to kill tumor cells 
[102-104].  
1.4.2 Tumor antigen targets in immunotherapy 
 
The discrimination of a tumor cell from a healthy cell is essential for a therapeutic targeting of 
cancer. The targeting of cancers by antibodies requires the expression of tumor antigens that 
are exclusively expressed or over-expressed on the tumor. A tumor can be discriminated by 
tumor-specific antigens or tumor-associated antigens. These tumor antigens comprise several 
categories. There are the oncogenic viral antigens for example from EBV in Burkitt’s 
lymphoma, HBV and HCV in hepatoma, HPV in cervical and perineal carcinoma. 
Additionally, there are certain fusion genes like BCR/ABL in CML, antigens with a limited 
normal expression in the testes and placenta in healthy tissue like MAGE and antigens that 
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are expressed in development but not in adult tissue for example CEA and αFP. In addition, 
there is a number of molecules, which are expressed on many normal cell types but whose 
phenotype is altered in malignant cells. This includes the molecules ras, p53, hTERT, NY-
ESO-1, altered self-epitopes like gangliosides, mucins or EpCAM.  
1.4.2.1 EpCAM as target molecule in immunotherapy 
 
The epithelial cell adhesion molecule (EpCAM) is one of the promising tumor associated 
antigens. EpCAM was initially described as a tumor associated antigen by Koprowski and 
colleagues in 1979 [105]. EpCAM expression is highly upregulated by several carcinoma 
cells [106], making it a favorable target for tumor therapy. Furthermore, EpCAM is 
considered a potential prognostic tumor marker [106-108] and the over-expression correlates 
with decreased in survival as in breast or in ovarian cancers. An exception is renal cell 
carcinoma, where the opposite is the case. Cancers with upregulated EpCAm expression are 
i.e. lung, colorectal, prostate and pancreatic carcinoma.  
EpCAM is a type I membrane protein of 314aa. EpCAM is a non-typical member of the CAM 
family, with an extracellular signaling sequence, followed by an epidermal growth factor-like 
repeat, a human thyroglobulin repeat and a cystein-poor domain. EpCAM has one single-
spanning transmembrane domain and an intracellular domain containing an NPXY 
internalization motif and several actin-binding sites. In contrast to the broad expression 
pattern of most other CAMs in normal tissues, the expression of EpCAM is restricted to 
normal epithelial cells. EpCAM is mainly expressed in adult tissues and restricted to cells of 
epithelial origin but it is also found during certain stages of early embryonic development and 
during differentiation and morphogenesis. In adult tissues, EpCAM is virtually expressed in 
all simple epithelia without any major change. EpCAM is known to mediate cell-cell adhesion 
but has several more roles. It is involved in cellular processes such as signaling in cell 
migration, proliferation and differentiation. Binding partners include actin and the 
cytoskeleton, mediating adhesion to the epithelial microenvironment, but also CD44v4-V7, 
tetraspanins and Claudin-7, which influence not only cell-cell adhesion, cell-matrix adhesion, 
but also apoptosis resistance, carcinogenesis promotion and metastasis (reviewed in [109]). 
On the other hand, EpCAM is typically over-expressed in a variety of epithelial cancers and 
derived metastasis, including prostate cancer and pancreatic adenocarcinoma. Nevertheless, 
EpCAM distribution and their location varies in these carcinomas. Upon tissue inflammation 
EpCAM is upregulated. Although little is known about the molecular mechanism of EpCAM 
Introduction 
 34 
regulation, it has been observed that TNF-α can down-regulate EpCAM and that this 
coincides with NF-κB activation.  
Several different antibody constructs have been generated against EpCAM expressed by 
tumor cells [110-117] with promising results in phase I/II clinical trials [118, 119]. 
Adecatumumab (MT201 Micromet), a fully human anti-EpCAM antibody [120], is currently 
in three ongoing clinical trials: two phase II studies with metastatic breast cancer and early 
stage prostate cancer and a phase I study testing the safety of the combination of Abs with 
taxotere. Pre-clinical studies have shown that MT201 mainly acts through antibody-dependent 
cellular (ADCC) and complement‐dependent  cytotoxicity  (CDC)  [121]. EpCAM‐directed bsAb immunotherapies are already very advanced into the clinics. MT110, a single‐chain EpCAMxCD3 bispecific antibody construct of  the BiTE class  [122],  led  to  the successful eradication  of  established  tumors  from  human  cancer  cell  lines mixed with  human  T cells  and  in  ovarian  cancer  tissue  of  patients.  Catumaxomab  (Removab, Trion 
Pharma/Fresenius), a hybrid mouse/rat antibody trispecific for EpCAM, CD3 and ‐ via its Fc portion –  for antigen‐presenting as well  as  for a variety of other  cytotoxic  immune cells, has been shown to efficiently reduce ovarian cancer patients suffering from ascites and in gastric cancer patients in phase II clinical studies. However, a relatively short half-
time, overt productions of cytokines, Fc-mediated side effects and bsAb immunogenicity limit 
the clinical application [94]. 
1.4.3 Engaging effector cells by bispecific antibodies 
 
There is a choice of immunological effector cells for the engagement by bsAbs. BsAb have 
been designed for many immunological effector cells i.e. macrophages, NK cells, neutrophils, 
B and T cells. One of the most potent effector cells of the immune systems are T cells. 
Engaging T cells by bispecific antibodies is advantageous due to their high cytotoxic 
potential. They are present in the body in abundance, have intrinsic search and destroy 
functions, and there is evidence for their potential to initially control malignant diseases. 
There are numerous reports on tumor rejection by T cells in animal models, and the presence 
of T cells inside tumors can significantly correlate with overall survival, as recently reported 
for patients with colon cancer and NHL [123, 124]. The invariant CD3 signaling complex on 
lymphocytes is the most common T cell antigen for bsAbs. Targeting T cell by bispecific 
antibodies to tumor cells has several advantages. This therapeutic strategy does not rely on the 
laborious generation of tumor specific T cell clones and does not require a regular antigen 
presentation by dendritic cells. Furthermore, it has been shown, that T cells can be engaged by 
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a bispecific antibody to recognize a frequent surface antigen on the tumor cell, and that the 
expression of MHC class I, usually required for antigen recognition, is not required ([125]). 
Moreover, not only cytotoxic CD8+ T cells can be targeted and redirected for lysis, but also 
CD4+ T cells. 
1.4.4 Bispecific antibody EpCAMxCD3  
The bispecific antibody EpCAMxCD3 is used in this work. It has a dual specificity for the 
binding of EpCAM and CD3. Both EpCAM and CD3 molecules are attractive  targets  for the  generation  of  bsAb  and  bispecific  single‐chain  antibody  constructs  for  anti‐cancer treatment  [115,  122,  126,  127].  EpCAMxCD3  has  been  generated  by  the  hybrid‐hybridoma  techique  from  the parental  hybridoma  anti  human EpCAM  (HEA125,  IgG1) and anti human CD3 (OKT3, IgG2A). Hence, EpCAMxCD3 is composed of mouse IgG1 and IgG2A constant heavy chain regions. This antibody has been shown to reduce the ascites formation in ovarian cancer patients [117, 128].  
1.5 Combination therapy for pancreatic and prostate cancer  
 
Both gene therapy and immunotherapy strategies have been tested for cancer therapy. 
However, in most studies only on approach is applied. The aim of this project was to test 
whether a combination of immunotherapy with EpCAMxCD3 and gene therapy with TRAIL-
over-expressing lymphocytes would be effective in pancreatic and prostate carcinoma. This is 
the first time, such an combined approach is tested (Fig 5).  
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Fig 5 Scheme of the therapeutic approach 
 
1.5.1 A novel therapy for pancreatic and prostate carcinoma combining TRAIL-over-
expressing lymphocytes and bispecific antibody EpCAMxCD3 
 
This work investigated the efficacy of a potential novel therapeutic approach This approach 
combines gene therapy with immunotherapy. The gene therapy part aims to use patient-
derived lymphocytes, which are genetically manipulated to over-express TRAIL as an 
apoptosis-inducing ligand. In the immunotherapy part these manipulated lymphocytes are 
“armed“ with EpCAMxCD3. Therefore, the induction of apoptosis would occur when 
manipulated T cells will be brought to a close contact with tumor cells by bispecific antibody 
(Fig 6). BsAb EpCAMxCD3 has a dual specificity for EpCAM, over-expressed by pancreatic 
and prostate tumor cells, and for the invariant CD3 signaling complex on lymphocytes. When 
these bsAb monovalently bind to the antigens they will bring the tumor cells and the T cells 
into a close contact and also active T cells to release cytotoxic molecules and thus to kill 
tumor cells. The gene therapy part allows the introduction of the effector protein TRAIL into 
lymphocytes. TRAIL is over-expressed on lymphocytes and has the ability to selectively 
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induce apoptosis in tumor cells. EpCAMxCD3 consequently can deliver these TRAIL-over-
expressing lymphocytes to EpCAM over-expressing tumor cells. The monovalent binding of 
CD3 on lymphocytes and the close contact to the bsAb-linked tumor cells, induces a 
polyclonal T cell activation. This polyclonal activation consequently can mount all 
differentiated T cells of the CD8 as well as CD4 phenotype, without the need for an MHC 
class I dependent receptor recognition of antigen. Hence there is no requirement for tumor 
specific T cells. This close contact to the tumor cell enables a cytotoxic lysis by CD8+ T cells, 
a stimulation of CD4+ helper T cells or creates room for additional genetically introduced T 
cell functions such as TRAIL.  
In a clinical setting, it could be possible to use patient’s lymphocytes. These would be isolated 
from the patient’s blood and transduced to over-express TRAIL ex vivo. These autologous 
“armed” lymphocytes would be re-administered back into the patient together with the 
bispecific antibodies. In the patient, the bsAb would recruit the TRAIL-over-expressing 
lymphocytes to the EpCAM-expressing tumor cells and eventually eradicate the tumor (Fig 
5). In this work, this approach is tested with lymphocytes from healthy blood donors in vitro 
and in vivo in animal models for prostate and pancreatic carcinomas. 
 
Fig 6 Scheme depicting the interaction of an EpCAM over-expressing tumor cells and a lymphocyte bridged by the 
bispecific antibody EpCAmxCD3 
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1.6 Aim of the study 
 
The aim of this project was to test the efficacy of a novel therapeutic approach for cancer 
therapy. This approach combines immunotherapy with bsAb EpCAMxCD3 and gene therapy 
with TRAIL. The potential efficacy of this approach was tested in experimental models of 
pancreatic and prostate carcinoma.  
Specific aims were i) to construct a lentiviral vector suitable for the transduction of human 
lymphocytes and the over-expression of TRAIL. The next aim was ii) to establish and to 
evaluate suitable xenograft models for the study of the chosen approach, iii) to test the 
efficacy and the anti-tumor potential of TRAIL-over-expressing lymphocytes and bsAb 
EpCAMxCD3 in vivo and iv) to elucidate the functional mechanisms underlying observed 
anti-tumor effects of TRAIL-over-expressing lymphocytes and bsAb EpCAMxCD3 in vivo 
and in vitro.  
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2 Results 
2.1 Validation of tumor cell lines for in vitro and in vivo xenograft models 
 
Finding a suitable model is essential for the analysis of potential anti-tumor effects of bsAb 
EpCAMxCD3 treatment together with TRAIL-over-expressing lymphocytes, which will be 
called TRAIL-L in the following. Several tumor cell lines were tested for their suitability in in 
vivo and in vitro models. The following parameters were analysed: the expression of EpCAM, 
growth kinetics of cell lines in vivo and the expression of TRAIL-receptors in tumor cells. 
2.1.1 Expression of EpCAM in pancreatic and prostate tumor cell lines 
 
The pancreatic tumor cell lines MIA-PaCa2, Colo357, AsPC-1 and BxPc-3 and the prostate 
tumor cell lines PC-3, LNCap and DU145 were analysed for the expression of EpCAM. All 
cell lines expressed EpCAM to approximately 100% on their cell surface, making them 
suitable candidates for an EpCAM-targeted treatment with EpCAMxCD3 bispecific antibody 
(data not shown).  
2.1.2 Transplantation efficiency and growth kinetics of tumor cell lines 
 
The tumor cell lines were tested for the transplantation efficiency and the growth kinetics of 
the tumor xenografts in vivo. BxPc-3, Mia-PaCa, PC-3 and LNCap were tested and a cell 
number of 1x106, 2.5x106 and 5x106 tumor cells were transplanted into NOD/SCID mice. The 
most optimal transplantation volume was 5x106. For DU145, Colo357 and AsPC-1 
experimental experience existed from collaborating groups. Based on these results (data not 
shown), the BxPc-3 and PC-3 tumor cell lines were chosen. Detectable tumors develop after 
one to two weeks and reach a maximal tolerable volume of 2 cm3 after three to four weeks. 
This time frame was most optimal for our study. Both cells lines have moderate growth 
kinetics, which would allow us to study the therapy approach in a two to three week time 
frame.  
2.1.3 Expression of TRAIL-receptors in BxPc-3 and PC-3 cell lines 
 
For the induction of apoptosis by TRAIL in the target cells, BxPc-3 and PC-3 were analysed 
for the expression of TRAIL-R1 and TRAIL-R2. In PC-3 22.1% of the cells were positive for 
TRAIL-R1 and 29.4% expressed TRAIL-R2. In BxPc-3 60.2% of the cells expressed TRAIL-
R1 and 18.8% expressed TRAIL-R2 (Fig 7). Based on EpCAM and TRAIL-R1 and –R2 
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expression and in vivo growth kinetics, the BxPc-3 and the PC-3 cell line, were chosen as the 
most optimal candidates for the model system.  
 
Fig 7 Expression of TRAIL-receptors on tumor cell lines in vitro 
To verify the expression of TRAIL- receptors in vitro, pancreatic BxPc-3 and prostate PC-3 tumor cells were analysed for 
TRAIL-R1 and TRAIL-R2 by flow cytometry. 
 
2.2 Over-expression of TRAIL in lymphocytes 
2.2.1 Construction of an inducible lentiviral vector for the over-expression of TRAIL 
and EGFP in human lymphocytes 
 
The lentiviral vector system based on HIV-1 was chosen for the transduction of lymphocytes. 
The original vector [129] was modified to over-express TRAIL. The following modifications 
were introduced: the human TRAIL gene, the marker gene EGFP linked by the picorna virus-
derived peptide element P2A (2A element of porcine teschovirus) and the transactivator 
rtTA2-M2 were cloned into the original expression vector pd500Trip-CMVmin-WPRE. 
Binding of the rtTA2-M2 transactivator to the TRE upstream of the promoter activates 
transcription. The peptide linker allows an equivalent expression of both genes due to a 
“ribosomal skip“ (described by Leisegang et al. [130]) compared to IRES elements. The final 
composition of the lentiviral vector pV3TP2AE is shown in (Fig 8). The final vector 
pV3TP2AE was verified for its identity and the correct configuration by sequencing. The 
pV3TP2AE vector consequently allows an inducible gene expression of TRAIL as well as an 
easy detection of transduced cells by EGFP.  
 
Fig 8 Scheme of the lentiviral vector pV3TP2AE 
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The lentiviral vector pV3TP2AE (A) was created for the expression of human TRAIL and EGFP linked by a P2A element 
driven by a CMVmin promoter. The tet-on vector contains self-inactivating long terminal repeats from HIV-1 (LTR, SIN), 
the transactivator rtTA2-M2, a tet-responsive element (TRE) and the woodchuck hepatitis virus post-transcriptional 
regulatory element (WPRE). 
 
2.2.2 Lentiviral transduction and TRAIL over-expression in human lymphocytes 
 
Lentiviral particles were produced by co-transfection of the 293T producer cells with three 
plasmids: the vector pV3TP2AE, and the helper plasmids pMD2 and psPAX, encoding the 
essential viral proteins. The virus titer was quantified by FACS analysis of transduced 293T 
cells (confer M&M). The production titers ranged between 1x106 and 1x108, which was high 
enough to use unconcentrated supernatant in all experiments.  
Peripheral blood mononuclear cells (PBMCs) were isolated from fresh heparinized blood of 
healthy donors via standard Ficoll gradient separation. To improve the efficiency of 
transduction, PBMCs were activated by IL-2 and anti-CD3 mAb (OKT3). The activation 
status was analysed five days later by FACS. The early activation marker CD69 and the late 
activation markers CD25 and CD95 were expressed (Fig 9 C). 
The vector pV3TP2AE efficiently transduced lymphocytes compared to other vectors (data 
not shown). The transduction procedure was optimized for lymphocytes and the following 
method generated the best results. A multiplicity of infection (MOI) between 10-25 was 
applied, since higher MOI did not result in increased transduction efficiency (data not shown). 
Transduction was done on RetroNectin® coated dishes. RetroNectin®, a recombinant 
fibronectin, supports transduction by supplying a binding matrix for lymphocytes and virus 
particles in close proximity. The virus was centrifuged onto the dishes prior to addition of the 
cells, with repetition of the procedure on the consecutive day. This optimized protocol 
achieved an average transduction efficiency of 35-50% in lymphocytes. TRAIL was 
efficiently over-expressed in pV3TP2AE-transduced lymphocytes (TRAIL-L) compared to 
mock-transduced lymphocytes (MOCK-L). The transduction efficiency was 56.7% TRAIL 
expression compared to 59.8% EGFP fluorescence detected by flow cytometry (a 
representative experiment is shown in Fig 9 A).  
2.2.3 Effect of lentiviral transduction of lymphocytes on their functions 
 
The manipulation of the PBMCs by isolation, handling in cell culture and the transduction 
procedure could potentially affect the functions of lymphocytes. Therefore TRAIL-L, 
MOCK-L and lymphocytes (L), which had been in cell culture for the same period of time, 
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were subjected to an allogenic mixed lymphocyte reaction. Therefore, TRAIL-L, MOCK-L 
and L as effector cells were incubated with freshly isolated, irradiated PBMCs from an 
unrelated donor and used as stimulant cells to analyse proliferation upon allogenic 
recognition. TRAIL-L and MOCK-L exhibited a robust proliferation upon incubation with 
stimulant cells (Fig 9 B). 
2.2.4 Effect of lentiviral transduction on CD4-CD8 T cell ratio 
 
Among transduced lymphocytes, 18.8% of all cells (44.3% of transduced cells) were CD4- 
and 28.4% of all cells (67% of transduced cells) CD8-positive T cells lymphocytes (Fig 9 D), 
indicating proliferative selection for cytotoxic T cells by the viral transduction. 
 
Fig 9 Efficiency of lentiviral transduction, functions and TRAIL over-expression in lymphocytes 
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(A) Activated lymphocytes were transduced with pV3TP2AE at MOI 10 as described in M&M: TRAIL over-expression and 
EGFP fluorescence related to transduction efficiency, were analyzed by FACS. Mock transduced lymphocytes served as a 
negative control. (B) Analysis of the proliferative functionality of TRAIL (TRAIL-L) and MOCK-transduced (MOCK-L) 
versus non-manipulated lymphocytes (L). The effector cells were stimulated by allogenic irradiated PBMCS (stimulant cells) 
in an allogenic mixed lymphocyte reaction. Proliferation was analysed by 3H-thymidine incorporation. (C) Activation status 
was verified on day 5 after activation with OKT-3 and IL-2 by FACS. (D) The T cell subpopulations of pV3TP2AE 
transduced lymphocytes were analysed by FACS. Mock-tranduced lymphocytes served as control (MOCK). 
 
2.2.5 Effect of lentiviral transduction on migratory properties of lymphocytes 
 
The effects of transduction on lymphocyte locomotion, lymphocyte migration velocity and the 
percentage of migrating lymphocytes were determined in 3D collagen gels by time-lapse 
video microscopy. Lentiviral transduction did not influence lymphocyte velocity compared to 
non-transduced lymphocytes (data not shown). 
2.2.6 Effect of lentiviral transduction on cytotoxic properties of lymphocytes 
 
In a cytotoxicity assay, the abilities of TRAIL-L to target carcinoma cells was analysed. 
Apoptosis induced by TRAIL-L in carcinoma cells was compared to cell death upon co-
incubation with MOCK-L. TRAIL-L were directly incubated with BxPc-3 cells in the ratios 
of: 1: 0.1, 1:1, 10:1 and 25:1. Apoptosis and cell death were analysed by staining of cells with 
annexinV-PE and propidiumiodide (PI) followed by flow cytometry (Fig 10). Within 4 hours 
of incubation, TRAIL-L and MOCK-L induced up to 25% cell death associated with DNA 
fragmentation. The addition of EpCAMxCD3 resulted in an up to 3-fold increase of PI+ 
cancer cells for TRAIL-L and MOCK-L. AnnexinV levels were low in all groups (3 - 5%, 
data not shown) suggesting low exposure of phosphatidylserine by BxPc-3. TRAIL-L most 
efficiently induced apoptosis in combination with EpCAMxCD3, as seen by PI+ cell death. 
The best results could be seen in a 1:10 target to effector cell ratio. Similar results were 
obtained for PC-3 cells (data not shown). 
Taken together, TRAIL-L and MOCK-L efficiently lysed tumor cells in vitro. EpCAMxCD3 
efficiently increased the induction of cancer cell death by TRAIL- and MOCK-L up to 3 fold.  
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Fig 10 Effect of TRAIL-L and bsAb EpCAMxCD3 on cytotoxic lysis of BxPc-3 tumor cells in vitro 
To test the cytotoxic efficacy of TRAIL-L on tumor cells, BxPc-3 cells were incubated with TRAIL- or MOCK-transduced 
lymphocytes in combination with EpCAMxCD3 at a dose of 10µg/ml for 4 hours as described in M&M. Cell death was 
analysed by PI incorporation into dead/dying cells. Data is shown as mean with standard deviation of individual experiments 
from different blood donors.  
 
Summarized, lymphocytes could be successfully transduced to over-express TRAIL and 
EGFP by the lentiviral vector pV3TP2AE. Due to the comparable expression level of TRAIL 
and EGFP in vitro, the expression of EGFP can serve as a marker for transduction efficiency. 
Lentiviral transduction did not affect the lymphocyte activation status (CD25 or CD69 
expression), proliferation (allogenic reaction), cytotoxic properties, migration in collagen gels 
and cytotoxic properties in vitro. 
2.3 Pharmacokinetics of bispecific antibody EpCAMxCD3 in vivo 
 
The pharmacokinetic properties of EpCAMxCD3 were analysed in vivo. Therefore, 
NOD/SCID mice were injected intraperitoneally (i.p.) with EpCAMxCD3 at a dose of 500 µg 
per mouse, followed by subsequent blood sampling at days 1, 2, 4, 7 and 14. The bsAb level 
in the blood was measured using an ELISA kit for human IgG. The EpCAMxCD3 serum 
concentration reached its maximum at day one after i.p. administration. The serum half-life 
(T1/2) of EpCAMxCD3 was approximately seven days (Fig 11 A). 
2.4 Efficiency of TRAIL-L and bsAb EpCAMxCD3 in vivo and in vitro 
 
To investigate the effects of the TRAIL-L and the bispecific antibody EpCAMxCD3 different 
in vivo models were used as described in the following paragraphs.  
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In the first model (I) the suitability of co-transplantation of tumor cells together with 
lymphocytes was analysed. 
 
In the second model (II) tumor cells were co-transplanted with pre-activated lymphocytes 
and the therapeutic effects of EpCAMxCD3 on xenograft tumor growth were analysed. 
 
In the third model (III) tumor cells were co-transplanted with TRAIL-L to investigate 
whether TRAIL-L enhanced the therapeutic effects of EpCAMxCD3 treatment on xenograft 
tumor growth. 
 
In the fourth model (IV) the combined effects of EpCAMxCD3 treatment in combination 
with TRAIL-L were analysed in developed xenograft tumors.  
 
In vivo model Xenograft
Transplantation of PC-3 mixed with pre-activated 
lymphocytes s.c.
I.
PC-3 Transplantation of Pc-3 s.c.
Description
BxPc-3 Transplantation of BxPc-3 s.c.
BxPc-3 + L Transplantation of BxPc-3 mixed with pre-
activated lymphocytes s.c.
PC-3 + L
In vivo model Xenograft Description
Begin of 
treatment
Treatment
II. BxPc-3 + L Transplantation of BxPc-3 mixed with pre-
activated lymphocytes s.c.
day 3 post cell 
transplantation
bispecific antibody EpCAMxCD3 - 10 mg/kg i.p.                                 
bispecific antibody EpCAMxCD3 - 1 mg/kg i.p.                                     
bispecific antibody EpCAMxCD3 - 0.1 mg/kg i.p.                                    
parental monoclonal antibody anti EpCAM and anti-CD3 1 mg/kg i.p.         
PBS i.p.
PC-3 + L Transplantation of PC-3 mixed with pre-activated 
lymphocytes s.c.
day 3 post cell 
transplantation
bispecific antibody EpCAMxCD3 - 10 mg/kg i.p.                                 
bispecific antibody EpCAMxCD3 - 1 mg/kg i.p.                                     
bispecific antibody EpCAMxCD3 - 0.1 mg/kg i.p.                                    
parental monoclonal antibody anti EpCAM and anti-CD3 1 mg/kg i.p.         
PBS i.p.
In vivo model Xenograft Description
Begin of 
treatment
Treatment
III. BxPc-3 + TRAIL-L Transplantation of BxPc-3 mixed with TRAIL-
over-expressing lymphocytes s.c.
day 3 post cell 
transplantation
bispecific antibody EpCAMxCD3 - 1 mg/kg i.p.                                   
bispecific antibody EpCAMxCD3 - 0.1 mg/k gi.p.                                    
bispecific antibody EpCAMxCD3 - 0.01 mg/kg i.p.                                  
parental monoclonal antibody anti EpCAM and anti-CD3 - 1 mg/kg i.p.               
irrelevant bispecific antibody CD19xCD3 - 1mg/kg i.p.                                       
PBS i.p.       
PC-3 + TRAIL-L Transplantation of PC-3 mixed with TRAIL-over-
expressing lymphocytes s.c.
day 3 post cell 
transplantation
bispecific antibody EpCAMxCD3 - 1 mg/kg i.p.                                   
bispecific antibody EpCAMxCD3 - 0.1 mg/k gi.p.                                    
bispecific antibody EpCAMxCD3 - 0.01 mg/kg i.p.                                  
parental monoclonal antibody anti EpCAM and anti-CD3 - 1 mg/kg i.p.               
irrelevant bispecific antibody CD19xCD3 - 1mg/kg i.p.                                       
PBS i.p.       
In vivo model Xenograft Description
Begin of 
treatment
Treatment
BxPc-3 Transplantation of BxPc-3 s.c. day 12 post 
cell 
transplantation
bispecific antibody EpCAMxCD3 - 0.1 mg/kg i.p. + TRAIL-L s.c.                                
bispecific antibody EpCAMxCD3 - 0.01 mg/kg i.p. + TRAIL-L s.c.                                    
TRAIL-L s.c.                                                                                           
bispecific antibody EpCAMxCD3 - 0.1 mg/kg i.p.                                        
PBS i.p.       
IV.
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2.4.1 Establishment of pancreatic and prostate xenograft models with co-transplanted 
lymphocytes for the treatment with bsAb EpCAMxCD3  
2.4.1.1 BxPc-3 + L and PC-3 + L xenograft morphology and growth kinetics  
 
The possibility to subcutaneously (s.c.) co-transplant human pre-activated lymphocytes 
together with human pancreatic BxPc-3 in vivo was tested in model I.). 
NOD/SCID mice were either injected s.c. with BxPc-3 tumor cells and were compared to 
mice injected with BxPc-3 tumor cells mixed in a 1:1 ratio with extra-corporally IL-2 and 
OKT3 pre-activated lymphocytes (BxPc-3 + L) (Fig 11 I.). The same model was used for PC-
3 xenografts. Tumor engraftment (tumor take), tumor growth kinetics and tumor morphology 
were analysed at day 25 after cell implantation. Essentially, there was no difference in tumor 
incidence and tumor growth kinetics between BxPc-3 + L and BxPc-3 (data not shown). All 
animals developed tumors and tumor growth was independent of co-administration of pre-
activated lymphocytes. Pre-activated lymphocytes did not influence BxPc-3 tumor stroma 
formation as seen by collagen distribution patterns and blood vessel morphology and density 
(Fig 11 C). Comparable results were obtained for PC-3 + L xenografts compared to PC-3 
(data not shown).  
2.4.1.2 Expression of EpCAM and TRAIL-receptors in BxPc-3 + L and PC-3 + L 
xenografts 
 
The expression of EpCAM, which is the target antigen for bsAb, and TRAIL-receptors was 
analysed in vivo by flow cytometry. EpCAM was expressed by all tumor cells in BxPc-3 + L 
and PC-3 + L xenografts (Fig 11 C, data not shown). The majority of the cells in the tissue 
also expressed TRAIL-R1 and TRAIL-R2 (Fig 11 D).  
2.4.1.3 Survival of co-injected lymphocytes in the xenograft tissue 
 
Transplanted lymphocytes were detected by immunohistochemistry in BxPc-3 + L tumors 24 
days after cell implantation (CD45+) (Fig 11 B), suggesting that human lymphocytes survive 
for a long time in BxPc-3 xenografts in the mouse. Of these CD45+ cells, almost all cells were 
CD4+ and CD8+ lymphocytes with only single CD16+ NK cells (data not shown).  
Taken together, the xenograft model of human tumor cells co-injected with lymphocytes 
showed a robust tumor engraftment and development. The lymphocytes survived for up to 24 
days in the tumor tissue and their presence did not influence the tumor morphology and 
growth kinetics of the BxPc-3 and PC-3 xenografts in vivo. EpCAMxCD3 had a 
Results 
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pharmacologically long serum half life of approximately 7 days. Therefore, these models of 
BxPc-3 + L and PC-3 + L mixed xenografts were considered suitable for the in vivo analysis 
of the anti-tumor efficiency of bsAb EpCAMxCD3 treatment.  
 
Fig 11 BsAb EpCAMxCD3 pharmacokinetics and validation of BxPc-3 + L pancreatic xenograft model 
I.) Scheme of in vivo experiment. (A) NOD/SCID mice were s.c. transplanted with BxPc-3 pancreatic tumor cells (5x106) 
mixed with extra-corporally pre-activated human lymphocytes (L) (5x106) as described in M&M. 
NOD/SCID mice (n=5) received one i.p. injection of EpCAMxCD3 at a dose of 500 µg and peripheral blood was taken 1, 2, 
4, 7, 14 days after the bsAb administration. BsAb EpCAMxCD3 concentration in the serum was determined by ELISA. (B) 
CD45+ cells were detected in tumor tissues by immunohistochemistry 24 days after the tumor cell/ lymphocyte implantation. 
400x magnification. (C) Trichrome staining of tumor tissues was used to evaluate collagen distribution (blue) and stroma 
formation. Nuclei are colored in red. 100x magnification. Double immunofluorescence technique was used to detect EpCAM 
expression on tumor cells (green) and CD31+ blood vessels (red). (D) Immunohistochemistry was used to detect the 
expression of TRAIL-R1 and TRAIL-R2 in BxPc-3 + L tumors. 400x magnification. Bar = 100 µm. 
 
2.4.2 EpCAMxCD3 treatment in BxPc-3 + L and PC-3 + L xenografts 
2.4.2.1 Tumor engraftment and growth retardation of BxPc-3 + L and PC-3 + L 
xenografts by EpCAMxCD3  
In the next model, BxPc-3 + L and PC-3 + L xenografts were injected with EpCAMxCD3 in 
treatment experiments. The anti-tumor efficacy of the bsAb and the ability of the bsAb to 
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deliver the lymphocytes to the tumor cells were analysed in these xenografts. The focus was 
on the optimal dose finding of EpCAMxCD3, which would allow the study of the TRAIL-L 
in the therapeutic approach.  
In the pancreatic model NOD/SCID mice were s.c. transplanted with BxPc-3 tumor cells 
mixed with pre-activated lymphocytes BxPc-3 + L and in the prostate model with PC-3 cells 
mixed with lymphocytes PC-3 + L (Fig 12 II.). Three days after cell implantation animals 
received i.p. injections of bsAb EpCAMxCD3 at a dose of 0.1 mg/kg, 1 mg/kg, 10 mg/kg. 
The control groups received control parental bivalent anti-CD3 and anti-EpCAM mAbs or 
PBS. The treatment was repeated four times with a three day interval.  
Repeated measurements of tumor growth during a period of 24 days, revealed a dose-
dependent anti-tumor effect of EpCAMxCD3 in xenografts. In BxPc-3 + L xenografts, mice 
which had received the highest dose of EpCAMxCD3 (10 mg/kg) had dramatically reduced 
tumor take; only 50% (4/8) of the animals developed small tumors compared to 100% (8/8) of 
mice in the control Abs group. The highest dose of EpCAMxCD3 retarded the BxPc-3 + L 
tumor growth most efficiently, compared to the animals which had received control parental 
antibodies (Fig 12 A, B). Furthermore, the anti-tumor effect of EpCAMxCD3 at doses of 1 
mg/kg and 0.1 mg/kg was considerable higher compared to control groups with PBS and 
control parental antibodies with a tumor take of 80% (4/5) in both control groups (Fig 12 C, 
D, A and E). The animals in the PBS control group also developed much larger tumors than in 
the EpCAMxCD3-treated groups. Overall, the treatment efficiency was dose-dependent 
compared to the groups of animals treated with PBS and parental control Abs (Fig 12 B - E). 
At day 24 the tumor weight was significantly reduced in all groups treated with EpCAMxCD3 
compared to the controls (Fig 12 F). Similar results were obtained for PC-3 + L xenografts 
treated with EpCAMxCD3 (Fig 12 G – L). 
Functionally available bsAb plasma level was 202 ± 45 ng/ml in BxPc-3 + L tumor-bearing 
mice treated with 10 mg/kg EpCAMxCD3 seven days after the last injection. The body 
weight of tumor-bearing mice was not affected by the EpCAMxCD3 treatment (data not 
shown), indicating an absence of severe toxic side effects. In addition, the formation of 
metastasis could not be detected by macroscopic inspection of organs and tissues and by 
immunohistochemistry with anti panCK Ab and by flow cytometry with anti-human MHC 
class I Ab (data not shown). 
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Fig 12 Efficiency of EpCAMxCD3 treatment in pancreatic BxPc-3 + L and prostate PC-3 + L tumor model 
II.) Scheme of in vivo experiment. NOD/SCID mice were s.c. transplanted with pancreatic BxPc-3 or prostate PC-3 tumor 
cells (5x106) mixed with extra-corporally pre-activated human lymphocytes (L) (5x106). Three days later animals were 
randomized to 5 groups (n=5-8 per group) and received i.p. injections of bsAb EpCAMxCD3 or controls. Animals received 
either control parental bivalent EpCAM and anti-CD3 mAb at a dose of 1 mg/kg (A, G), EpCAMxCD3 at doses 10 mg/kg 
(B, H), 1 mg/kg (C, I), 0.1 mg/kg (D, J) or PBS (E, K). Treatment was repeated 4 times with a three-day interval as described 
in M&M. Tumor growth was measured every third day. Data is presented as growth kinetics of individual tumors. The 
weight of tumors is presented at the end-point of experiment at day 24 (F, L). ∗ p<0.05. 
 
2.4.2.2 Apoptosis induction in BxPc-3 + L and PC-3 + L xenografts by bsAb 
EpCAMxCD3 
 
The growth retardation of BxPc-3 and PC-3 tumors and the reduced tumor engraftment could 
be due to several mechanisms. First, the anti-tumor effects of EpCAMxCD3 treatment of 
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BxPc-3 + L and PC-3 + L tumors were analysed for the induction of apoptosis. Cryosections 
of tumors were subjected to TUNEL assay and to immunohistochemistry to detect active 
caspase 3. There was no difference in the density and in the percentage of active caspase 3-
positive cells between EpCAMxCD3 treated tumors and controls (Fig 13). Analysis of 
TUNEL staining revealed similar results.  
 
Fig 13 Effects of EpCAMxCD3 on apoptosis in BxPc-3 + L and PC-3 + L  
To evaluate whether anti-tumor effects of EpCAMxCD3 and co-transplanted lymphocytes were due to apoptosis induction, 
BxPc-3 + L tumors were subjected to TUNEL assay and to immunohistochemistry to detect active caspase 3 (A). The density 
of apoptotic cells visualized by TUNEL staining and (B) the density and percentage of active caspase 3-positive cells in 
BxPc-3 + L tumor tissues (n=4 per group). ∗ p<0.05. 
 
 
2.4.2.3 Reduced Proliferation in BxPc-3 + L and PC-3 + L xenografts by bsAb 
EpCAMxCD3 
 
Second, tumor tissues were immunohistochemically analysed for changes in tumor cell 
proliferation. In BxPc-3 + L and in PC-3 + L tumors, a significant reduction of Ki-67-positive 
cells could be detected in EpCAMxCD3 treated groups compared to controls (Fig 14).   
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Fig 14 Effects of EpCAMxCD3 on apoptosis in BxPc-3 + L and PC-3 + L  
To evaluate whether anti-tumor effects of EpCAMxCD3 and co-transplanted lymphocytes were due to proliferative changes, 
BxPc-3 + L and PC-3 + L tumors were subjected to immunohistochemistry to detect active Ki-67. ∗ p<0.05. 
 
Summarized, EpCAMxCD3 treatment retarded the tumor growth and reduced the tumor 
engraftment in BxPc-3 + L and PC-3 + L xenografts. However, tumor growth retardation was 
not due to the induction of apoptosis at to the time of observation but a reduced number of 
proliferating cells could be detected. The tumor analysis at the endpoint of the treatment on 
day 24 after cell transplantation, is quite late and reactions of the tumor cells towards the 
treatment could have happened earlier. 
2.4.3 Establishment of pancreatic and prostate xenograft models with co-transplanted 
TRAIL-L for the EpCAMxCD3 treatment  
 
In the next in vivo model II, the question was, whether the anti-tumor effect of EpCAMxCD3 
could be enhanced by using TRAIL-over-expressing lymphocytes (TRAIL-L). Based on the 
results from the BxPc-3 and PC-3 xenografts with co-injected human lymphocytes, the in vivo 
experiments were modified for TRAIL-L. The observation, that the 1 mg/kg and the 0.1 
mg/kg dose of EpCAMxCD3 treatment was also very efficient, the dosage was further 
decreased. With lower doses of bsAb, the analysis of the contribution of the TRAIL-L is 
possible. To analyse the therapeutic effect of EpCAMxCD3 in combination with TRAIL-L, 
human pancreatic BxPc-3 cells were s.c. co-transplanted with human TRAIL-L (BxPc-3 
+TRAIL-L)  into NOD/SCID mice. The same model was established for human prostate PC-3 
cell lines (PC-3 + TRAIL-L).  
2.4.3.1 Activation of transgene expression by doxycycline in vivo 
 
The lymphocytes were transduced with the inducible lentiviral vector pV3TP2AE. Therefore 
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it was necessary to analyse whether the transgene in transduced lymphocytes was efficiently 
“switched on“ and to check a potential basal transgene expression in vivo. To exclude 
apoptotic effect of TRAIL in vivo, lymphocytes were transduced with a control vector to 
over-express the marker gene EGFP. NOD/SCID mice were s.c. transplanted with BxPc-3 
cells mixed with EGFP-transduced lymphocytes and received doxycycline with the drinking 
water to induce the transgene expression. Animals (n=3) received doxycycline at a dose of 
200 µg/ml or at a dose of 1 mg/ml with the drinking water. A control group of animals (n=3) 
received drinking water without doxycycline. Cryosections of tumor tissues from animals, 
which had received doxycycline, showed an efficient expression of the transgene EGFP in 
lymphocytes (Fig 15). However, the control group, which did not receive doxycycline in the 
drinking water, showed a basal expression of EGFP in the tissue, indicating that the CMVmin 
promoter is leaky in this lentiviral vector construction (data not shown). 
 
Fig 15 Induction of transgene expression in BxPc-3 + EGFP-L xenografts  
NOD/SCID mice were s.c. transplanted with BxPc-3 pancreatic tumor cells (5x106) mixed with EGFP- transduced human 
lymphocytes (EGFP-L) (5x106). Animals received doxycycline in the drinking water (n=3 per group). To test whether the 
transgene was successfully switched on in the conditional tet-on vector, tumors were analysed for EGFP as a marker gene. 
Shown is a BxPc-3 + EGFP-L cryosection from animals treated with 200µg/ml doxycycline in the drinking water. 
Immunofluorescence and immunohistochemistry for EGFP were used to detect transduced and conditionally activated 
lymphocytes. 400x magnification. 
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2.4.4 BsAb EpCAMxCD3 treatment in BxPc-3 + TRAIL-L and PC-3 + TRAIL-L 
xenografts 
2.4.4.1 Growth retardation of BxPc-3 + TRAIL-L and PC-3 + TRAIL-L xenografts by 
bsAb EpCAMxCD3 
 
In EpCAMxCD3 treatment experiments, human pancreatic BxPc-3 cells were s.c. 
transplanted with human TRAIL-L (BxPc-3 + TRAIL-L) into NOC/SCID mice. (Fig 16 III.). 
Three days after cell implantation, animals received i.p. injections of bsAb EpCAMxCD3. 
The animal groups received EpCAMxCD3 at a dose of 0.01 mg/kg, 0.1 mg/kg and the 
treatment control groups received parental bivalent anti-CD3 and anti-EpCAM mAbs or PBS. 
The bsAb treatment was repeated four times with a three-day interval. Another control group 
received BxPc-3 co-transplanted with only pre-activated lymphocytes and PBS treatment 
BxPc-3 + L. This group served as a negative control for the use of TRAIL-L. The same model 
was used for the human prostate PC-3 cell lines: PC-3 + TRAIL-L and PC-3 + L. 
In BxPc-3 + TRAIL-L and PC-3 + TRAIL-L xenografts, tumor take was 100% (6/6) in the 
PBS, the parental anti-CD3 and anti-EpCAM mAb, irrelevant bsAb CD19xCD3 and the 
BxPc-3 + L control group. The two groups treated with EpCAMxCD3 at a dose of 0.01 
mg/kg and 0.1 mg/kg had a reduced tumor take of 83% (5/6) (Fig 16 C). Repeated 
measurements of tumor growth during a period of 23 days revealed, that the tumor growth of 
BxPc-3 + TRAIL-L xenografts was reduced in all groups compared to the BxPc-3 + L group 
with co-transplanted pre-activated lymphocytes, which developed the largest tumors.  
The growth retardation was most significant between groups, which had received bsAb 
EpxCAMxCD3 at a dose of 0.1 mg/kg and 0.01 mg/kg, compared to the treatment control 
groups, which had received PBS, parental bivalent anti-CD3 and anti-EpCAM mAb or 
irrelevant bispecific CD19xCD3. Even very low doses of EpCAM (0.01 mg/kg) resulted in a 
reduced tumor volume (Fig 16 A). At day 23 the tumor weight was significantly reduced in 
the BxPc-3 + TRAIL-L groups treated with EpCAMxCD3 compared to controls (Fig 16 B). 
Similar results were obtained for PC-3 + TRAIL-L xenografts treated with EpCAMxCD3 
(Fig 16 A, B). Surprisingly, a very low dose of EpCAMxCD3 (0.01 mg/kg) was the most 
effective dose in retarding PC-3 growth. 
Interestingly, in BxPc-3 tumors, which had been co-transplanted with TRAIL-L, intra-tumoral 
liquid filled cysts could be observed. Cysts were detected in all BxPc-3 + TRAIL-L groups, 
but not in the BxPc-3 + L control group. This observation could not be made for PC-3 + 
TRAIL-L or the PC-3 + L xenografts. There was no apparent relationship between the cyst 
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formation and antibody treatment. However, the largest cysts were formed in the groups that 
received TRAIL-L lymphocytes and EpCAMxCD3. These cysts, which filled the BxPc-3 + 
TRAIL-L tumors, made the comparison of the volume and weight determination impossible 
(Fig 16 C). 
The body weight of tumor-bearing mice was not affected by the EpCAMxCD3 treatment 
(data not shown). Furthermore, animals that received TRAIL-L did not develop metastasis I 
lungs, liver and spleen as analysed macroscopically and by immunohistochemistry anti 
panCK (human cytokeratins 4, 5, 6, 8, 10 and 18) and by flow cytometry anti-human MHC I 
(data not shown). 
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Fig 16 Efficiency of bsAb EpCAMxCD3 treatment in pancreatic BxPc-3 + TRAIL-L and prostate PC-3 + TRAIL-L 
xenografts 
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III.) Scheme of in vivo experiment. NOD/SCID mice were s.c. transplanted with BxPc-3 pancreatic or PC-3 prostate tumor 
cells (5x106) mixed with TRAIL-transduced human lymphocytes (TRAIL-L) (5x106). Three days later animals were 
randomized to 6 groups (n=6) and received i.p. injections of bsAb EpCAMxCD3 or controls. Treatment was repeated 4 times 
with a three day interval as described in M&M. Animals received either bsAb EpCAMxCD3 at a dose of 0.1mg/kg or 0.01 
mg/kg, control parental bivalent anti-human EpCAM and anti-CD3 mAbs or irrelevant bsAb CD19xCD3 at a dose of 1 
mg/kg or PBS. An additional control group had received non-tranduced lymphocytes (L) co-injected with tumor cells and 
had been treated with PBS. (A) External tumor size was measured every third day. Data is presented as growth kinetics of 
mean of individual tumors with standard deviation. (B) The weight of tumors is shown at the end-point of the treatment at 
day 23. ∗ p<0.05. (C) The table shows the tumor take and cyst formation in pancreatic BxPc-3 and prostate PC-3 xenografts.  
 
2.4.4.2 Apoptosis induction, proliferation and blood vessel density in BxPc-3 + TRAIL-
L and PC-3 + TRAIL-L xenografts by bsAb EpCAMxCD3 
 
The growth retardation of BxPc-3 + TRAIL-L and PC-3 + TRAIL-L tumors could be due to 
several mechanisms. First, BxPc-3 + TRAIL-L and PC-3 + TRAIL-L tumors were analysed 
for the induction of apoptosis. Cryosections of tumors were subjected to TUNEL assay and to 
immunohistochemistry to detect active caspase 3. There was no major difference in the 
density and in the percentage of active caspase 3 – positive cells between EpCAMxCD3 
treated tumors and controls (Fig 17 A, B). Analysis of TUNEL staining revealed similar 
results. These results were comparable to those from BxPc-3 + L and PC-3 + L xenografts. 
Therefore, tumor growth retardation was not due to the induction of apoptosis at the time of 
observation. 
The analysis of the tumor tissue at the endpoint of the bsAb treatment on day 23 could be 
critical in our treatment experiments. For an earlier time of observation, the experiment with 
BxPc-3 co-transplanted with TRAIL-L and subsequent treatment with EpCAMxCD3 was 
repeated as described and stopped on day 14 after cell transplantation. Nevertheless, 
immunohistological analysis revealed comparable numbers of apoptotic cells in the tumor 
tissue (data not shown).  
Second, to understand the tumor growth retardation after the bsAb treatment, tumor tissue 
samples were analysed for changes in tumor cell proliferation and in the blood vessels. In 
BxPc-3 + TRAIL-L and PC-3 + TRAIL-L tumors, a significant reduction in the number of 
CD31+ blood vessels could be observed. The density of CD31+ blood vessels was decreased 
by around 30-40% in BxPc-3 and PC-3 tumors co-transplanted with TRAIL-L compared to 
control tumors with non-transduced lymphocytes. Also the number of Ki-67+ cells was 
strongly decreased by around 40% in EpCAMxCD3 treated groups compared to the parental 
bivalent anti-CD3 and anti-EpCAM mAb, irrelevant bsAb CD19xCD3 control groups (Fig 17 
C, D).  
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Summarized, low doses of EpCAMxCD3 were sufficient to retard the tumor growth in BxPc-
3 + TRAIL-L and PC-3 + TRAIL-L xenografts. Co-transplanted TRAIL-L in BxPc-3 + 
TRAIL-L xenografts further retarded the tumor growth compared to the BxPc-3 + L group. In 
the EpCAMxCD3 treated tumor tissues, a significant reduction of CD31+ blood vessel number 
and a reduced number of proliferating cells could be detected. However, the induction of 
apoptosis could not be detected at the time of observation. The repetition of the bsAb 
treatment experiment with a time of analysis on day 14 did not result in a different result. This 
result showed, that the analysis of time points earlier than 14 days is necessary for the 
explanation of the mechanisms underlying the growth retardation in xenografts.  
However, earlier time points cannot be analysed in this in vivo model due to the small size of 
the xenografts and the availability of engrafted tumor material.  
 
Fig 17 Effects of bsAb EpCAMxCD3 treatment on apoptosis induction, proliferation and blood vessel density in BxPc-
3 + TRAIL-L and PC-3 + TRAIL-L xenografts 
To evaluate whether the anti-tumor effects of TRAIL-L and EpCAMxCD3 were due to apoptosis induction, BxPc-3 and PC-
3 tumor samples were subjected to TUNEL assay and to immunohistochemistry to detect active caspase 3. (A) Density and 
percentage of apoptotic cells stained for active caspase 3. (B) Density of apoptotic cells visualized by TUNEL staining. (C) 
To evaluate whether anti-tumor effects of TRAIL-L and EpCAMxCD3 influenced tumor cell proliferation, BxPc-3 and PC-3 
tumors were subjected to immunohistochemistry to detect Ki-67 density. (D) To evaluate the impact on blood vessel density, 
tissue sections were stained for CD31 blood vessel density. ∗ p<0.05. 
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2.4.5 Efficiency of TRAIL-L and bsAb EpCAMxCD3 in vitro 
2.4.5.1 Migration of lymphocytes and contacts duration of carcinoma cells and 
lymphocytes linked by bsAb EpCAMxCD3 
 
The time of observation is critical for the explanation of the mechanism of the growth 
retardation in BxPc-3 and PC-3 xenografts co-transplanted with TRAIL-L and treated with 
EpCAMxCD3 in vivo. To understand these mechanisms and to analyse early events in the 
tumor cell and their interaction with lymphocytes following the bsAb treatment, in vitro 
experiments were set up.  
Bispecific antibody EpCAMxCD3 has the dual specificity to target lymphocytes to tumor 
cells by binding to CD3 expressed on lymphocytes and by binding to EpCAM on tumor cells. 
EpCAMxCD3 together with either TRAIL-L or pre-activated lymphocytes had shown an anti-
tumor effect in vivo. To analyse the ability of EpCAMxCD3 to bring lymphocytes in close 
contact with carcinoma cells, a collagen gel 3D tumor reconstruct system was utilized. BxPc-
3 and human lymphocytes were co-cultivated in a collagen matrix, which closely resembles 
the tumor microenvironment. Lymphocytes are able to migrate freely in the gels. Dynamic 
cell-cell interactions were analysed using time-lapse video microscopy. Contact duration 
between lymphocytes and tumor cells was approximately three times longer in the presence of 
EpCAMxCD3 compared to control Abs (Fig 18 A). Pre-loading of lymphocytes with 
EpCAMxCD3 more efficiently increased the contact time with carcinoma cells. To delineate 
effects of EpCAMxCD3 on lymphocyte locomotion, lymphocyte migration velocity and the 
percentage of migrating lymphocytes in 3D collagen gels were determined. EpCAMxCD3 did 
not influence lymphocyte velocity (Fig 18 B). Lymphocyte migration velocity in 3D gels was 
as high as 60 times of that of tumor cells. Similar results were obtained for TRAIL-L (data not 
shown). The proportion of actively migrating lymphocytes was slightly decreased after the 
exposure to EpCAMxCD3 compared to controls (Fig 18 C). 
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Fig 18 Effects of bsAb EpCAMXCD3 on migratory properties of lymphocytes and duration of contacts between 
lymphocytes and tumor cells 
To evaluate the influence of EpCAMxCD3 on lymphocyte migration velocity and their interactions with tumor cells, the 
motility of pe-activated lymphocytes was monitored in 3D collagen gels using time-lapse microscopy. Lymphocytes and 
BxPc-3 cells were mixed at a concentration of 2x105 cells per collagen gel. Lymphocytes were either pre-incubated with 
EpCAMxCD3 at 10 µg/ml or bsAb was added directly to the collagen solution prior to the 3D gel polymerization. Control 
irrelevant bsAb CD19xCD3 or control bivalent parental anti-human EpCAM mAb were added to the collagen solution prior 
to the 3D gel polymerization. Lymphocyte migration and their interactions with carcinoma cells were monitored for 1.5 
hours. (A) Contact time of migrating lymphocytes and tumor cells. Contacts between a single lymphocyte and a single tumor 
cell were analysed using a „frame to frame“ method in CapImage software as described in M&M. (B) Effects of 
EpCAMxCD3 on lymphocyte migration velocity and (C) the percentage of migrating lymphocytes in 3D collagen gels. 
 
2.4.5.2 Apoptosis induction by bsAb EpCAMxCD3 in 3D tumor reconstructs 
 
To further investigate the effects of EpCAMxCD3 in vitro, a collagen gel 3D tumor 
reconstruct system was utilized. These 3D gels mimic a tumor microenvironment and allow 
an easy and controlled setting for the study of tumor cell and lymphocyte interactions, 
cytokine production and apoptosis induction. 3D gels consist of a collagen matrix in which 
carcinoma cells are embedded with lymphocytes and incubated together with fibroblasts. 
Lymphocytes are able to freely migrate in these 3D gels. EpCAMxCD3 or control Abs were 
added to preformed gels to allow diffusion (Fig 19). 
!"
#
$
%
&'
&(
'%
'#
'$
)'
)(
*
+
,
-.
/
-0
1
2
3.
-4
+
,
05
6
4,
7
,
+
0!
8
9
:
;
*
!
<
*
=
&
>
?
*
=
)
:
;
*
!
<
?
*
=
)
:
;
*
!
<
?
*
=
)
;
3@
A+
.
1
0'
0B
*"
C
D
6
;
B
+
/
D
-@
06
4E
3.
-4
+
,
05
F
7
C
D
6
;
B
+
/
D
-@
0G
@
A+
/
4-
D
00
00
00
00
56
6
H6
4,
7
I"
:;*!<
*=&>?*=)
:;*!<?*=)
:;*!<?*=)
;3@A+.10'0B
,+0!89
%
J
&%
&J
'%
'J
%
&%
'%
)%
#%
Results 
 60 
 
Fig 19 Scheme depicting the composition of collagen gel 3D tumor reconstructs 
 
To analyse short-term effects of bsAb treatment, the induction of apoptosis was analysed in 
3D tumor reconstructs. The effects of EpCAMxCD3 were analysed after 24 and 72 hours. A 
protein array system was utilized to detect the presence of apoptosis-related proteins. In 3D 
tumor reconstructs BxPc-3 or PC-3 tumor cells, human lymphocytes and fibroblasts were co-
cultivated in the collagen matrix. In these 3D gels, the incubation of pre-activated 
lymphocytes with EpCAMxCD3 resulted in the production of cleaved caspase 3, catalase, 
cytochrome c and Hsp70. In control 3D reconstructs incubated with control irrelevant bsAb 
CD19xCD3 no apoptosis-related proteins could be detected (Fig 20 A), suggesting a 
contribution of bsAb EpCAMxCD3 to the apoptosis induction in vitro.  
To investigate the question whether the effects of EpCAMxCD3 on apoptosis-induction could 
be enhanced by TRAIL-L, BxPc-3 or PC-3 tumor cells were mixed with TRAIL-L and 
fibroblasts in 3D tumor reconstructs. The presence of apoptosis-related proteins was detected 
(Fig 20 B). Compared to 3D reconstructs with pre-activated lymphocytes and tumor cells,  
apoptosis-related proteins were dramatically upregulated after 24 hour incubation and the 
presence of Bax, pro-caspase-3, cleaved caspase 3, catalase, claspin, cytochrome c, TRAIL-
R2, FADD, Fas/TNFSF6, HIF-1a, HO1/HMOX1/Hsp32, Hsp27, Hsp60, Hsp70, 
HTRA2/Omi, p27/kip1, SMAC/Diablo, Survivin and XIAP was detected. There was no major 
difference in the expression level between BxPC3 and PC-3 3D tumor reconstructs. The 
analysis of the pixel density of the spots revealed that the addition of EpCAMxCD3 to the 
gels did not influence the expression of apoptosis-related proteins (Fig 20 C). Addition of 
EpCAMxCD3 to 3D tumor reconstructs did not influence the expression of apoptotic proteins 
after 24 hours.   
Since the manipulation of lymphocytes by isolation, handling in cell culture and the 
transduction procedure could potentially affect the functions of lymphocytes, the 3D tumor 
reconstructs were repeated with TRAIL-L compared to mock-tranduced lymphocytes 
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(MOCK-L). Therefore, 3D reconstructs were prepared consisting of i) BxPc-3 mixed with 
TRAIL-L or ii) BxPc-3 mixed with TRAIL-L incubated with EpCAMxCD3 and were 
compared to 3D reconstructs consisting of iii) BxPc-3 mixed with control MOCK-L or iv) 
BxPc-3 mixed with MOCK-L incubated with EpCAMxCD3. The expression levels of 
apoptosis-related proteins were not significantly different between these groups. The protein 
expression result after 24 hour incubation was stronger compared to 72 hours. The panel of 
induced apoptosis-related proteins was the same as in the previous experiments shown in (Fig 
20, data not shown) 
 
Fig 20 Effects of TRAIL-L and bsAb EpCAMxCD3 on apoptosis induction in 3D tumor reconstructs 
The ability of TRAIL-L and EpCAMxCD3 to induce apoptosis-related proteins was analysed in 3D tumor reconstructs. 
Supernatants were collected after 24 hours and apoptosis-related proteins were detected with a human apoptosis antibody 
array kit. (A,B) X-ray film images of membranes with spots of apoptosis-related proteins from pooled supernatants (n=4) 
from 3D tumor reconstructs incubated for 24 hours with bsAb EpCAMxCD3 at a dose of 10µg/ml or with PBS as a control. 
Three pairs of positive control spots are located in the corner of each array. (A) X-ray films from gels consisting of BxPc-3 
cells and pre-activated lymphocytes mixed with fibroblasts. The location of the protein spots on the membranes is indicated 
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by numerical (1-12) and literal (A-E) coordinates. The incubation of pre-activated lymphocytes with EpCAMxCD3 resulted 
in the detection of cleaved caspase 3(B6), catalase (B7), cytochrome c (B12) and Hsp70 (C10). 
 (B) X-ray films from gels consisting of BxPc-3 or PC-3 cells and TRAIL-L mixed with fibroblasts and incubated with 
EpCAMxCD3 or with PBS. The location of the protein spots on the membranes is indicated by numerical (1-12) and literal 
(A-E) coordinates. The presence of Bax (B2), pro-caspase-3 (B5), cleaved caspase 3 (B6), catalase (B7), claspin (B10), 
cytochrome c (B12), TRAIL-R2 (C2), FADD (C3), Fas/TNFSF6 (C4), HIF-1α (C5), HO1/HMOX1/Hsp32 (C6), Hsp27 
(C8), Hsp60 (C9), Hsp70 (C10), HTRA2/Omi (C11), p27/kip1 (D3), SMAC/Diablo (D8), Survivin (D9) and XIAP (D11) 
was detected. (C) Analysis of the pixel density as the average signal of the duplicate spots representing each apoptosis-related 
protein quantified using ImageJ software. One representative analysis of 3D tumor reconstructs of PC-3 mixed with TRAIL-
L with bsAb EpCAMxCD3 or with PBS is shown (upper B panel).  
 
 
2.4.5.3 Production of TNF-α , IFN-γ , granzyme B and perforin induced by 
EpCAMxCD3 by pre-activated lymphocytes in 3D tumor reconstructs 
 
To analyse the production of cytokines, pre-activated lymphocytes were mixed with 
carcinoma cells and incubated with fibroblasts. EpCAMxCD3, parental bivalent EpCAM 
mAb or irrelevant bsAb CD19xCD3 were added to the polymerized gels. EpCAMxCD3 was 
used at a dose of 10 µg/ml in 3D tumor reconstruct experiments, since this concentration had 
been found to be optimal in previous cytotoxic T cell assays [128]. The addition of 
EpCAMxCD3 to 3D tumor reconstructs with pre-activated lymphocytes significantly 
increased the production of IFN-γ and TNF-α compared to controls (Fig 21). Levels of IFN-γ 
and TNF-α were low in control 3D tumor reconstructs without any Abs or in gels without 
carcinoma cells (data not shown). The secretion of cytolytic granzyme B was not influenced 
by EpCAMxCD3 in 3D tumor reconstructs with pre-activated lymphocytes. However, 
perforin levels were increased under the influence of EpCAMxCD3 after 72h of incubation 
compared to controls (Fig 21). To investigate whether EpCAMxCD3 induces polyclonal 
activation of T cells including regulatory T cells, we analyzed secretion of inhibitory 
cytokines IL-10 and TGF-β1. Only trace amounts of IL-10 were detectable in 3D tumor 
reconstructs with pre-activated lymphocytes. The level of TGF-β1 was around 100-200 pg/ml 
and was not affected by EpCAMxCD3 (data not shown).  
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Fig 21 Effects of bsAb EpCAMxCD3 on the production of IFN-γ , TNF-α , granzyme B and perforin by pre-activated 
lymphocytes in 3D tumor reconstructs 
The production of IFN-γ, TNF-α, granzyme B and perforin in collagen gel 3D tumor reconstructs was analysed. BxPc-3 
carcinoma cells were mixed with non-activated or pre-activated human lymphocytes and fibroblasts and EpCAMxCD3, 
control parental anti-human EpCAM mAb, or irrelevant bsAb CD19xCD3, respectively, were added to 3D tumor 
reconstructs (n=4 per group) after the collagen gel polymerization. Supernatants from 3D tumor reconstructs were collected 
after 24 or 72 hours of incubation and analysed by ELISA. ∗ p<0.05. 
 
2.4.5.4 Activation of non-stimulated PBMCs by EpCAMxCD3 in the presence of 
carcinoma cells in 3D tumor reconstructs 
 
To evaluate the ability of EpCAMxCD3 to activate PBMCs in the presence of carcinoma 
cells, 3D tumor reconstructs with non-stimulated PBMCs were used. Bivalent anti-CD3 mAb 
was used as a positive control and irrelevant bsAb CD19xCD3 or parental bivalent anti-
EpCAM mAb as negative controls. Activation of PBMCs was analyzed by the production of 
the effector cytokines IFN-γ, TNF-α and IL-2. EpCAMxCD3 induced a strong production of 
IFN- γ,  TNF-α and to a lesser extend IL-2 (Fig 22 A). EpCAMxCD3 was more efficient in 
stimulating IFN- γ and TNF-α in PBMCs than a bivalent anti-CD3 mAb administered at the 
same dose after 24 hours and TNF-α after 72 hours of incubation. Granzyme B levels were 
50% higher in 3D tumor reconstructs after 24 hours compared to controls. There was no 
difference in granzyme B after 72 hours (Fig 22 B). The perforin level was increased after 24 
hours, reaching an comparable level after 72 hours in all groups. Similarly, a loading of non-
stimulated PBMCs with EpCAMxCD3 for 2 hours prior to 3D tumor reconstruct experiments 
resulted in an increased production of IFN-γ and TNF-α compared to an addition of 
EpCAMxCD3 to the 3D gels. Thus in 24 hours of incubation the level of IFN-γ increased by 
45% and in 72 hours by 70%. In 24 hours of incubation the production of TNF-α was 
increased by 20%, compared with an about 8 times increase in TNF-α production in 72 hours 
(data not shown). In contrast to 3D tumor reconstructs with pre-activated lymphocytes, 
EpCAMxCD3 induced the production of the inhibitory cytokine IL-10 with non-stimulated 
lymphocytes. Production of TGF-β1 was between 50 and 100 pg/ml (Fig 22 C). Since 
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monocyte derived IL-1β can induce the TGF-β production by fibroblasts, its concentration 
was analysed in 3D tumor reconstructs. The IL-1β level was around 300 pg/ml in all 3D 
tumor reconstructs and EpCAMxCD3 did not influence IL-1β production. IL-10, IL-1β and 
TGF- β1 were not detectable in 3D tumor reconstructs without PBMCs.  
 
Fig 22 Effects of bsAb EpCAMxCD3 on the production of IFN-γ , TNF-α , IL-10, TGF-β1 granzyme B and perforin by 
non-stimulated PBMCs in 3D tumor reconstructs 
The ability of EpCAMxCD3 to induce the effector cytokines IFN-γ, TNF-α and IL-2 by non-stimulated PBMCs was 
analysed in 3D tumor reconstructs (A). BxPc-3 carcinoma cells were mixed with non-stimulated PBMCs and fibroblasts and 
were incubated in 3D collagen gels for 24 or 72 hours (n=4). EpCAMxCD3, control parental anti-human EpCAM mAb, 
irrelevant bsAb CD19xCD3 or control bivalent anti-CD3 mAb, respectively, were added to 3D tumor reconstructs after the 
collagen gel polymerization. (C) The ability of EpCAMxCD3 to induce the production of IL-10 and TGF-β1 by non-
activated PBMCs was analysed. (B) The levels of granzyme B and perforin in collagen gels were analysed. Cytokine levels 
in supernatants from 3D collagen gels were analysed by ELISA. ∗ p<0.05. 
 
2.4.5.5 Production of cytokines induced by bsAb EpCAMxCD3 by non-activated 
lymphocytes in 3D tumor reconstructs 
 
Lymphocytes are able to produce a variety of cytokines upon activation apart from effector 
cytokines such as IFN-γ and TNF-α, which can shape the immune response in vivo. The 
production of cytokines by lymphocytes was analysed in 3D tumor reconstructs in vitro (Fig 
21). 3D tumor reconstructs consisted of BxPc-3 mixed with non-stimulated lymphocytes and 
fibroblasts and were either incubated with EpCAMxCD3 or with control irrelevant bsAb 
CD19xCD3. Out of 36 analysed cytokines and chemokines, 16 molecules could bed detected 
(Fig 23). The expression of GROα,  sICAM-1, IL-1α, IL-1β, IL-6, IL-8, MIF, MIP-1α, MIP-
1β, Serpin E1 and RANTES was similar in 3D tumor reconstructs incubated with 
EpCAMxCD3 and in 3D reconstructs with CD19xCD3. However, IFN-γ was exclusively 
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detected in 3D reconstructs incubated with EpCAMxCD3. In addition in 3D reconstructs 
incubated with irrelevant bsAb CD19xCD3 G-CSF, GM-CSF, TNF-α, IP-10, I-TAC, IL-16 
and IL-1ra (Fig 23).  
These cytokines could be grouped into the effector cytokines IFN-γ and TNF-α, the acute 
phase cytokines IL-1α, IL-1β, IL-6 and the inflammatory sICAM-1, and the chemoattractants 
IL-8, MIF, MIP-1α, MIP-1β, Serpin E1, G-CSF, GM-CSF, GROα,  IL-16, IP-10, I-TAC and 
RANTES.  
 
Fig 23 Effects of bsAb EpCAMxCD3 and lymphocytes on cytokine production in 3D tumor reconstructs and in tumor 
lysates 
To analyse and compare the cytokine panels supernatants of 3D tumor reconstructs were collected after 24 hours and 
cytokines were detected using a human cytokine protein array kit. X-ray images of membranes with spots for cytokines in 
pooled supernatants from 3D tumor reconstructs consisting of BxPc-3 tumor cells, non-activated lymphocytes and fibroblasts 
incubated with bsAb EpCAMxCD3 at a dose of 10 µg/ml or with controls. Three pairs of positive control spot are located in 
the corner of each array. The location of the protein spots on the membranes is indicated by numerical (1-12) and literal (A-
E) coordinates. The expression of CXCL-1/GROα (A6), sICAM-1 (A8), IL-1α (Β2), IL-1β (Β3), IL-6 (B8), IL-8 (B9), MIF 
(D6), MIP-1α (D7), MIP-1β (D8), Serpin E1 (D9) and RANTES (E2) was similar in 3D reconstructs incubated with 
EpCAMxCD3 or incubated with irrelevant bsAb CD19xCD3. INF-γ (Α9) was exclusively detected in 3D reconstructs 
incubated with EpCAMxCD3. In addition, in 3D tumor reconstructs with irrelevant bsAb CD19xCD3 G-CSF (A4), GM-CSF 
(A5), TNF-α (E4), IP-10 (D3), I-TAC (D4), IL-16 (C5) and IL-1Ra (B4) were expressed. 
 
Taken together, apoptosis could be detected in 3D tumor reconstructs by the induction of 
apoptosis-related proteins in vitro. In 3D tumor reconstructs of carcinoma cells mixed with 
pre-activated lymphocytes, addition of EpCAMxCD3 resulted in the induction of apoptosis-
related proteins compared to no induction in control gels. The induction of specific proteins 
was the highest in 3D gels from cancer cells mixed with TRAIL-L. In these gels, the 
incubation with EpCAMxCD3 resulted in no difference compared to the control group, 
indicating a high contribution of TRAIL-L to the induced apoptosis in vitro. The ability of 
TRAIL-L or MOCK-L to induce apoptosis-related proteins in vitro was not further enhanced 
by EpCAMxCD3. It was demonstrated that EpCAMxCD3 potently stimulated pre-activated 
lymphocytes and non-stimulated PBMCs to secrete effector cytokines in 3D tumor 
reconstructs in the presence of EpCAM-expressing carcinoma cells. In 3D tumor reconstructs 
composed of carcinoma cells mixed with lymphocytes and fibroblasts, the addition of 
EpCAMxCD3 resulted in the increased production of the effector cytokines IFN-γ and TNF-α 
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and in the production of granzyme B and perforin by pre-activated lymphocytes. Experiments 
with non-stimulated PBMCs resulted in lower levels of these effector molecules. However, 
the inhibitory cytokines IL-10 and TGF-β1 could be detected after 24 hours. The levels of IL-
10 and TGF-β1 decreased after 72 hours. EpCAMxCD3 was shown to monovalently activate 
non-stimulated PBMCs. Furthermore, in vitro experiments in collagen gels showed the ability 
of bsAb EpCAMxCD3 to target lymphocytes to the tumor cells. EpCAMxCD3 mediated a 
prolonged contact time without affecting the migratory proportion and velocity of 
lymphocytes.  
2.4.6 Infiltration of BxPC3 + L and BxPc-3 + TRAIL-L xenografts with host 
macrophages 
 
EpCAMxCD3 increased the anti-tumor efficiency of TRAIL-L and was effective in BxPc-3 + 
TRAIL-L xenografts. At the time of analysis, a significantly reduced number of proliferating 
cells and a diminished blood vessel density were observed after the treatment. However, the 
involvement of apoptosis as detected by immunohistochemistry can be excluded. In addition, 
necrotic areas could not be observed in the tumor tissues (data not shown).   
With the observed production of cytokines by lymphocytes in 3D tumor reconstructs in vitro, 
the cytokine production was analysed in the tumor tissues. Tumor extracts from BxPc-3 + L 
xenografts treated with EpCAMxCD3 (1 mg/kg) were compared to tumor lysates from BxPc-
3 + L xenografts treated with PBS for their local cytokine expression at the endpoint of the 
treatment at day 23 (Fig 24 A). Detectable levels of sIACM-1, IL-1α, IL-1β, IL-1ra, MIF and 
Serpin E1 could be found. The only difference between EpCAMxCD3 and PBS treated BxPc-
3 + L xenografts, was the absence of sICAM-1 in bsAb treated mice. Compared to the in vitro 
cytokine levels, the detected cytokine levels were lower and less cytokines could be detected 
in the tumor. 
The observation, that these cytokines were present in the tumor tissue, led to the question, 
whether these chemoattractants would affect immune cells of the mouse. Consequently, 
BxPc-3 and PC-3 tumor tissues were analysed for the infiltration with mouse immune cells. 
CD68+ - and F4/80+ - positive mouse macrophages and single Gr-1+ -positive granulocytes 
were detected in the xenografts. In all tumors, CD68+ and F4/80+ macrophages were found at 
the rim in the periphery of the tumor and inside the stroma. In BxPc-3 xenografts a clear 
difference could be detected between tumors, which had received co-injected TRAIL-L or 
pre-activated lymphocytes with EpCAMxCD3 treatment and tumors, which had received 
PBS. EpCAMxCD3 treatment of BxPc-3 tumors promoted the infiltration of tumor islets with 
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CD68+ and F4/80+ macrophages. In the PBS group, CD68+ and F4/80+ macrophages were 
detected at the rim and in the outer stroma of the tumors. In the EpCAMxCD3 treated groups, 
macrophages could be found to penetrate deeper into the tumor stroma and more single 
infiltrating cells could be detected inside the tumor islets (Fig 24, data not shown).  
Also, the possibility of a local NF-κB mediated inflammation was analysed. 
Immunohistochemical analysis for NF-κB by staining for c-Rel and Rel A were negative (data 
not shown). 
Summarized, the cytokine production by co-transplanted lymphocytes in the xenografts, 
attracted host CD68+ and F4/80+ macrophages into the tumor islets, without inducing a NF-
κB mediated inflammation. 
 
Fig 24 Effects of bsAb EpCAMxCD3 on cytokine production in tumor lysates and effects of bsAb EpCAMxCD3 and 
co-injected TRAIL-L on xenograft infiltration with host macrophages 
(A) To analyse and compare the cytokine panels in vivo, tumor lysates were collected and cytokines were detected using a 
human cytokine protein array kit. X-ray images of membranes with spots for cytokines in pooled tumor lysates from of 
BxPc-3 + L xenografts treated with bsAb EpCAMxCD3 or with PBS. Three pairs of positive control spot are located in the 
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corner of each array. The location of the protein spots on the membranes is indicated by numerical (1-12) and literal (A-E) 
coordinates. MIF (D6), CXCL-1/GROα (A6), IL-1α (Β2), IL-13 (C4), Serpin E1 (D9), IL-1Ra (B4) and sICAM-1 (A8) 
could be detected in tumor lysates at the EpCAMxCD3 or PBS treatment endpoint. (B) Cryosections of BxPc-3 xenografts 
were analysed for the infiltration with host immune cells by immunohistochemistry. Representative stainings from 
established BxPc-3 + L tumors treated PBS compared to BxPc-3 + TRAIL-L treated with EpCAMxCD3 at a dose of 1 mg/kg 
are show. Tumor tissues were stained for mouse CD68; arrows indicate infiltrating host cells. 400x magnification.  
 
2.4.7 EpCAMxCD3 treatment in developed BxPc-3 xenografts 
 
The transplantation of tumor cells mixed with effector cells is an experimental model, which 
is described in the literature. However, this co-injection does not reflect the clinical situation 
very well, when the cancer is already fully developed. To make the results more comparable 
to a clinical situation, another xenograft model was used. The pancreatic BxPc-3 cell line was 
chosen due to the greater sensitivity to EpCAMxCD3 treatment compared to prostate PC-3 
cell line in the previous experiments.  
2.4.7.1 Growth retardation of developed BxPc-3 xenografts by bsAb EpCAMxCD3 
treatment and co-injection of TRAIL-L  
In this model, NOD/SCID mice were s.c. transplanted with BxPc-3 tumor cells. At the time, 
when tumors reached an average size of 80 mm3, TRAIL-L were s.c. injected in the periphery 
of the established tumor. EpCAMxCD3 treatment started at the time of TRAIL-L 
transplantation and was administered i.p. (Fig 25 IV.) The animals received i) s.c. TRAIL-L 
in combination with EpCAMxCD3 treatment at a dose of 0.1 mg/kg, ii) s.c. TRAIL-L in 
combination with EpCAMxCD3 treatment at a dose of 0.01 mg/kg and control groups 
received iii) s.c. TRAIL-L alone, iv) EpCAMxCD3 treatment alone at a dose of 0.1 mg/kg or 
v) PBS. The treatment was repeated three times with a three-day interval.  
Tumor measurements were started with the begin of the EpCAMxCD3 treatment on day 
twelve. Repeated measurement of tumor growth over a period of ten days revealed no 
significant difference in tumor volume and tumor weight, due to massive intra-tumoral cysts 
in the groups, which had received TRAIL-L alone or in combination with EpCAMxCD3 
groups (Fig 25 A). The PBS treated control group did not have detectable cysts (data not 
shown). Therefore, the tumor were analysed with ImageJ software for their vital tissue areas. 
Hematoxylin and eosin stainings of cross-tumor cryo sections were analysed for their viable 
tumor area. The groups that had received TRAIL-L alone, EpCAMxCD3 treatment alone and 
TRAIL-L in combination with EpCAMxCD3 treatment showed an approximately 40% 
reduced viable tumor area compared to the cyst-free PBS control group (Fig 25 C, D). The 
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largest cyst were found in the group that received TRAIL-L and EpCAMxCD3 at a dose of 
0.1 mg/kg.  
To evaluate the short term effect of the EpCAMxCD3 treatment and the transplanted TRAIL-
L, a group of animals was analysed at an early time point after three days (after the begin of 
the bsAb treatment). Ina ll groups, which had received TRAIL-L alone or in combination with 
EpCAMxCD3 intratumoral cysts were detected as early as 3 days after the initiation of the 
treatment on day 12 (Fig 25 D). The PBS treated control group did not have detectable cysts.  
2.4.7.2 Proliferation, blood vessel density and apoptosis induction in developed BxPc-3 
xenografts treated by bsAb EpCAMxCD3 and transplanted with TRAIL-L 
 
The tumor tissues were analysed for changes in proliferation, blood vessel density and 
apoptosis induction. The CD31+ blood vessel density was significantly reduced in all groups, 
which had received TRAIL-L alone or in combination with EpCAMxCD3, compared to the 
PBS control group. The density and percentage of active caspase 3 and TUNEL staining 
revealed no significant difference between the groups (Fig 25 B).  
Examples of immunohistochemical stainings from BxPc-3 xenografts treated with PBS 
compared with BxPc-3 xenografts with s.c. injected TRAIL-L in combination with 0.1 mg/kg 
EpCAMxCD3 treatment are shown in (Fig 26). 
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Fig 25 Efficiency of bsAb EpCAMxCD3 treatment and s.c. injection of TRAIL-L in developed BxPc-3 xenografts 
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(V.) Scheme of in vivo experiment. NOD/SCID mice were s.c. injected with BxPc-3 pancreatic tumor cells (5x106). TRAIL-
L were s.c. injected in combination with EpCAMxCD3 treatment when tumors reached a size 80 mm3 at day 12. On this day 
animals (n=5 per group) were s.c. injected with TRAIL-L (5x106) around the tumor. The treatment with bsAb EpCAMxCD3 
or controls was administered to the animals the same day by i.p. injections. Treatment was repeated 3 times with a three day 
interval as described in M&M. Animals either received s.c. TRAIL-L in combination with EpCAMxCD3 treatment at a dose 
of 0.1 mg/kg, s.c. TRAIL-L in combination with EpCAMxCD3 treatment at a dose of 0.01 mg/kg, control groups received 
s.c. TRAIL-L alone, EpCAMxCD3 treatment alone at a dose of 0.1 mg/kg or PBS. (A) Relative size increase of the tumors is 
shown from day 12. (B, C) To evaluate whether the anti-tumor effects of TRAIL-L and EpCAMxCD3 were due to apoptosis 
induction, BxPc-3 tumor samples were subjected to TUNEL analysis and to immunohistochemistry to detect active caspase 
3. Density and percentage of apoptotic cells in stained for active caspase 3 and tissue samples subjected to TUNEL assay. 
Changes in blood vessel density were analysed by immunohistochemistry stained for CD31. (D, E) One group of animals 
was sacrificed 3 days after the start of the treatment. Tumor morphology and intra-tumoral cyst occurrence was analysed in 
tumor cross sections. BxPc-3 xenografts treated for 10 days and tumors treated for 3 days were analysed by hematoxylin and 
eosin stainings (HE). Pictures of treated animals and HE stainings as cross sections. 100x magnification. (B) Analysis of full 
tumor cross sections for vital tumor area analysed by ImageJ software. ∗ p<0.05. 
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Fig 26 Immunohistochemistry of developed BxPc-3 xenografts after bsAb EpCAMxCD3 treatment and injection of 
TRAIL-L 
Representative sample picture of cryosections of developed BxPc-3 xenografts stained and analysed for active caspase 3, 
TUNEL, Ki-67 and CD31 by immunohistochemistry. Pictures from control BxPc-3 tumors with PBS and BxPc-3 tumors 
after injection of TRAIL-L and EpCAMxCD3 treatment at a dose of 0.1 mg/kg are shown. (A, B) Apoptosis induction 
(active caspase 3 and TUNEL). 400x magnification. (C) Proliferation (Ki-67) upper panel: 400x magnification, lower panel: 
100x magnification. And (D) blood vessel density (CD31) 250x magnification. 
 
2.4.7.3 Infiltration of BxPc-3 xenografts with host macrophages 
 
Many of the cytokines detected in 3D tumor reconstructs and in the tumor lysates of BxPc-3 + 
L and BxPc-3 + TRAIL-L xenografts were chemokines. Therefore, BxPc-3 tumor tissues 
were analysed for potential infiltrating host cells. Cryosections were stained for CD68+ and 
F4/80+ host macrophages. Mouse cells positive for CD68 and F4/80 were detected at the rim 
and to a different extend inside the stroma in all animals. In BxPc-3 xenografts with 
transplanted TRAIL-L alone, with EpCAMxCD3 treatment alone or with transplanted 
TRAIL-L in combination with EpCAMxCD3 treatment single infiltrating CD68+ and F4/80+ 
host cells could be detected inside the tumor islets. In the PBS treated control group, no single 
infiltrating cells could be detected. A comparison between the xenograft models revealed 
further differences. In BxPc-3 derived xenografts with co-injected lymphocytes: BxPc-3 + L 
and BxPc-3 +TRAIL-L, single infiltrating F4/80+ host cells could be detected inside BxPc-3 + 
TRAIL-L tumors treated with EpCAMxCD3 at day 23 after cell transplantation (= 20 days 
after start of the bsAb treatment) (Fig 27 A). Compared to these observations, even more 
F4/80+ host cells could be detected inside developed BxPc-3 tumors after 10 days (Fig 27 B) 
and after 3 days of treatment with EpCAMxCD3 (Fig 27 C).  
Taken together, in the mouse model with developed BxPc-3 xenografts, EpCAMxCD3 
treatment was most effective in combination with s.c. transplanted TRAIL-L. The tumor 
tissue revealed a significant reduction of CD31+ blood vessel density and a reduced number 
of proliferating cells in tumors, which had been treated with EpCAMxCD3 transplanted with 
TRAIL-L. The data indicates that apoptosis induction was not the major mechanism for the 
observed reduced vital tumor area in BxPc-3 xenografts after EpCAMxCD3 treatment at the 
time of the tumor tissue analysis. This verified the anti-tumor effects of EpCAMxCD3 son the 
growth retardation in the BxPc-3 + L and the BxPc-3 + TRAIL-L xenografts. The 
EpCAMxCD3 effects were independent of the application of the lymphocytes. The presence 
and increased infiltration with mouse macrophages suggests a contribution of these host cells 
to the induced anti-tumor effects by EpCAMxCD3 and TRAIL-L.  
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Fig 27 Effects of bsAb EpCAMxCD3 treatment and co-injection of TRAIL-L on xenograft infiltration with host 
macrophages 
Cryosections of BxPc-3, BxPc-3 + L and BxPc-3 + TRAIL-L xenografts were analysed for the infiltration with host immune 
cells by immunohistochemistry. (A) Representative stainings from BxPc-3 + L tumors treated with PBS compared to BxPc-3 
+ TRAIL-L treated with EpCAMxCD3 at a dose of 0.1 mg/kg are show at day 23 after cell transplantation and 20 days after 
begin of the bsAb treatment. (B) Representative stainings from developed BxPc-3 tumors treated with EpCAMxCD3 at a 
dose of 0.1 mg/kg are show at day 22 after cell transplantation and 10 days after begin of the bsAb treatment. (C) 
Representative stainings from established BxPc-3 tumors treated with EpCAMxCD3 at a dose of 0.1 mg/kg are show at day 
15 after cell transplantation and 3 days after begin of the bsAb treatment. Tumor tissues were stained for mouse F4/80, 
arrows indicate infiltrating cells. 250x magnification.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Equipment and consumables 
 
Analytic balance scale (Mettler P220)   Mettler Toledo, Gießen  
Autoradiography film (Amersham HyperfilmTM 
ECL)  GE Healthcare Ltd, Pollards Wood, UK  
Caliper  
Cell culture dishes TPP, Trasadingen, Switzerland  
Cell culture flasks  TPP, Trasadingen, Switzerland  
Cell culture plates  TPP, Trasadingen, Switzerland  
Centrifuge     
- Biofuge 15 R Heraeus, Hanau  
- Varifuge 3.0 R  Heraeus, Hanau  
Centrifuge tubes (15 ml and 50 ml)  TPP, Trasadingen, Switzerland  
Chamber slides  Nunc, Rochester, NY, USA 
CO2 -incubator (Sanyo MCO-20AIC)   MS Laborgeräte, Wiesloch  
CO2 incubator   
Coverslips  Knittelgläser, Braunschweig  
Cryostat (CM 3050) Leica Microsystems, Wetzlar  
Cryotubes  Nunc, Wiesbaden  
Electrophoresis power supply (Phero-Stab. 500V)    Biotec Fisher, Reiskirchen  
Electrophoresis unit (Horizon 11-14)    Life, Karlsruhe  
Embedding molds  Labonord, Mönchengladbach  
FACS LSRII Becton Dickinson, Heidelberg  
Gel documentation system (E-Box)  Vilber Lourmat, Switzerland 
Gloves  VWR, Bruchsal  
Hemacytometer glasses  Fisher Scientific, Nidderau  
Ice maschine (AF 80)  Scotsman (Enodis), Herborn  
Laminar flow hood  Heraeus, Hanau  
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Light microscope  Leica, Wetzlar  
Magnetic stirring hot plate (MR 3001)  Heidolph, Schwabach  
Microcentrifuge (Biofuge 15R)  Heraeus, Hanau  
Microcentrifuge tubes (1,5 ml and 2 ml) Eppendorf, Hamburg  
Microscope slides (Superfrost plus)  Menzel, Braunschweig  
Microwave (HMT 843C)  Bosch-Siemens, München  
NanoDrop® ND-1000 spectrophotometer NanoDrop Technologies, Wilmington, USA 
Neubauer hemacytometer Sigma, Taufkirchen  
Parafilm M Neolab, Heidelberg  
Pasteur pipettes Buddenberg, Mannheim  
pH-meter (pH 538)  WTW, Weilheim  
Pipette controller  pipetus Integra, Fernwald  
Pipette tips (20 µL, 200 µL, 1000 µL) Starlab, Ahrensburg  
Pipettes  Gilson, Middleton, WI, USA  
Power supply (Phero-Stab.500)  Biotech Fischer, Reiskirchen  
Reagent tubes (1,5 ml, 2 ml)  Sarstedt, Nümbrecht  
Repeat pipettor, multistep  Eppendorf, Hamburg  
Shaker (Unimax 2010)  Heidolph, Schwabach  
Spectrophotometer (Smart Spec 3000)  Biorad, München  
Stericup-Filter (0,22 µm)  Millipore, Eschborn  
Thermomixer  Eppendorf, Hamburg  
Vortexer (REAX 2000)  Heidolph, Schwabach  
Waterbath Kottermann, Hänsingen  
Weighing dishes Neolab, Heidelberg  
3.1.2 Media, supplements and reagents for cell culture 
 
DMSO (Dimethylsulfoxide, >99%) AppliChem, Darmstadt 
Albumin (fractionV) Serva, Heidelberg, Germany  
Biocoll  Biochrom, Berlin 
Calcium chloride Sigma, Steinheim 
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Chloroquine Sigma, Steinheim 
Collagen  
Disodiumhydrogenphosphate Roth, Karlsruhe 
DMEM (Dulbecco’s Modified Eagle 
Medium, high glucose) 
PAA, Cölbe 
Doxycycline Sigma, Steinheim  
Dulbecco’s phosphate buffered saline Invitrogen, Karlsruhe 
FBS (Fetal Bovine Serum)  Sigma, Steinheim  
HBSS, Hank’s buffered salt solution 
(10x) 
Sigma, Steinheim 
HEPES PAA, Cölbe 
Human AB serum Sigma, Steinheim 
Human AB Serum Invitrogen, Karlsruhe, Germany 
IL-2 Biosource, Camarillo, CA, USA 
L-glutamine  PAA, Cölbe 
PBS (Phosphate buffered saline) Gibco/Invitrogen, Karlsruhe 
Penicillin-Streptomycin PAA, Cölbe 
Polybrene Sigma, Steinheim  
Protamine sulfate Sigma, Steinheim  
Retronectin  Takara, Saint-Germain-en-Laye, France 
RPMI1640 Medium PAA, Cölbe 
Sodium azide Roth, Karlsruhe 
Sodium chloride Roth, Karlsruhe 
Trypanblue  Biozol, Eching 
Trypsin-EDTA PAA, Cölbe 
Water (Aqua ad injectabilia)  Braun, Melsungen 
x-vivo Cambrex, Charles City, USA 
3.1.3 Kits 
 
DAB Kit Invitrogen, Karlsruhe, Germany 
Human apoptosis antibody array kit ( Proteome 
R&D Systems, Abingdon, UK 
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Profiler) 
Human cytokine antibody array kit ( Proteome 
Profiler) R&D Systems, Abingdon, UK 
IFN-γ ELISA Kit Cell Sciences, Canton, MA, USA 
TNF-α ELISA Kit R&D Systems, Abingdon, UK 
TUNEL (TACS TdT in situ apoptosis 
detection kit) R&D Systems, Abingdon, UK 
Vectastain ABC Elite Kit Linaris, Wertheim-Bettingen, Germany 
3.1.4 Chemicals and biochemicals 
 
7AAD Sigma, Steinheim 
Acetone  J.T.Baker, Deventer, NL 
Agar-Agar AppliChem, Darmstadt 
Agarose Life Technologies, Karlsruhe 
Ampicilline Roth, Karlsruhe 
Avidin D: Texas Red Vector, Burlingame, CA, USA 
Avidin-Biotin Blocking Kit  Vector, Burlingame, CA, USA 
Biocoll Inno-Train Diagnostics Gmbh, Kronberg, 
Germany 
Bovine serum albumin (BSA) New England Biolabs, Frankfurt 
Citric acid Sigma, Steinheim 
DAPI (4’,6-Diamidino-2-phenylindol 
Dihydrochlorid) 
Sigma, Steinheim 
Di-sodium hydrogen phosphate Merck, Darmstadt 
Diaminobenzidine (DAB) Kit Invitrogen, Karlsruhe 
DMSO (Dimethylsulphoxide) Roth, Karlsruhe 
DNA Isolation Kit (DNeasy™ Tissue Kit) Qiagen, Hilden 
DNA Ladder (Mass ruler  DNA ladder 
mix) 
Fermentas, St. Leon-Rot 
EDTA-disodium  Sigma, Steinheim 
embedding medium  for cryo-sections, 
O.C.T. 
Engelbrecht, Edermünde 
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Entellan (mounting medium) VWR, Bruchsal 
Ethanol  Roth, Karlsruhe 
Ethidium bromide   Applichem, Darmstadt 
Fluoromount G Biozol, Eching 
Gel extraction and PCR Purification Kit Qiagen, Hilden 
Gel extraction Kit (QIAquick™) Qiagen, Hilden 
Glycerine Roth, Karlsruhe 
Goat serum  Alexis, Grünberg 
Hematoxylin solution, (Mayer’s) Sigma, Steinheim  
Heparin  StemCell Technologies Inc., Vancouver, 
BC, Canada  
Hydrochloric acid  J.T.Baker, Deventer, NL 
Iodoacetic acid Sigma, Steinheim 
Isopropanol  Roth, Karlsruhe 
Kanamycin  Roth, Karlsruhe 
Klenow fragment  Fermentas, St. Leon-Rot 
Manganese chloride Roth, Karlsruhe 
Methanol Roth, Karlsruhe 
MOPS  Sigma, Steinheim 
Mung bean nuclease Fermentas, St. Leon-Rot 
Paraformaldehyde (37%) Merck, Darmstadt 
Pfu Polymerase  Roche, Basel, Switzerland 
PI Sigma, Steinheim 
Plasmid Maxipreparation Kit  Qiagen, Hilden 
Plasmid Minipreparation Kit  Qiagen, Hilden 
Potassium chloride  Riedel- de Haën, Seelze 
Potassium dihydrogenphosphate  Merck, Darmstadt 
Pwo Polymerase Roche, Basel, Switzerland 
Restriction enzymes NEB 
Rubidium chloride Sigma, Steinheim 
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Sodium acetate Fluka, Buchs, CH 
Sodium chloride Merck, Darmstadt 
Sodium citrate Riedel- de Haën, Seelze 
T4-DNA-ligase Fermentas, St. Leon-Rot 
Tris Base Sigma, Steinheim 
Triton X-100   Sigma, Steinheim 
Trypton Life Technologies, Karlsruhe 
Tween-20  Serva, Heidelberg 
Xylene Merck, Darmstadt 
Xylene-Cyanol Sigma, Steinheim 
Yeast Extract Life Technologies, Karlsruhe 
ZytoChem-Plus HRP polymer Kit  Zytomed Systems, Berlin 
3.1.5 Antibodies 
3.1.5.1 Antibodies in vivo  
 
EpCAMxCD3 (HEA125xOKT3) and CD19xCD3 (HD37xOKT3) bsAb were produced by 
hybrid-hybridoma technique and purified by affinity chromatography over protein A-
Sepharose CL-4B (Amersham Pharmacia Biotech, Freiburg, Germany) followed by HPLC 
purification on a Bakerbond ABx column (J.T. Baker, Phillipsburg, NJ) as described [128]. 
Parental anti-human EpCAM hybridoma (HEA125, IgG1) was raised in the laboratory of G. 
Moldenhauer [106, 131]. Hybridoma OKT3 (IgG2A) directed against the ε-chain of the CD3 
molecule was purchased from the ATCC. Both parental mAb were purified by affinity 
chromatography. 
3.1.5.2 Antibodies for FACS 
 
goat anti mouse  Jackson Immunoresearch 
goat anti mouse –PE Alexis (Enzo), Farmingdale, NY, USA 
iso-type control – FITC Jackson Immunoresearch, West Grove, PA, 
USA 
iso-type control – PE Jackson Immunoresearch, West Grove, PA, 
Materials and Methods 
 81 
USA 
Mouse anti human MHC-class I (HLA-
A,B,C) mAb 
BD Pharmingen, Heidelberg, Germany 
Mouse anti human MHC-class I mAb W6/32 hybridoma, own production 
mouse anti human TRAIL (2E5) mAb Alexis (Enzo), Farmingdale, NY, USA 
mouse anti human CD25 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti human CD4 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti human CD45 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti human CD69 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti human CD8 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti human CD95 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti human EpCAM mAb (HEA125) homemade 
mouse anti human TRAIL-R1 mAb ProSci, Poway, CA, USA 
mouse anti human TRAIL-R2 mAb ProSci, Poway, CA, USA 
3.1.5.3 Antibodies for immunohistochemistry 
 
rat anti mouse F4/80 mAb Acris Antibodies, herford, Germany 
mouse anti human CD45 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti human CD16 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti human CD4 mAb BD Pharmingen, Heidelberg, Germany 
mouse anti humam CD8 mAb BD Pharmingen, Heidelberg, Germany 
rat anti mouse CD31 mAb BD Pharmingen, Heidelberg, Germany 
rat anti mouse Gr-1 (Ly-6g/Ly-6C) mAb BioLegend, San Diego, CA, USA 
mouse anti human c-rel mAb Cell Signaling, Danvers, MA, USA 
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mouse anti human Rel A mAb Cell Signaling, Danvers, MA, USA 
mouse anti GFP (JL-8) mAb Clontech, Montain View, CA, USA 
mouse anti human EpCAM mAb (HEA125) Homemade 
goat anti rat Alexei Fluor 594 IgG Molecular Probes, Eugene, USA 
goat anti mouse Alexa Fluor 488 IgG Molecular Probes, Eugene, USA 
rabbit anti human TRAIL-R1 mAb ProSci, Poway, CA, USA 
rabbit anti human TRAIL-R2 ProSci, Poway, CA, USA 
rabbit anti human active caspase 3 pAb R&D Systems, Abingdon, UK 
rabbit anti humanactive caspase 3 pAb R&D Systems, Abingdon, UK 
rat anti mouse CD68 mAb Serotec, Oxford, UK 
rabbit anti human Ki-67 mAb Thermo Scientific, Rockford, IL, USA  
goat anti mouse IgG biotynilated Vector, Burlingame, CA, USA 
rabbit anti rat IgG biotynilated Vector, Burlingame, CA, USA 
panCK Sigma Aldrich 
3.1.6 Primers 
 
Primer for the cloning of the peptide linker P2A between the two genes TRAIL and EGFP 
into the pV3TP2AE vector.  
Nucleic acid sequence P2A:  
5’-gga agc ggc gcc acg aac ttc tct ctg tta aag caa gca gga gac gtg gaa gaa aac ccc ggt ccc-3’  
5’ primer TRAIL in and P2A (1) 
5’-ttc cac gtc tcc tgc ttg ctt taa cag aga gaa gtt cgt ggc gcc gct tcc gcc aac taa aaa ggc ccc gaa 
aaa act gg-3’ 
3’ primer EGFP in and P2A (2) 
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5’-aac ttc tct ctg tta aag caa gca gga gac gtg gaa gaa aac ccc ggt ccc atg gcc aca acc atg gtg 
agc aag ggc gag ga-3’ 
5’ primer TRAIL out with SpeI site (3) 
5’-cag act agt cac cat ggc tat gat gga ggt ccg-3’ 
3’ primer EGFP out with BamHI site (4) 
5’-cct gga tcc tca ctt gta cag ctc gtc cat gcc-3’ 
3.1.7 Lentiviral plasmids and vectors 
 
All plasmids for production of lentiviral particles contain a SV40 origin of replication and an 
ampicilline resistance gene. 
pV3TP2AE 
 
The vector was originally created by Vogel et al. [129] and modified for the expression of 
human TRAIL and EGFP (short: pV3TP2AE) by standard cloning techniques. The binary 
vector is a second generation self-inactivating SIN vector that allows a conditional expression 
of the transgene under the control of a tet-responsive promotor element (TRE) in the presence 
of doxycycline (Tet-on). Binding of this rtTA2-M2 transactivator to 3 copies upstream of a 
minimal cytamegalovirus (CMVmin) promoter activates transcription. The TRAIL and EGFP 
genes were combined by the Picorna virus-derived peptide elements P2A (2A element of 
porcine teschovirus) as described by Leisegang et al. 2008 [130]). The pV3TP2AE construct 
contains the HIV-1 5’-LTR consisting of the truncated unique sequence 3 (SIN U3), the 
unique sequence 5 (U5) and the redundant sequence R. The rtTA2M2 reverse transactivator is 
under the control of the phosphoglycerate kinase (pPGK) promotor and is followed by the 
bovine growth hormone polyadenylationsignal (BGH polyA). Further elements are the central 
DNA flap sequence (TRIP) and the woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE).  
pV3E 
 
LTR R U5 BGH polyA WPRE SIN U3 U5ReGFPTRAILCMVminTRIPrtTA2-M2 pPGK P2A
LTR R U5 BGH polyA WPRE SIN U3 U5ReGFPCMVminTRIPrtTA2-M2 pPGK
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The vector pV3E, served as control vector for pV3TP2AE and was cloned accordingly just 
with the insertion of the EGFP gene.  
psPAX2 (kindly provided by L. Naldini, Turino, Italy) 
 
The psPAX2 packaging construct is coding for the proteins needed for packaging of the viral 
vector in the producer cell. It carries the gag, pol, tat and rev genes which express the HIV-1 
proteins for the capsid/nucleocapsid (gag), the polymerase/reverse transcriptase/integrase 
(pol), transcription transactivating protein Tat (tat) and expression regulating protein Rev 
(rev). 
pMD2.G (kindly provided by L. Naldini, Turino, Italy) 
 
The pMD2.VSV-G envelope construct contains the Vesicular Stomatitis Virus Glycoprotein 
(VSV-G) and the first intron of the human β-globine gene (β G-Intron) [132]. The VSV-G is 
used to pseudotype the viral envelope in order to transduce a broad host range. 
3.1.8 Bacterial strains 
 
For all transformation experiments E. coli K12 were made chemo-competent as described in 
(Hanahan, 1983). For lentiviral vectors only recA-negative strains HB101 (from Life 
Technologies, Rockville, MD, USA) and TOP10 (Topo-TA cloning Kit; Invitrogen, 
Karlsruhe) were used to prevent inter- and intramolecular recombination. 
HB101 
Genotype: F- mcrB mrr hsdS20 (rB-, mB-) recA13 supE44 ara14 galK2 lacY1 proA2 
rpsL20(Sm
r
) xy15 λ- leu mtl1 
TOP10 
Genotype: F- mcrA Δ( mrr-hsdRMS-mcrBC) φ80 lacZΔM15 Δ lacX74 recA1 araD139 
Δ(araleu) 7697 galU galK rpsL (StrR) endA1 nupG 
CMVenh
Gag
Pro
Pol
RRE
tat/revdV
pA
CMV !G-Intron VSV.G pA
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3.1.9 Commercial cell lines 
 
Primary skin fibroblasts were provided by Dr. H.-J. Stark (DKFZ, Heidelberg, Germany).  
The packaging cell lines human epithelial kidney HEK-293T cell line was obtained from 
American Type Culture Collection (Manassas, VA, USA). Pancreatic cancer cell lines AsPC-
1, BxPc-3, Colo357 and MIA-PaCa2, and prostate cell lines PC-3, DU-145 and LNCap were 
obtained from the American Type Culture Collection (Manassas, VA, USA). Fibroblasts, 
293T and pancreatic cell lines were cultured in DMEM medium supplemented with 10% FCS 
and 10 mM HEPES and prostate cell lines in RPMI medium supplemented with 10% FCS and 
10 mM HEPES.  
3.1.10 Animals 
 
Four-to five-week-old female NOD/SCID mice (NOD.CB17-Prkdcscid/NcrCrl), were 
purchased from Charles River Laboratories (L’Arbresle, France) and were house at the animal 
facility of the DKFZ.  
3.2 Molecular methods 
3.2.1 Production of competent bacteria 
 
For production of competent bacteria, that can be transformed with DNA, the following 
protocol was used (Dagert and Ehrlich, 1979). Bacteria were placed on a LB-agar dish and 
incubated over night at 37°C. One single bacterial colony was taken up in 5 ml LB- medium 
and was placed over night on a shaker at 37°C. Two hundred fifty millilitre of prewarmed 
LB-medium were inoculated with 1 ml of this bacterial culture. The suspension was incubated 
at 37°C on a shaker until the bacterial suspension reached an OD590 value of 0.5. Then 
bacterial suspension was cooled on ice. All following steps were performed on ice and 
solutions were precooled at 4°C. Bacteria were centrifuged at 2900 g for 10 min at 4°C and 
pellet was mixed with 15 ml of buffer A (10 mM calcium chloride, 30 mM potassium acetate, 
100 mM rubidium chloride, 79 mM mangan(II) chloride, 15% glycerine [v/v], pH 5,8). 
Following incubation for 2 h on ice, cells were sedimented at 1250 g for 10 min, 4°C and 
were mixed with 4 ml of buffer B (10 mM MOPS, 10 mM rubidium chloride, 75 mM calcium 
chloride, 15% glycerine [v/v], pH 7). One hundred microliter aliquots were snap frozen in 
liquid nitrogen and stored at -80°C. 
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3.2.2 Media for bacterial cell culture 
 
LB- Liquid medium  
For production of 5x LB-medium, 50 g Trypton, 25 g yeast extract and 25 g NaCl were 
diluted in 1L dH2O and autoclaved. Prior usage medium was diluted 1:5 with sterile dH2O. 
Ampicilline was mixed in the final medium to a concentration of 50 µg/ml.  
LB agar  
Thirty two grams of LB-agar were mixed in 1 L 1x LB-medium and autoclaved. Upon 
cooling down at 40°C, ampicilline (end concentration: 50 µg/ ml) was added and agar was 
placed in Petri dishes. Dishes were stored up to one month at 4°C.  
3.2.3 Cloning of the lentiviral vector pV3TP2AE 
 
The HIV-1-based Tet-on lentiviral vector which was used in all lymphocyte transduction 
experiments. The vector was originally created by Vogel et al. [129] and modified for the 
expression of human TRAIL and EGFP (short: pV3T2AE) by standard cloning techniques. 
The binary vector is a second generation self-inactivating SIN vector that allows a conditional 
expression of the transgene under the control of a tet-responsive promotor element (TRE) in 
the presence of doxycycline (Tet-on). Binding of this rtTA2-M2 transactivator to 3 copies 
upstream of a minimal cytamegalovirus (CMVmin) promoter activates transcription. The 
TRAIL and EGFP genes were combined by the Picorna virus-derived peptide elements P2A 
(2A element of porcine teschovirus) as described by Leisegang et al. 2008 [130]). The 
pV3T2AE construct was verified by sequencing.  
The TRAIL and the EGFP gene were amplified and linked by the P2A peptide linker. 
Therefore, the TRAIL and the EGFP gene were amplified each from the pHRPS-CMV-
TRAIL-IRES-EGFP-WPRE plasmid (Till Wenger (44) modified from the original 
Tronoplasmid pWPTS-GFP and Clontech pIRES2-EGFP (4)) by a touch down PCR with 
primers pairs also encoding the P2A amino acid sequence. 
Touch-down PCR  
with the primer pairs (1) and (3) for the TRAIL gene and (2) and (4) for the EGFP gene (in 
3.1.6). 
94°C 5’ 
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94°C 30’’ 
60°C 30’’          5x 
72°C 30’’ 
 
94°C 30’ 
57.5°C 30’’        5x 
72°C 30’’ 
 
94°C 30’’ 
55°C 30’’          5x 
72°C 30’’ 
 
94°C 30’’ 
52.5°C 30’’       5x 
72°C 30’’ 
 
94°C 30’’ 
50°C 30’’           5x 
72°C 30’’ 
 
72°C 7’ 
cool 
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The resulting fragments (TRAIL-P2Apart and P2Apart-EGFP) were annealed first without 
primers in another touch down PCR  
 
94°C 40’’ 
-1°C/ 6’’          5x 
72°C 2’ 
and then the full length fragment (TRAIL-P2A-EGFP) amplified with the primers (3) and (4) 
in a standard PCR : 
94°C 30’’ 
94°C 30’’ 
56°C 30’’           30x 
72°C 2’ 
72°C 7’ 
cool 
The original lentiviral vector pd500Trip-CMVmin-WPRE (pV3) (by Vogel et al. [129]) was 
opened by restriction digest with SpeI and BamHI. The full length fragment (TRAIL-P2A-E) 
was also digested with SpeI and BamHI, ligated into pV3 and HB101 bacteria were 
transformed. Positive clones were picked by Colony PCR and amplified in HB101. The 
resulting plasmid was opened with SalI and NheI and the rtTA2-M2 transactivator from the 
plasmid pd500-PGK-rtTA2M2-BGHpolya (pV7) (by Vogel et al.) was ligated into the 
plasmid and amplified in HB101. The resulting vector pd500-BGHpolyA-rtTA2M2-
BGHpolya-TRIP-CMVmin-TRAIL-P2A-EGFP-WPRE (pV3TP2AE) was verified by 
sequencing (Eurofins MWG Operon). 
3.2.4 Transformation of bacteria 
 
Chemically competent bacteria are able to uptake plasmids following a heat shock at 42°C. In 
detail, 50 µl of competent bacteria were thawed on ice and were incubated with up to 200 ng 
plasmid-DNA in a maximum of 10 µl dH2O. Following incubation on ice for 30 min a heat 
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shock at 42°C was performed for 90 sec. Subsequently, the bacteria-plasmid mixture was 
incubated for 2 min on ice and then was mixed with 500 µl of pre-warmed LB-medium and 
incubated for 40 min at 37°C. Bacteria were subsequently plated on pre-warmed LB-agar 
dishes and incubated for 15-18 h for selection of ampicilline resistant clones.  
3.2.5 Plasmid mini preparation  
 
Following transformation, single bacterial colonies were picked and incubated over night in 5 
ml LB medium (supplemented with 50 µg/ ml ampicilline) on a shaker (200 rpm) at 37°C. 
Subsequently, bacterial cells were sedimented for 5 min at 6000rpm. The bacterial pellet was 
lysed and the plasmid DNA was isolated and purified according to the manufacturers 
recommendations (Qiagen). 
3.2.6 Plasmid maxi preparation 
 
The plasmid maxi-preparation serves for isolation of large amounts (over 100 µg) of highly 
purified plasmid DNA. The maxi-preparation was performed with the Plasmid Maxi 
preparation Kit (Qiagen) provided with DNA binding columns with silica membranes. Two 
hundred milliliter of bacterial over night culture were seimented for 15 min at 6000 rpm at 
4°C. The bacterial pellet was lysed and the plasmid DNA was isolated and purified according 
to the manufacturers recommendations (Qiagen). The plasmid was purified by a subsequent 
ethanol precipitation.  
3.2.7 Analysis of DNA purity 
 
DNA samples were diluted in dH2O and DNA concentration as well as DNA purity was 
measured spectrometrically by NanoDrop at 260 and 280 nm. An extinction of 1 at 260 nm 
corresponds to 50 µg/ml DNA and protein contamination is detected at 280 nm. The quotient 
of extinction at 260 and 280 nm (E260/E280) determines purity and should have a value 
between 1.8 and 2.  
3.3 Cell biological methods 
3.3.1 Culture of cell lines 
 
Cells were cultured in an incubator at 37°C and 5% CO2. Media were supplemented, if not 
indicated differently, with 10% [v/v] FCS and 10 mM HEPES (pH 7.4). Media were pre-
warmed at 37°C prior use. FCS was heat-inactivated for 30 min at 56°C. For determination of 
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the number of viable cells, cell suspension was diluted 1:1 in Trypan blue solution (0.125%). 
Cells were counted using an improved Neubauer counting chamber.  
3.3.2 Passaging of adherent cell lines 
 
Media from 80-90% confluent cell cultures were aspirated and cells were washed once with 
5-10 ml PBS. After aspirating PBS, 1 ml 1xTrypsin was added and cells were incubated at 
37°C and 5% CO2 until they were completely detached. Trypsin was inactivated by addition 
of supplemented culture medium. Cells were thoroughly resuspended followed by 
determination of cell concentration and split ratio.  
3.3.3 Cryostorage of eukaryotic cell lines 
 
Established cell lines were frozen at -80 °C long term storage. Cells were pelleted at 1500 
rpm for 2 min. Aliquots of 5x106-1x107 cells were resuspended in heat-inactivated FCS and 
10% (v/v) DMSO in a total volume of 1 ml in cryotubes. To allow a constant decrease in the 
temperature at a rate of 1 °C per minute, cryotubes were placed in a freezing container filled 
with isopropanol. Subsequently, cryotubes were immediately transferred to the -80 °C freezer.  
3.3.4 Thawing of cells 
 
To avoid the toxic side effects of DMSO in freezing medium, thawing of cells was performed 
as fast as possible. Cryotubes were placed in the warm waterbath at 37°C until a little piece of 
ice clot was still visible in the cryotube. Cell suspension was transfered to 10 ml of pre-
warmed supplemented cell culture medium. After centrifugation at 1500 rpm for 1 min, 
supernatant was removed and pellet was carefully resuspended in fresh medium in a new 
culture flask. Media were changed 24 h later, in order to dispose the rest of toxic DMSO. 
Cells were passaged after 1-2 days depending on cell growth rate.  
3.3.5 Isolation of PBMCs 
 
PBMC were isolated from peripheral blood of healthy donors by a Biocoll gradient. Donor 
material was obtained following the University of Heidelberg Ethical Committee approval.  
Fresh, heparinized blood was diluted 1:2 in ice-cold PBS supplemented with 2mM EDTA. A 
layer of 35ml of diluted cell suspension was added to 15ml Bicoll and was centrifuged at  
400 g for 45 min at RT (without acceleration and without brakes). The interphase with the 
mononuclear cellswas gently aspirated, resuspended in PBS/EDTA and centrifuged at 300 g 
for 15 minutes. The cell pellet was resuspended in PBS/EDTA and and centrifuged at 200 g 
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for 10 minutes to remove platelets. This step was repeated with PBS. The PBMCs were then 
resuspended in X-Vivo medium supplemented with 5% [v/v] AB Serum, 4 mM L-Glutamin, 
300 U/ml IL-2 and 50 ng/ml OKT3 and plated at a density of 3x106 cells/ml. Monocytes were 
removed by plastic adherence.  
3.3.6 Culture of lymphocytes 
 
The isolated PBMCs were activated for 3 days with 300 U/ml IL-2 and 50 ng/ml OKT3 and 
after that the medium was supplemented with 100 U/ml IL-2. IL-2 and OKT3 were 
supplemented to the medium every 3 days and the cells were adjusted to a density of 3x106 
cells/ml every few days. For all experiments with pre-activated cells, lymphocytes were 
cultivated for five days and used on day five. For the transduction of lymphocytes, the 
lymphocytes were activated with 300 U/ml IL-2 and 50 ng/ml OKT3 for one day and 
transduced with fresh medium supplemented with 300 U/ml IL-2 and 50 ng/ml OKT3 on day 
two and three. After that, the medium was supplemented with 100 U/ml IL-2. IL-2 and 
OKT3. The transduced cells were used on day five, since they could be considered safety 
level S1 on that day.  
3.3.7 Production of lentiviral particles 
 
Lentiviral particles were produced in HEK-293T cells, which were transfected with lentiviral 
vector plasmids (3.1.7). The cell line HEK-293T (293T) derives from human embryonic 
kidney cells that were transformed with Typ 5-Adenovirus-DNA (Graham and van der Eb, 
1973). They are also stably transfected with the T-antigen from SV40, which enables 
amplification of plasmids with an SV40-Replication origin (DuBridge et al., 1987). For the 
production of lentiviral particles 293T have to be kept in low passages (passage < 20) and 
subconfluent in cell culture. The calcium phosphate method was used for a transient 
transfection with the lentiviral plasmids. The mixture of DNA and a calcium chloride solution 
in a phosphate buffer leads to the formation of a DNA-calcium phosphate co- precipitate that 
is taken up by 293T cells through phagocytosis. From the endosomes the DNA molecule 
reaches the nucleus where its transient transcription takes place. Addition of chloroquine to 
293T cells enhances the transfection efficiency. Chloroquine decreases acidification in the 
lysosomes and results in a higher stability of DNA through inhibition of lysosomal DNAses 
and/or swelling and displosion of endosomes (Guy et al., 1995). The plasmids required for 
virus production (3.1.7) contain an SV40 replication origin and thus are replicated upon 
transfection in 293T cells. As a result an increased number of viral transcripts and proteins 
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within a transfected 293T cell and thus an increased number of released viral particles is 
achieved. Twenty four hours prior transfection, 293T cells were cultured in 10 cm cell culture 
dishes. The cells should have 50 -70% confluence on the day of transduction. One hour prior 
to transfection the media were removed and replaced by fresh media. Immediately prior to 
transfection chloroquine was added to cell culture dish at an end concentration of 25 µM. 
20µg transfer-vector (pV3TP2AE), 14 µg packaging construct psPAX2 (enabling expression 
of HIV gag, pol, rev and tat) and 7 µ g packaging construct pMD.2-VSVG (enabling 
expression VSV-G) were diluted up to 500 µ l water (Aqua ad injectabilia) followed by 
addition of 50 µL 2.5 M calcium chloride. The solution was thoroughly mixed by “bubbling” 
with a pipet and 500 µL 2 x HBS- buffer (281 mM NaCl, 100 mM HEPES, 1.5 mM Na2HPO4 
[pH 7.12 ± 0.01]) was added carefully. The precipitates were allowed to form for 
approximately 10 min. Subsequently, the precipitate was added drop by drop to cells and 
mixed gently by shaking the dish. After 8-10 hours the medium containing the precipitate was 
replaced by fresh medium. After 15-18 hours of incubation, the first supernatant was 
discarded and the medium was replaced with fresh medium. 24 hours later (day 2) supernatant 
containing viral particles was collected, while fresh medium was added to the transfected 
cells. 24 hours later (day 3) supernatant was collected again. Directly after the collection, viral 
particle containing supernatants (day 2 and 3) were centrifuged to remove cell debris and 
supernatant was filtrated through 0.22 µm-filters. Virus containing supernatant was aliquoted 
and stored at -20°C.  
3.3.8 Quantification of lentiviral vector titers 
 
For determination of the viral titer, 293T cells were transduced with serial dilutions of the 
viral supernatant (thawed from -20 °C stock). The titer is indicated in TU/ml (293T 
Transducing Units) and determined indirectly through the percentage of cells expressing 
EGFP, which is included in all lentiviral vectors. The titer was calculated using the following 
formula: Titer (TU/ml) = (number of seeded 293T cells) x (percentage of transduced cells) x 
dilution factor. 293T cells were seeded to an approximate confluence of 80% on the day of 
transduction in 1 ml medium in a 24- well plate. Twenty four hours later, medium was 
exchanged with fresh medium followed by addition of the poly-cation polybrene (5 µg/ml), 
which acts as a bridge between negatively charged virus particles and cells and thus enhances 
transfection efficiency. Serial 10x-fold dilutions of concentrated viral supernatant were added 
to 293T cells (101 - 103). Immediately prior transduction, cell numbers were determined in 
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three separated wells. 293T cell were trypsinized 72 h after transduction and prepared for 
FACS analysis to determine EGFP-expression. 
3.3.9 Transduction of lymphocytes 
 
Following an IL-2 and OKT3 activation of lymphocytes for 24 h the cells were transduced. 
Transduction was done based on centrifugation of the virus onto coated plates and subsequent 
addition of the lymphocytes in 2 cycles on the 2 consecutive days. Transduction was done on 
Retronectin®-coated plates (TaKaRa, Saint-Germain-en-Laye France). The 24-well plates 
were pre-coated with Retronectin (20µg/ml) at 4°C over night, blocked for 30 min with 5% 
BSA/ PBS (fraction V, Serva, Heidelberg, Germany). The coated plates were then loaded 
with viral supernatants (SN). Therefore viral SN was diluted to the required MOI in volume 
of 400 µl/ well in PBS and 8 µg/ml protaminesulfate (Sigma, St. Louis, MO, USA) and was 
then spun down onto the 24-well plates at 3000 rpm at 4°C for 30 min. This step was repeated 
3 times until the final MOI 10-20 was reached. 24h -pre-activated lymphocytes were seeded 
in the plates (2,5*105 cells/ 24-well) over night at 37°C in a 5% CO2 incubator. The same 
procedure was repeated in a second cycle of transduction after 24 h and the lymphocytes were 
transferred to the second virus-coated plate.  
3.3.10 Flow cytometry 
 
Activation marker expression of activated lymphocytes were analysed by flow cytometry 
using the BD LSR II machine (Becton–Dickinson, Heidelberg, Germany). Lymphocytes were 
stained with fluoresceinisothiocyanate (FITC)-conjugated or phycoerythrin (PE)-conjugated 
anti-CD25, anti-CD69 and anti-CD95 mAbs (BD Biosciences, Heidelberg, Germany). 
EpCAM expression on carcinoma cells was evaluated using unconjugated anti-epithelial 
specific antigen (HEA125) mAb (homemade). Expression of TRAIL-receptors 1 and 2 (DR4 
and DR5, respectively) on tumor cell lines was verified. (Biolegend, San Diego, CA, USA; 
Sigma, St. Louis, USA; ProSci, San Diego, CA, USA). Expression of CD4 and CD8 on 
lymphocytes was analysed by mAB anti human CD4 and anti human CD8 (BD Pharmingen, 
Heidelberg, Germany). Organs and tumors of transplanted animals were stained for 
micrometastasis by staining for anti human MHC class I (     ). Expression of TRAIL on 
lymphocytes was detected using anti human TRAIL (2E5) mAb. As secondary Ab we used 
PE-labelled anti mouse IgG1 pAb (Human & Mouse Ig adsorbed) (R-PE) (Alexis, 
Farmingdale, USA). Briefly, 1x106 cells were incubated with Gammunex® (Talecris 
Biotherapeutics, Frankfurt, Germany) at 4°C for 10 min to inhibit unspecific binding of 
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antibodies. After washing with PBS/ 5% FCS, the cells were incubated with the desired 
primary antibody. PE-conjugated goat anti-mouse IgG (BD Pharmingen, Heidelberg, 
Germany) or FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, Birmingham, 
AL, USA) were used as secondary Ab and cells were incubated at 4°C for 30 min. After 
washing with, cells were respuspended in PBS/ 5% FCS and analysed by flow cytometry. The 
data was analyzed using BD FACS Diva software (Becton–Dickinson, Heidelberg, Germany). 
PE- or FITC-labeled mouse IgG (BD Pharmingen, Heidelberg, Germany) served as isotype 
controls. Dead cells were excluded by 7-Aminoactinomycin D (7AAD) staining. 
3.3.11 Detection of cytokines 
 
Supernatants of 3D tumor reconstructs were collected after 24 and 72 hours of incubation 
with EpcAMxCD3 or control Ab. TNF-α and IFN-γ levels in the supernatants of collagen gel 
3D tumor reconstructs were measured by ELISA (R&D Systems, Abingdon, UK), (Cell 
Sciences, Canton, MA, USA) and Abcam (Cambridge, UK). Analyses were performed 
according to the manufacturer’s recommendations. 
Relative levels of cytokines and chemokines in tumor lysates and in supernatants form 3D 
tumor reconstructs were evaluated using a human cytokines antibody array kit (Proteome 
Profiler, R&D Systems, Abingdon, UK). Tumor lysates were obtained at the endpoint of the 
bsAb treatment experiment. The presence of the following 36 cytokines and chemokines ws 
evulated: C5a, CD40 ligand (CD154), G-CSF, GROα (CXCL1), I-309 (CCL1), sICAM-1 
(CD54), IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-
16, IL-17, IL-17E, IL-23, IL-27, IL-32a, IP-10 (CXCL10), I-TAC (CXCL11), MCP-1 
(CCL2), MIF, MIP-1α (CCL3), MIP-1β (CCL4), Serpin E1 (PAI-1), RANTES (CCL5), SDF-
1 (CXCL12), TNF-α and sTREM-1.  
3.3.12 Migration 
 
To evaluate the effects of EpCAMxCD3 on the migratory properties of lymphocytes in 3D 
collagen gels, 2x105 activated lymphocytes and 2x105 BxPc-3 cells were mixed in a collagen 
type I solution. EpCAMxCD3 and control bivalent anti-EpCAM mAb or irrelevant bsAb 
CD19xCD3 were added to the collagen solution at a dose of 10 µg/ml. In one set of 
experiments lymphocytes were pre-incubated with EpCAMxCD3 for 2 hours prior to the 
migration experiments. A POCmini microscope chamber (LaCon GbR, Ulm, Germany) was 
filled with the mixture of lymphocytes and tumor cells in a collagen solution. This mixture 
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formed a polymerized collagen gel after 15 min of incubation at 37°C in a CO2 incubator. The 
POCmini chamber with the polymerized 3D collagen gel was then placed on the heating plate 
(36.6°C, LaCon, Ulm, Germany) under the microscope (Leitz, Wetzlar, Germany). Cells in 
3D collagen gels were focused under 40x magnification. Images were recorded using a Kappa 
digital videocamera (DX2, Kappa GmbH, Gleichen, Germany) and were taken consequently 
with a 30 second interval during a period of 1.5 hours. Sequential TIFF images were 
transferred into the AVI-video format using Animation Shop software. The analyses of cell 
movements were performed with CapImage 8.4 software (Dr. Zeintl Biomedical Engineering, 
Heidelberg, Germany). Interactions between cells were analyzed under 2:1 zoom using a 
“frame to frame” method. Percentage of migrating lymphocytes, lymphocyte velocity and 
duration of contacts between lymphocytes and carcinoma cells were evaluated. Only duration 
of contacts between carcinoma cells and actively moving lymphocytes with its clear onset and 
termination of interaction was calculated. 
3.3.13 3D tumor reconstructs 
 
To create 3D tumour reconstructs and to mimic tumour microenvironment BxPc-3 cells, 
lymphocytes and fibroblasts were cultured in a collagen type I gel on chamber slides (Nunc, 
Rochester, NY). The collagen type I gel was prepared as described previously [116]. Briefly, 
to prepare the working collagen solution, 5.1 ml from a stock of 3 mg/ml of collagen type I 
(PureColTM, Inamed Biomaterials, Fremont, CA) were added to 798 µ l of DMEM medium 
with 5% FCS and 330 µl of 0.34 M NaOH. Cancer cells (106 cells per ml) (BxPc-3 or PC-3)  
Were mixed with lymphocytes (107 cells per ml) (pre-activated lymphocytes, TRAIL-
transduced or MOCK-transduced lymphocytes) and fibroblasts (104 cells per ml) were mixed 
in the collagen solution and were seeded in 8-well chamber slides in a volume of 0.5 ml. This 
mixture formed a polymerized collagen gel after incubation at 37°C in a CO2 incubator for 
1.5 hrs. A volume of 250 µ l of medium containing 10 µg/ml EpCAMxCD3 bsAb, 50 U/ml 
IL-2 and 5 µg/ ml doxycycline was added on top of 3D tumour reconstructs. Gels and 
supernatants were harvested after 24 or 72 hrs of incubation at 37°C in the CO2 incubator.  
3.3.14 Apoptosis detection in 3D tumor reconstructs 
 
Apoptotic proteins in supernatants of collagen gel 3D tumor reconstructs were detected using 
a human apoptosis antibody array kit (Proteome ProfilerTM, R&D Systems, Abingdon, UK) 
according to themanufacturers recommendations. Pooled supernatants (n=4) of 3D tumor 
reconstructs with TRAIL- or MOCK-transduced lymphocytes were collected after 24 h or 72 
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h of incubation with bsAb EpCAMxCD3 or control Ab (10µg/ml). The presence of the 
following 35 apoptosis-related proteins was evaluated: Bad (B1), bax (B2), Bcl-2 (B3), Bcl-x 
(B4), pro-caspase 3 (B5), cleaved caspase 3 (B6), catalase (B7), cIAP-1 (B8), cIAP (B9), 
claspin (B10), clusterin (B11), cytochrome c (B12), TRAIL R1/ DR4 (C1), TRAIL R2/DR5 
(C2), FADD (C3), Fas/TNFSF6 (C4), HIF 1α (C5), HO-1/HMOX1/Hsp32 (C6), HO-
2/HMOX2 (C7), Hsp27 (C8), Hsp60 (C9), Hsp70 (C10), HTRA1/Omi (C11), Livin (C12), 
PON2 (D1), p21/CIP1/CDNK1A (D2), p27/Kip1 (D3), Phospho-p53(S15) (D4), Phospho-
p53(S46) (D5), Phospho-p53(S392) (D6), Phospho-p53(S635) (D7), SMAC/Diablo (D8), 
survivin (D9), TNF R1/TNFRSF1A (D10) and XIAP (D11). The numbers in brackets confer 
to the description in the figure. Three pairs of positive control spots are located in the corners 
of each array. Xray films and positive spots were quantified by pixel density in each spot 
using ImageJ 1.42 software. 
3.3.15 In vitro cytotoxicity assay 
 
To test cytotoxic activity of TRAIL-transduced lymphocytes, BxPc-3 or PC-3 tumor cells 
were incubated with TRAIL- or MOCK-transduced lymphocytes. Briefly, BxPc-3 or PC-3 
cells were pre-labelled with anti MHC class I- APC mAb ( BD Pharmingen, Heidelberg, 
Germany). TRAIL- and MOCK-transduced lymphocytes were pre-loaded with bsAb 
EpCAMxCD3 (10 µg/ ml) for 1h on ice. Tumor cells and lymphocytes were mixed and 
incubated in a CO2 incubator at 37°C for 4 h. The following target : effector cell ratios of 
1:0.1, 1:1, 1:5 and 1:10 were evaluated. Cytotoxic activity of lymphocytes and apoptosis 
induction in tumor cells were analysed by FACS analysis using AnnexinV-PE and PI (Sigma, 
St. Louis, CA, USA) staining. Mixed cells were gated on MHC class I –APC positive cells.  
3.3.16 Allogenic mixed lymphocyte reaction 
 
Fresh allogenic stimulant lymohocytes were obtained from several donors unrelated to the 
effector lymphocyte donors and were seeded at a concentration of 105 cells/well in dublicates 
in 96 round bottom well plates. TRAIL- or MOCK-transduced effector lymphocytes (105) 
were incubated with irradiated stimulant lymphocytes (30 Gy) in a 1:1 or 1:10 ratio. Stimulant 
and IL-2 and anti-CD3 mAb pre-activates effector lymphocytes cultured alone served as 
controls. Plates were incubated at 37 °C in a humidified atmosphere with 5% CO2 for 3 days 
and then 1 µCi/well of tritiated (3H) thymidine (Amersham Bioscience) was added and 
incubated over night. Cells, incubated in 96 well plates, were harvested (Inotec Biosytsmes, 
Rockville, MS, USA) onto glass fibre filter mats (Inotec Biosytems, Rockville, MS, USA).. 
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Filter mats were allowed to dry at 56 °C for 30 min and sealed in sample bags containing 4 ml 
scintillation fluid (Betaplate Scint). Filter mats were analysed on a Microbeta 1450™ liquid 
scintillation counter to determine 3H-thymidine uptake by cells. The stimulation index was 
calculated as 3H-thymidine uptake in the test wells divided by the 3H-thymidine uptake in the 
control wells with stimulant cells.  
3.3.17 Immunohistochemistry 
 
Immunohistochemistry was performed on 6 µm frozen tumortissue sections using the 
standard avidin-biotin technique with a Vectastain ABC Elite kit from Linaris (Wertheim-
Bettingen, Germany). Briefly, tissue samples were fixed in aceton followed by incubation 
with 20% normal goat or rabbit serum in PBS to block unspecific binding of Abs. After 
incubation with primary mAb and PBS washing steps, tissue samples were incubated with 
biotinylated secondary Ab. DAB (Invitrogen, Karlsruhe, Germany) was used as a chromogen. 
The following primary Abs were used: rat anti-mouse CD31 mAb detecting endothelial cells 
and mouse anti-human CD45 mAb detecting lymphocytes both from BD Pharmingen 
(Heidelberg, Germany), rabbit anti human TRAIL-R1 (DR4) and TRAIL-R2 (DR5) Ab 
(ProSci, Poway, CA, USA), rat anti mouse F4/80 Ab detecting mouse macrophages (acris 
Antibody, Herford, Germany), rat anti mouse Gr-1 (Ly-6G/Ly-6C) Ab detecting granulocytes 
(Biolegend, San Diego, CA, USA), rat anti mouse CD68 AB (Serotec, Oxford, UK) and 
rabbit anti human Ki-67 (Thermo Scientific, Rockford, IL, USA). Homemade mouse anti-
human EpCAM (HEA125) mAbs were purified from hybridoma supernatants. Biotinylated 
goat anti-mouse IgG and biotinylated rabbit anti-rat IgG from Vector (Burlingame, CA, USA) 
were employed as secondary Abs. For double immunofluorescence staining goat anti-rat 
Alexa Fluor 594 IgG and goat anti-mouse Alexa Fluor 488 IgG (Molecular Probes, Eugene, 
USA) were used as secondary Abs. Omission of primary Ab was used as a negative control. 
Proliferation was detected using Ki67 rabbit anti human Ab (Thermo Fisher Scientific, 
Waltham, MA, USA). Apoptosis was detected by active caspase 3 staining (rabbit anti-human 
pAb, R&D Systems, Abingdon,UK) and by TUNEL assay (TACS TdT in situ apoptosis 
detection kit (R&D Systems, Abingdon, UK) performed according to the manufacturer’s 
recommendations and modified by signal enhancement using a Vectastain ABC Elite kit and 
color development using a DAB kit. Tissue stainings were examined using a Leica DMRB 
microscope. Images were captured using a SPOT Flex digital color camera (Diagnostics 
Instruments Inc., Sterling Height, MI, USA) and analysed with SPOT Advanced software 4.6. 
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Hematoxylin and eosin stainings of cross tumor sections were analysed for vital tumor area by 
Image J software version 1.42. 
3.4 Animal experiments 
 
All animal experiments were approved by the Ethical Committee of the Regierungspräsidium, 
Karlsruhe, Germany. 
3.4.1 Subcutaneous pancreatic and prostate xenograft models 
 
I. To validate a xenograft tumor model, BxPc-3 cells were transplanted s.c. either alone or 
with pre-activated human lymphocytes mixed in a 1:1 ratio. Animals were randomized to four 
groups and received (i) BxPc-3 cells (5x106), (ii) BxPc-3 cells (5x106) mixed with pre-
activated lymphocytes (5x106), BxPc-3 cells (2.5x106) mixed with pre-activated lymphocytes 
(2.5x106) or (iii) BxPc-3 cells (1x106) mixed with pre-activated lymphocytes (1x106). Tumor 
take (engrafment, outgrowth) and size were monitored for 24 days after cell implantation. On 
day 25 tumors were dissected, weighed, embedded in OCT, snap frozen and stored at -80°C 
for further analysis.  
II. In EpCAMxCD3 treatment experiments, BxPc-3 or PC-3 tumor cells (5x106) were mixed 
with pre-activated lymphocytes (5x106) in PBS and were transplanted s.c. to the right flank of 
NOD/SCID mice in a volume of 100µl. Three days later, animals were randomized to three 
groups and received i.p. injections of EpCAMxCD3 (i) at a dose of 0.1 mg/kg, (ii) 1 mg/kg or 
(iii) 10 mg/kg. Control tumor bearing mice received (iv) parental bivalent anti-human CD3 
(OKT3) and anti-human EpCAM (HEA125) mAbs at a dose of 1 mg/kg or (v) PBS.. Animals 
received five injections of EpCAMxCD3 or control Abs administered i.p. every third day. 
Tumor size was measured externally every third day using a caliper. Animals were sacrificed 
at day 24 after tumor cell implantation. Tumors were dissected, weighed, embedded in OCT, 
snap frozen and stored at -80°C for further analysis. Tumor size was measured externally 
every third day using a caliper. Tumor volume was calculated according to the formula: V 
=π/6*a2*b, where a is the shortest diameter and b is the longest diameter.  
III. In TRAIL experiments, BxPc-3 or PC-3 tumor cells (5x106) were mixed with TRAIL-
transduced lymphocytes (5x106) in PBS and were transplanted s.c. to the right flank of the 
mice in a volume of 100µl. Three days later, nimals were randomized to five groups and 
received i.p. injections of EpCAMxCD3 at a dose of (i) 0.01 mg/kg, (ii) 0.1 mg/kg, (iii) 
irrelevant bsAb CD19xCD3, (iv) parental bivalent anti human CD3 (OKT3) and anti human 
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EpCAM (HEA125) mAbs at a dose of 1 mg/kg or (v) PBS. Control mice (vi) were 
transplanted with a mixture of non-rtnasduced pre-activated human lymphocytes and tumor 
cells, and received PBS. All animals received 1 mg/ml doxycycline and 5% glucose in the 
drinking water. Animals received five injections of EpCAMxCD3 or control Abs 
administered i.p. every third day. Tumor size was measured externally every third day using a 
caliper. Animals were sacrificed at day 23 after tumor cell implantation. Tumors were 
dissected, weighed, embedded in OCT, snap frozen and stored at -80°C for further analysis. 
Tumor volume was calculated according to the formula: V =π/4*a2*b, where a is the shortest 
diameter and b is the longest diameter.  
IV. To evaluate the effects of TRAIL-transduced lymphocytes and bsAb EpCAMxCD3 on the 
growth of developed tumors, NOD/SCID mice were engrafted s.c. with BxPc-3 tumor cells. 
Twelve days later, BxPc-3 tumors reached a volume of 30-40 mm3 and the treatment was 
initiated. TRAIL-transduced lymphocytes (5x106) were pre-loaded with bsAb EpCAMxCD3 
(1µg/ml) for 1 h and then transplanted s.c. around the tumor. Animals were randomized to 
three groups and received i.p. injections of bsAb EpCAMxCD3 at a dose of (i) 0.01 mg/kg or 
(ii) 0.1 mg/kg or (iii) PBS. Control BxPc-3 tumor bearing mice received only (iv) bsAb 
EpCAMxCD3 at a dose of 0.1 mg/kg or (v) PBS. bsAb EpCAMxCD3 treatment was repeated 
3 times with a 3 day interval. All animals received 1 mg/ml doxycycline and 5% glucose in 
the drinking water. Tumor size was measured externally every third day using a caliper. 
Tumors Animals were sacrificed on day 22 after tumor cell implantation. were dissected, 
weighed, embedded in O.C.T. Tissue -Tek (Sakura, Japan), snap frozen and stored at -80°C 
for further analysis. Tumor volume was calculated according to the formula: V =π*a*b*h, 
where a is the shortest diameter, b is the longest diameter and h the height of the xenograft.  
3.4.2 Analysis of metastasis formation 
 
The occurrence of metastasis in BxPc-3 + EGFP-L engrafted mice was evaluated on the day 
of sacrifice. Briefly: after isolation, liver, lungs and spleen were treated with collagenase I 
(Sigma, St. louis, MO, USA) filtered, washed and stained with anti human MHC class I mAb 
(W6/32 hybridoma, own production) and samples were analysed by flow cytometry. In 
addition, cryosections of BxPc-3 + EGFP-L tumors and organs were stained anti human 
panCk, to detect single metastatic cells.  
3.5 Statistical analysis 
 
Data is presented as mean of with standard deviation. Student’s t-test was used to evaluate the 
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differences between the groups. The growth kinetics was evaluated using variance analysis 
(variance analysis with repeated measurement and Post-Hoc-Test for comparison of groups 
after Dunnett) over time with ∗ = p< 0.05 considered statistically significant. 
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4 Discussion 
 
The over-all aim of this project was to test whether a combination of TRAIL-L with bsAb 
EpCAMxCD3 would effectively eliminate pancreatic and prostate tumors in vitro and in 
xenograft models. Pre-activated lymphocytes and EpCAMxCD3 effectively retarded the 
tumor growth of BxPc-3 pancreatic and PC-3 prostate xenografts. The combination with 
TRAIL-L strongly enhanced this efficacy, resulting in the need of much lower doses of 
EpCAMxCD3. Tumor growth retardation was associated with a reduced tumor cell 
proliferation and with a reduced blood vessel density. In 3D in vitro tumor reconstructs, 
TRAIL-L dramatically increased the expression of apoptosis-related proteins, which may 
contribute to the cytotoxic effects induced by pre-activate lymphocytes and EpCAMxCD3 by 
upregulation of the effector cytokines IFN-γ and TNF-α. In addition, EpCAMxCD3 
stimulated the expression of multiple chemokines in 3D tumor reconstructs. These 
chemokines may potentially contribute to the observed increased infiltration of the tumor 
xeongraft tissues with CD68+ and F4/80+ macrophages.  
4.1 Establishment and evaluation of suitable xenograft models to study the efficacy of 
TRAIL-L and EpCAMxCD3 
 
The pancreatic tumor cell line BxPc-3 and the prostate tumor cell line PC-3 were chosen for 
the xenograft tumor models based on the transplantation efficiency and the s.c. tumor growth 
kinetics on NOD/SCID mice. EpCAM used as target antigen for the bsAb EpCAMxCD3 
treatment was expressed by both cell lines in vitro and in derived xenografts in vivo. This was 
expected since several publications show that EpCAM is commonly expressed at a high level 
and with high frequency on differentiated cancer cells of the adenocarcinoma of the prostate 
and of the pancreas [107, 133, 134]. Interestingly, a number of studies has recently used anti-
EpCAM antibodies for isolation of cancer stem cells i.e. from human pancreas and prostate 
tumor tissues [135-137], since EpCAM was identified as a cancer stem cell marker in 
pancreatic and prostate cancer. Therefore, the present approach may target not only the 
majority of normal cancer cells, but also highly aggressive EpCAM-over-expressing cancer 
stem cells. 
The death ligand TRAIL was used as therapeutical gene. TRAIL has the unique characteristic 
to selectively induce apoptosis in malignant cells and not in normal cells, which akes it an 
ideal tool for cancer therapy. However, the sensitivity of tumor cells towards TRAIL is 
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crucial for the success of a treatment with TRAIL. Despite TRAIL’s ability to induce 
apoptosis in a wide variety of human tumor cell lines, there are many reports describing the 
resistance of tumor cells towards TRAIL. Since an underlying reason for TRAIL resistance 
may be an abundant receptor expression, the expression of the apoptosis-inducing TRAIL-
receptors (TRAIL-R1 and -R2) was verified for the BxPc-3 and PC-3 cell lines and derived 
xenografts. Both cell lines expressed TRAIL-R1 and -R2 in vitro and in vivo. Sensitivity to 
TRAIL in vitro has been shown for both BxPc-3 and PC-3 cell lines in our group by 
Kallifatidis et al. [138] and by others [139-144]. Upon addition of recombinant TRAIL the 
viability of BxPc-3 was decreased to approx. 20% and the viability of PC-3 was decreased to 
60% [138]. The higher TRAIL sensitivity of the cell line BxPc-3 could be the reason for the 
observed more efficient tumor growth retardation in BxPc-3 xenografts by TRAIL-L than in 
PC-3 xenografts, as discussed in detail later. 
The efficiency of the combined TRAIL-L and EpCAMxCD3 treatment was studied in tumor 
xenograft models. Carcinoma cells were mixed with lymphocytes and subsequently engrafted 
s.c. into NOD/SCID mice. This approach of co-transplanted cell is preferable to s.c. 
engraftment of tumor cells followed by an i.v. administration of lymphocytes due to the 
potential redistribution of lymphocytes and their removal from the circulation in mouse 
organs. A similar in vivo tumor model was used by Schlereth et al. [115] and Brischwein et 
al. [122] studying the therapeutic effects of the single-chain bsAb EpCAMxCD3 constructs 
MT102 and MT110 in xenograft SW480 colon tumors. A lymphocyte to tumor cell ratio of 1:1  was used to mimic the situation within human tumors. In the studies presented here 
xenografts were formed despite the presence of the lymphocytes demonstrating that the 
administration of a mixture of pre-activated lymphocytes and tumor cells does not affect 
xenograft PC-3 or BxPc-3 tumor growth and its morphology. Both xneografted tumor entities 
established a robust blood vessel network and a collagen containing stroma. Similar results 
were obtained upon co-transplantation of TRAIL-L together with tumor cells. Our findings 
that pre-activated lymphocytes survive in BxPc-3 tumors for more than 24 days further 
underline that the xenograft model is well suited for the suggested gene-immunotherapy. 
4.2 TRAIL delivery by human lymphocytes 
 
Human lymphocytes of healthy donors were used as vehicles for the delivery of TRAIL as an 
apoptosis-inducing agent to tumor cells. Although the delivery of TRAIL as a therapeutic 
protein is widely explored by other groups, its delivery by lymphocytes has not been 
described before.  
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TRAIL has already been delivered to tumors by cellular carriers such as mesenchymal stem 
cells (MSCs), which have tumor targeting properties [70-73]. However, the use of T cells as 
vehicles is advantageous to the delivery of TRAIL by MSCs, since T cells as effector cells of 
the immune system have a variety of anti-tumor properties. Among them is the ability to lyse 
tumor cells by perforin, granzyme B, or the production of the multifunctional effector 
cytokines IFN-γ and TNF-α. Therefore, the over-expression of TRAIL in lymphocytes may 
enhance the anti-tumorigenic action of these immune cells.  
Additional methods to deliver TRAIL to tumor cells have been used, such as the viral 
transduction of the TRAIL coding sequence directly in tumor cells or by a systemic 
application. The direct gene delivery with adenoviral vectors has been the most abundantly 
studied [74-83], while also other vectors were tested for their suitability [84-87]. However, 
the delivery of TRAIL by lentiviral vectors has rarely been described for this application [88-
90].  
The lentiviral transduction of lymphocytes with TRAIL has not been described before. 
However, lymphocytes have been transduced with other genes i.e. antigen-specific receptors. 
These receptors, which typically recognize native cell-surface antigens e.g. human leukocyte 
antigen-restricted, heterodimeric T cell antigen receptor, or chimeric antigen receptors CARs 
(reviewed in [145], [146]) help to artificially retarget T cells. The present approach does not 
follow this receptor-recognition based concept to target cancer cells. It relies on the 
hypothesis that bsAb EpCAMxCD3 efficiently targets TRAIL-L to the tumor cells and 
enables a close cell-cell contact by the dual specificity for the tumor associated antigen 
EpCAM and CD3 expressed on lymphocytes.  
In the actual work, the lentiviral vector system was used to achieve the over-expression of the 
apoptosis-inducing ligand TRAIL in human lymphocytes. Lentivirus-derived vectors are very 
efficient for gene transfer due to their stable integration into the genome of dividing and non-
dividing cells. Also they are less susceptible to gene silencing by host restriction factors. 
However, it should be clearly mentioned, that the retroviral integration into the host genome 
has been associated with the risk for insertional mutagenesis [147-149]. Thus, in a clinical 
gene therapy trial attempting to treat ten children with X-linked severe combined 
immunodeficiency (SCID-X1) disease using gammaretroviral-based vectors [150, 151]. Four 
patients developed secondary leukemia after an initially successful therapy. This was due to 
cellular proto-oncogene activation by the retrovirus [152-154]. This risk of secondary cancer 
may be specifically due to retrovirus based vectors like the MLV-based vectors since these 
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express viral oncogenes. They have the ability to integrate nearby cellular proto-oncogenes 
both in animal models and in human gene therapy trials [152, 155-161]. The use of lentiviral 
vectors for gene therapy could solve this concern about insertional mutagenesis of retroviral 
vectors. Whereas gammaretroviruses preferentially integrate around transcription start sites 
and CpG islands, consistent with host gene promoter features, lentiviruses integrate 
preferentially in active transcription units, with no bias along the transcript, nor for introns or 
exons [149], thereby minimizing the risk for insertional mutagenesis. Additional advantages 
of the lentiviral vector system are the efficient preparation and production of vectors with 
very high titers, the transduction of target cells independently of their cell cycle phase and a 
stable long term expression of the transgene.  
In the present study, the lentiviral vector pV3TP2AE, a SIN vector of the second generation 
was used. This vector was constructed for a tetracycline induced transgene expression under 
the control of the CMVmin promoter. Human TRAIL and the marker gene EGFP were 
expressed as a single transgene linked by the P2A peptide linker. Peptide-linkers, such as P2A 
are superior to bicystronic systems using an IRES element and circumvent cross-inhibition of 
two promoters on one vector [130]. With the pV3TP2AE vector  we were able to successfully 
transduce human lymphocytes to express TRAIL on the cell surface with an average 
efficiency of 40-60% and to express the marker gene EGFP in equivalent percentage. 
Increasing the MOI 10 up to MOI 300 did not further improve the transduction efficiency 
(data not shown). Thus, MOI above 100 resulted in an integration of the vector but not in 
expression of the transgene (data not shown). To avoid interference with neighboring genes or 
insertional mutagenesis, all experiments were conducted with MOI 10.  
The majority of the transduced lymphocytes were cytotoxic CD8+ T cells. Why the lentiviral 
vector seems to have a preference for CD8+ T cells is not clear. A reason may be the favor of 
lentiviruses for the integration in active transcription units, dependent on chromatin 
accessibility, cell cycle effects and tethering proteins [162-165]. The preference for CD8+ T 
cells, is probably related to an activation of the antiviral functions of CD8+ T cell by viral 
antigens during the transduction procedure.  
The isolation and subsequent transduction procedure with pV3TP2AE did not affect the 
lymphocyte’s function to proliferate upon an allogenic stimulus. Moreover, transduction did 
not influence the ability of lymphocytes to migrate in 3D gels or to lyse tumor cells in in vitro  
cytotoxicity assay. Thus, transduced lymphocytes may be well suited as carriers for the 
delivery of TRAIL to tumor cells.  
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The successful application of gene therapy requires the development of vectors that can 
provide a regulatory control of therapeutic gene expression i.e. during embryonal 
development or expression of cytotoxic genes. The “Tet-on” system in pV3TP2AE allows the 
conditional expression of both TRAIL and EGFP after stimulation by doxycycline as 
demonstrate din our in vitro experiments. The pV3TP2AE vector was only induced when 
doxycycline was added. However, the promoter proved to be leaky in vivo since without the 
addition of doxycycline into the drinking water, a basal expression of the marker gene EGFP 
in transduced cells was detected in xenograft tissues. This leakiness may be attributed to the 
fact that rtTA retains some affinity for tetO sequences even without doxycycline and to the 
unwanted residual activity of the tetO CMV responder even when the active rtTA is absent 
[166]. This phenomenon has been described and could potentially be repaired by the addition 
of an additional insulator element [166, 167]. However, the leak in this Tet-based systems 
was acceptable since this therapeutic approach is based on the direct transplantation of 
TRAIL-L with a desired direct effect of the implanted cells.  
The TRAIL-R system is controversially described for its role as a metastasis suppressor or as 
a promoter of metastasis [168]. TRAIL has a physiological role in tumor surveillance, tumor 
development and tumor protection. TRAIL knockout mice are more susceptible to 
experimental and spontaneous tumor metastasis [169] suggesting that TRAIL suppresses 
metastasis. Similarly, TRAIL-R deficient mice appear to develop fewer primary tumors [170]. 
These data are confirmed by Grosse-Wilde et al. where TRAIL suppressed metastasis 
formation, although an effect on growth rates of primary tumors were not observed in this 
particular study [171]. The transplantation of TRAIL-sensitive tumor cells into syngeneic 
TRAIL-deficient mice led to an increased subcutaneous tumor growth and experimental liver 
metastasis [169, 172] supporting an anti-tumorigenic action of TRAIL. There seems to be a 
strong tissue dependence of TRAIL-mediated tumor immune surveillance [169, 173, 174]. 
However, autochthonous mouse tumor models using TRAIL and TRAIL-R-deficient mice 
revealed a strong tissue dependency of tumor suppression by TRAIL and TRAIL-R. Some 
tumor tissues resist TRAIL-induced apoptosis and rather start to metastasize. This is related to 
the induction of NF-κB by TRAIL [175-178]. However, in our experiments, the activation of 
NF-κB (c-Rel, RelA) could not be detected in xenografts with co-transplanted TRAIL-L at 
the endpoint of the experiment on day 23 (data not shown), suggesting that the death-inducing 
properties are fully active in our model. In addition, in BxPc-3 and PC-3 tumor models, 
metastasis could not be detected, which indicates a safe application of TRAIL in our 
experiments. This is in contrast to a recent report from Trauzold et al. [168], who reported 
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that TRAIL promotes invasion and metastasis in an apoptosis resistant orthotopically 
xenograft of Colo357 pancreatic ductal adenocarcinoma. The difference between the finding 
of the present work and the results of Trauzold et al. may be due the choice of the s.c. 
xenograft model over the orthotopic xenograft model.  
Taken together, the delivery of TRAIL by over-expression in human lymphocytes is 
described for the first time in the present study. TRAIL-L are functional and the TRAIL 
delivery by lymphocytes was safe without detectable side effects in animal models.  
4.3 Targeting EpCAM on tumor cells and CD3 on lymphocytes by bsAb 
EpCAMxCD3 
 
EpCAMxCD3 has a long half-life in mouse serum (t1/2 ~ 7 days) and was detectable in blood 
even seven days after the last administration. EpCAMxCD3 was abundantly distributed in the 
tumor tissues with a decreasing gradient with more distance from the blood vessels (data not 
shown). This is of great advantage for the proposed gene-immunotherapy since it suggests 
long-term effectivity. In comparison, the single-chain bsAb EpCAMxCD3 used by Schlereth 
et al., MT102, reduced the tumor growth of experimental SW480 colon tumors, but had to be 
administered daily due to its terminal elimination half-time of around 5.3 hours [115]. Also 
the hybrid rat/mouse bsAb EpCAMxCD3 (Removab, Catumaxomab) by Lindhofer et al. had 
a terminal elimination half-life of only 2.5 days in patients (Fresenius/ TRION pharma). The 
increased serum half-life of our recombinant bsAb EpCAMxCD3 may provide a considerable 
clinical advantage over single-chain bsAb constructs.  
The contact time between migrating lymphocytes and tumor cells was three times longer in 
the presence of EpCAMxCD3 compared to control antibodies in 3D in vitro tumor 
reconstructs. The increased time of a direct contact between target and effector cells indicates 
that EpCAMxCD3 facilitates interactions between lymphocytes and tumor cells regardless of 
T cell receptor specificity. This is in agreement with Zeidler et al. [128], who showed that 
EpCAMxCD3 brings T cells and tumor cells into close contact, redirecting T cells to kill 
carcinoma cells. This finding is further supported by our data demonstrating an increased 
cytotoxicity upon addition of EpCAMxCD3 in vitro. Apoptosis and cell death after incubation 
of tumor cells with TRAIL-L or MOCK-L lymphocytes was significantly increased in the 
presence of EpCAMxCD3, demonstrating the high potency of this bispecific antibody. These 
findings indicate that EpCAMxCD3 can potentiate the anti-tumor efficacy of lymphocytes, 
which may be applied for the site-specific delivery of anti-cancer agents such as TRAIL. 
Unfortunately, the experimental setting in 3D tumor reconstructs did not allow for the 
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monitoring of the fate of tumor cells following lymphocyte contact. In this regard it would 
have been interesting to know after which time lymphocytes would eliminate the tumor cells 
and whether this elimination would have been complete. 
Most importantly, the binding of EpCAMxCD3 to CD3 molecules on lymphocytes did not 
influence the migratory properties of lymphocytes. Our results on lymphocyte velocity are in 
agreement with Niggemann et al. [179] showing a similar migration percentage and velocity 
of T cells in 3D collagen gels.  
After the binding to CD3 molecules on lymphocytes with one arm and to EpCAM antigen on 
tumor cells with the other arm, bsAb lead to the activation of lymphocytes in an antigen-
independent manner in 3D reconstructs. There was an induction of IL-2 production. 
Furthermore, EpCAMxCD3-induced activation of lymphocytes which leads to the production 
of effector cytokines and cytolytic substances including TNF-α, IFN-γ, perforin and granzyme 
B. In agreement with these results presented here, Wimberger et al. [118] comfirmed that 
tumor resident T cells following treatment with a single chain bsAb EpCAMxCD3 efficiently 
lysed malignant cells in vitro. Also, EpCAMxCD3 efficiently retarded BxPc-3 and PC-3 
tumor growth in vivo. The treatment was not associated with therapy-related toxic side effects 
in tumor-bearing mice. This indicates a local production of effector cytokines and an absence 
of TNF-α and IFN-γ in the systemic circulation. BsAb EpCAMxCD3 is composed of mouse 
IgG1 and IgG2A constant heavy chain regions and has low affinity to human Fc receptors. This 
property of EpCAMxCD3 would also reduce Fc-mediated side effects. By contrast, the 
therapeutic efficacy of other bsAb constructs greatly relies on the Fc portion, for instance, in 
case of mixed rat/mouse heavy chains [102, 180]. 
We identified several potential mechanism for the anti-tumor efficacy of EpCAMxCD3. In 
the 3D tumor reconstruct model, EpCAMxCD3 potently increased the production of 
granzyme B and perforin, suggesting a contribution of these lytic molecules to tumor cell 
killing. This finding corresponds to other in vitro models, which used other recombinant bsAb 
EpCAMxCD3. In these studies the bsAb potently increased the cytotoxic action of T cells by 
perforin and granzyme B-mediated lysis of the tumors cells within 1-3 days which was 
associated with the induction of apoptosis [118, 181, 182]. In comparison, the mechanism of 
action of the human bispecific EpCAMxCD3 antibody Catumaxomab mainly relies on 
antibody-dependent cellular (ADCC) and complement-dependent cytotoxicity (CDC) [102].  
Taken together, EpCAMxCD3 has a long half-life in vivo, which would be beneficial for a 
clinical application. The increased contact time between tumor cells and lymphocytes can 
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facilitate the reaction of TRAIL-L with the tumor cells. EpCAMxCD3 potently activated 
lymphocytes, and induced the production of granzyme B and perforin, which can have 
cytotoxic abilities on tumor cells. 
4.4 Combination therapy with TRAIL-L and EpCAMxCD3 
 
EpCAMxCD3 very efficiently reduced tumor engraftment and retarded tumor growth in 
BxPc-3 and PC-3 xenografts with pre-activated lymphocytes in vivo. Tumor take was 
decreased by EpCAMxCD3 in a dose-dependent manner, without any detectable side effects 
of the bsAb. In the highest dose of EpCAMxCD3 (10 mg/kg) tumor take was only 50% and 
the growing tumors were smaller compared to control groups. Lower doses of EpCAMxCD3 
(1 mg/kg and the 0.1 mg/kg) had a similar efficiency, arguing for the reduction in bsAb doses. 
Therefore, we decided to use lower EpCAMxC3 concentrations for combination experiments 
with TRAIL-L to circumvent potential cytotoxic side effects. In this regard, Amann et al. 
reported severe side effects of high dose of the anti murine EpCAMxCD3 bsAb in 
immunodeficient mice due to the rapid release of inflammatory cytokines. High doses of this 
recombinant bsAb were even lethal in mice [110]. 
As expected, in presence of TRAIL-L very low doses of EpCAMxCD3 efficiently retarded 
the tumor growth of xenografts. To minimize the effect of blood donor variation, individual 
animals per group received lymphocytes from different donors. Compared to the experiments 
with pre-activated lymphocytes, only very low doses of EpCAMxCD3 were necessary to 
achieve a pronounced anti-tumor effect and to efficiently retarded tumor growth. The delivery 
of TRAIL by lymphocytes was safe since no obvious side effects were detectable. This is in 
contrast to mouse experiments of other laboratories, in which the application of recombinant 
TRAIL for the elimination of glioma induced hemiparesis and weight loss at high doses of 
TRAIL [64]. Such side effects were not observed in the present study, which might be due to 
the short half life of applied high doses of recombinant TRAIL and its rapid clearance [183]. 
In addition, the delivery of TRAIL by lymphocytes may be involved in reduction of the 
suggested liver toxicity of this death ligand.  
In BxPc-3 xenografts intra-tumoral cysts were observed after the treatment. Furthermore, 
cysts could be detected as early as three days after initiation of the treatment, suggesting that the effective mechanism behind this phenomenon is a specific early reaction to the treatment.Since cyst could only be detected in xenografts with transplanted TRAIL-L that 
had received EpCAMxCD3, received TRAIL-L or EpCAMxCD3 alone, the formation of cyst 
could be a potential treatment result. There are several potential explanations for the cysts. 
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We ruled out that the cyst formation was due to hemorrhage or necrosis since no blood or 
necrotic tissue areas were detectable. The liquid was clear, free of cells, fibrin clots or 
deposits and often filling the whole tumor. A potential explanation for the cysts could be the 
formation of a transsudate, via changed intra-tumoral vascular permeability. Blood vessels 
can be stimulated by a local cytokine production and consequently cell-free liquids 
accumulate. Cysts are a well-known phenomenon in pancreatic carcinoma of patients, 
especially pseudocysts are commonly found [184], however, cysts have not been described in 
s.c. xenograft models of established pancreatic cell lines. The possibility that cyst formation 
could be due to doxycycline administration was ruled out, since the PBS control group has 
also received doxycycline and was cyst-free. Only one mouse model with a polycystic kidney 
disease is described with cyst-acceleration upon doxycycline, due to inhibition of MMPs and 
changes in intracellular Ca2+ and Zn2+levels [185]. However, in BxPc-3 xenografts treated 
with high-dose of EpCAM mAb alone, cyst formation was observed independently of 
doxycycline (personal communication A. Salnikov).  
Taken together, EpCAMxCD3 very efficiently retarded tumor growth in xenograft models of 
the tumor cell lines BxPc-3 and PC-3 in a dose-dependent manner. The use of lymphocytes as 
vehicles for TRAIL potently enhanced the anti-tumor effect of even very low doses of bsAb, 
which could provide a pharmacokinetic advantage in a clinical setting. Tumor-bearing 
animals did not have treatment-related side effects from either TRAIL or the bsAb. The 
development of cysts inside BxPc-3 xenografts could be a potential result of the 
EpCAMxCD3 treatment but cannot be fully explained yet.  
4.5 Analysis of the anti-tumor effect of EpCAMxCD3 and transplanted TRAIL-L in 
vivo and in vitro  
 
The combination of TRAIL-L with low doses of EpCAMxCD3 very efficiently retarded 
tumor growth in xenograft models. Although an increase in apoptosis could not be detected at 
the endpoint of EpCAMxCD3 treatment (active caspase 3, TUNEL) on day 23, TRAIL-L 
efficiently induced apoptosis in 3D in vitro tumor reconstructs.  
Apoptosis was analysed at the endpoint of the bsAb treatment on day 23 after the co-injection 
of cancer cells with the respective lymphocytes. However, an increase in apoptosis could not 
be detected (active caspase 3, TUNEL). These results may be misleading, since tumor cells 
and lymphocytes were co-transplanted and may have interacted already at the time of 
injection. Therefore, the time of observation could be critical and we assume that apoptosis 
might have been visible at earlier time points. In line with this assumption, TRAIL-induced 
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apoptosis has been shown by Kim et al. used TRAIL-transduced MSCs in glioma xenografts. 
The strongest apoptosis was seen 7 days after injection and the effect of TRAIL declined 
within 2 weeks [71]. Our tumors analysed on day 23, could be persistent or apoptosis-resistent 
sub-populations of the initially injected tumor mass. Furthermore, treatment with 
EpCAMxCD3 on the days 4, 7, 10, 13 and 16 is a considerable period of time earlier than the 
time of analysis at day 23. Furthermore, it is possible that the anti-tumor effect of the bsAb 
could involve other mechanism than apoptosis.  
For the study of short term effects of EpCAMxCD3 and TRAIL-L on tumor cells, apoptosis 
induction was analysed in vitro. TRAIL-L induced multiple apoptosis-related proteins in 3D 
tumor reconstructs after 24 and 72 hours. The detection of in vitro anti-tumor effect after 24 
hours, is in agreement with the time of apoptosis induction mediated by other recombinant 
bsAb EpCAMxCD3 [118, 181, 182, 186]. In addition, the trifunctional bispecific antibody 
EpCAMxCD3 eliminated prostate tumor cells in co-culture experiments with PBMCs after 24 
hours [182] and also in primary ovarian cancer cells in vitro [118]. However, EpCAMxCD3 
did not enhance the effects of TRAIL in 3D reconstructs, suggesting a high impact of the 
lymphocytes over-expressing TRAIL. For recombinant TRAIL, a similar time frame was 
observed for the induction of apoptosis in glioma cell lines by others in vitro by terminal 
transferase-catalysed in situ end-labeling technique [64]. Also TRAIL-transduced MSCs 
induced apoptosis in vitro in co-culture models of lung cancer metastasis and glioma [70, 71]. 
However, another potential explanation for the observed cell death could be differences in 
death mechanisms used by lymphocytes such as cell-lytic proteins like perforin or granzyme 
B, which were fond to be secreted in 3D tumor reconstructs.  
Furthermore, in an in vitro cytotoxicity assay bsAb EpCAMxCD3 significantly increased 
tumor cell death after incubation of tumor cells together with MOCK-L or TRAIL-L in 
different ratios. The cell death reached a maximum at the effector - to - target cell ratio of 
10:1. However, annexinV-staining was negative and the addition of a blocking-antibody for 
TRAIL did not have an effect on the outcome. The cell death observed after 4 hour incubation 
with TRAIL-L was not mediated by TRAIL but potentially by another effector mechanism by 
lymphocytes. This observation is in agreement with Haas et al., who showed that the single-
chain bsAb EpCAMxCD3 (MT110) did not induce detectable levels of apoptosis in vitro 
before 15 hours of incubation [181]. In agreement with our data, the incubation of 24 hours 
and 72 hours was most effective on tumor cell eradication in vitro as shown by Riesenberg et 
al. and Flieger et al. [182, 186] who used the trifunctional bsAb EpCAMxCD3.  
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EpCAMxCD3 and TRAIL-L reduced the blood vessel density in vivo. The anti-angiogenic 
effect can partly be attributed to TRAIL-L. My colleague, Dr. Kallifatidis et al. showed that 
recombinant TRAIL significantly decreased CD31+ blood vessel density in pancreatic MIA-
PaCa2 xenografts tumors in vivo [138]. Similar effects were shown on HUVEC cells in vitro 
(unpublished data). The anti-angiogenic effect of TRAIL has also been described by Li et al. 
and Aladina et al. [187, 188] by inducing apoptosis in endothelial cells. This result is 
supported by our data, since the treatment with EpCAMxCD3 in high doses and pre-activated 
lymphocytes also did not result in a major difference in the CD31+ blood vessel density (data 
not shown). Another reason for the reduced blood vessel density could be the release of IFN-γ 
and TNF-α by the lymphocytes. IFN-γ is known to have inhibitory effect on angiogenesis by 
inducing the chemokines CXCL9 (MIG), CXCL10 (IP-10) and CXCL1 (I-TAC), which 
inhibit the chemotaxis of endothelial cells [189-192]. In addition IFN-γ as well as TNF-α 
downregulate the pro-angiogenic chemokine CXCL12 (SDF-1) [193]. A local TNF-α 
production has also been connected to proliferation arrest and apoptosis in endothelial cells 
[194, 195]. 
EpCAMxCD3 and pre-activated lymphocytes or TRAIL-L decreased proliferation of BxPc-3 
and PC-3 tumor cells in vivo. Compared to xenografts with pre-activated lymphocytes, 
TRAIL-L dramatically increased the anti-proliferative effect of bsAb. The most dramatic 
effect was detected in the PC-3 xenograft model. In the BxPc-3 xenograft model the decrease 
in proliferation was significant but not as dramatic as in PC-3. Interestingly, the localization 
of the highest amount of bsAb was recriprocal to the region of the highest proliferation. Ki-
67+ cells were remarkably localized at the outer part of the tumor islets close to the tumor 
stroma with the blood vessels (data not shown). A possible explanation for the changes in 
proliferation observed in mixed xenografts of carcinoma cells with pre-activated 
lymphocytes/ TRAIL-L could be the interaction of the bsAb with EpCAM on tumor cells. 
The works of Munz et al. and Osta et al. [196, 197] underlined its role in promotion of gene 
transcription and cell proliferation. Cells expressing EpCAM have been demonstrated to 
proliferate more rapidly, grow in an anchorage-independent manner and have a reduced 
requirement of growth factors. Consistently, it could been shown that knock-down of 
endogenous EpCAM in tumor cells decreases cell proliferation and migration [196, 197]. 
Recently, the impact of cell-to-cell contact for EpCAM signaling and the intracellular 
signaling pathway has been demonstrated by Denzel et al. [198]. This finding high-lights the 
role of EpCAM as an anti-tumor target. In addition, in tumors treated with EpCAMxCD3 and 
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co-transplanted with TRAIL-L the reduction in proliferation was the highest, indicating the 
contribution from TRAIL-L. Another  reason  for  the  decreased  proliferation  is  the  induction  of  cytokines  by  pre‐activated lymphocytes or/and by the bsAbs as shown for EpCAMxCD3 in patients [117]. Alternatively EpCAMxCD3-induced IFN-γ and TNF-α production by lymphocytes may be 
responsible. IFN-γ and TNF-α inhibit cell proliferation. IFN-γ has been reported to inhibit cell 
cycle progression [199, 200]. TNF-α has been reported for a dual role in the induction of 
cancer cell death and angiogenesis [201]. However, TNF-α has also been descrived to 
contribute the local inflammation of tumors and to induce tumor cell death at high doses 
[195]. 
To mimic a clinical situation more closely, a developed tumor model was used in addition. 
The model of tumor cells co-injected with lymphocytes as also applied by Schlereth et al. 
[115] and Brischwein et al. [122] is suited for treatment studies of a tumor cell mass, like an 
in vivo cytotoxicity assay. In the literature numerous cancer treatment models are 
accomplished in preformed solid tumors, which are then analysed for tumor growth 
retardation, tumor shrinkage or even tumor eradication. Therefore, the anti-tumor effects of 
transplanted TRAIL-L and EpCAMxCD3 were analysed in a developed tumor model of 
BxPc-3 cells s.c. transplanted into NOD/SCID mice. The treatment in our study was started 
upon reaching an average tumor size of 80 mm3. TRAIL-L were transplanted s.c. around the 
tumor and not directly into the tumor since the direct injection into the tumor may induce 
tumor cell death and the lymphocytes could be lost by systemic distribution. EpCAMxCD3 
and TRAIL-L efficiently retarded tumor growth of developed BxPc-3 tumors, verifying the 
results from the previous tumor model, in which tumor wells were co-transplanted together 
with lymphocytes. Therefore, EpCAMxCD3 treatment in combination with TRAIL-L is also 
effective on the developed xenograft model of pancreatic BxPc-3, which is closer to the 
clinical situation. 
In 3D tumor reconstructs, EpCAMxCD3 potently stimulated IFN-γ secretion by pre-activated 
lymphocytes, whereas the production of TNF-α was less pronounced. In contrast, TNF-α was 
the predominant cytokine produced in 3D reconstructs with non-stimulated PBMCs in the 
presence of EpCAMxCD3. The latter findings are in agreement with the clinical data showing 
that TNF-α level was markedly increased in ascites from ovarian cancer patients treated with 
EpCAMxCD3 [117]. The  finding,  that PC‐3 and BxPc‐3  tumor growth  inhibition by  the combined  treatment  with  lymphocytes  and  EpCAMxCD3  was  not  associated  with 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therapy‐related toxic side effects in tumor‐bearing mice, indicates a local production of effector  cytokines and an absence of TNF‐α and  IFN‐γ  in  the  systemic  circulation. The expression of cytokines has also been shown for Catumaxomab. This hybrid mouse/rat antibody that is specific for EpCAM, CD3 and ‐ via its Fc portion – for antigen‐presenting cells,  as  well  as  for  a  variety  of  other  cytotoxic  immune  cells,  has  been  shown  to efficiently  reduce  ovarian  cancer  patients  suffering  from  ascites  and  in  gastric  cancer patients in phase II clinical studies. Similar results have been gained by Strauss et al. and Marme  et  al.  with  this  present  EpCAMxCD3  in  ovarian  cancer  patients  on  ascites formation  [117, 128]. Both works detected a massive  induction of TNF‐α,  indicating  a very strong local immune stimulation.  
Noteworthy is that EpCAMxCD3 induced production of inhibitory cytokine IL-10 in 
reconstructs with PBMCs but not with pre-activated lymphocytes. This may indicate a 
nonspecific activation of regulatory T cells by EpCAMxCD3. Since regulatory T cells are the 
major source of inhibitory cytokines in PBMCs [202, 203] TGF-β1 production was analysed 
in 3D tumor reconstructs. The TGF-β1 level was only marginally increased in 3D tumor 
reconstructs with EpCAMxCD3 after 72 hours of incubation. The possibility that monocyte-
derived IL-1β could contribute to the TGF-β1 production in 3D reconstructs with non-
stimulated PBMCs via stimulation of fibroblasts was ruled out, because IL-1β levels were 
similar in all 3D reconstructs. Since the binding of bsAb containing IgG1 and IgG2A constant 
heavy chain regions to human monocytes is usually weak, the potential activation of T cells 
via binding of EpCAMxCD3 to Fc receptors on monocytes is rather unlikely in 3D tumor 
reconstruct experiments.  
Taken together, these results indicate that EpCAMxCD3 is a strong inducer of lymphocyte 
effector functions such as secretion of tumoricidal cytokines. The response of lymphocytes to 
EpCAMxCD3 is dependent on their activation state.  
To investigate the microenvironment created in 3D tumor reconstructs and the release of 
cytokines, a panel of several cytokines and chemokines was analysed in 3D gels. The 
induction of many cytokines was detected including G-CSF, GROα, sICAM-1, IL-1α, IL-1β, 
IL-1ra, IL-6, IL-8, IL-16, IP-10, I-TAC, MIF, MIP-1α, MIP1β, serpin E1, RANTES, TNF-α, 
IFN-γ. In tumor extracts the presence of sICAM, IL-1α, IL-1ra, MIF and Serpin E1 could be 
detected. The presence of these cytokines in the tumors indicates that the activated 
lymphocytes are potentially reactive against the tumor cells. The difference in cytokine 
expression between in vivo and in vitro could be explained by an accumulation of the 
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cytokines in the 3D tumor reconstructs. In vivo cytokines can be distributed by the bloodflow 
and a tissue gradient can be created. Since the kit specifically detects human cytokines, we 
can conclude that the source are the lymphocytes. The majority of the detected cytokines are 
chemokines, which are able to induce chemotaxis of nearby responsive cells. The pro-
inflammatory IL-1α, IL-1β, IL-6, sICAM-1 can promote the infiltration of immune cells to 
the site of production, others like MIF have an anti-migratory or chemotactic function like IL-
8, MIP-1α, MIP-1β, G-CSF, IL-16, IP-10, I-TAC, RANTES, GROα and Serpin E1. TNF-α 
and IFN-γ released by the activated T cells also act synergistically to change endothelial cells, 
allowing increased blood flow, increased vascular permeability, and increased emigration of 
leukocytes, fluid, and protein into a site of inflammation. However, other bsAb like the 
irrelevant CD19xCD3 bsAb also induced the production of TNF-α and IFN-γ. On the 
contrary, the omission of antibodies in 3D tumor reconstructs did not induce the production of 
TNF-α and IFN-γ by lymphocytes. 
These results indicate that EpCAMxCD3 is a strong inducer of lymphocyte effector functions 
such as secretion of tumoricidal cytokines and that the response of lymphocytes to 
EpCAMxCD3 is dependent on their activation state.  
The presence of chemokines in the 3D gels and in the tumor lysates could potentially attract 
immune cells of the thus, could be the reason for the infiltration of tumors with immune cells. 
TNF-α can induce an endothelial cell activation. Endothelial cell activation can potentially 
facilitate activated effector T lymphocytes to enter infected tissue as well as recruiting 
neutrophils and macrophages. The NOD/SCID mouse model has a severe combined 
immunodeficiency which affects T- and B- lymphocyte development, has a NK cell 
functional deficit, an absence of circulating complement. These mice only possess innate 
immune cells such as monocytes, macrophages and granulocytes/ neutrophils. 
Immunohistochemistry revealed the infiltration of tumor tissues with mouse monocytes/ 
macrophages (CD68), mature macrophages (F4/80) and single granulocytes (Gr-1). In BxPc-3 
tumors many CD68 and F4/80 positive cells were located at the rim of the tumor and in the 
stroma. In addition, in tumors which had been treated with EpCAMxCD3 alone, with s.c. 
injected TRAIL-L or in combination, CD68 and F4/80 positive macrophages were also found 
to leave the blood vessels and infiltrate the tumor islets.  
The role of tumor associated macrophages (TAM) in tumor development is currently under 
investigation. TAMs are found in many solid tumors [204]. TAMs derive from circulating 
monocytes and are directed into the tumor by chemokines. Many tumor cells also produce 
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cytokines such as colony-stimulating factors that prolong the survival of TAMs in the tissue. 
Activated, TAMs can kill tumor cells or destroy the vascular endothelium of the tumor. 
However, TAM also produce growth factors involved in angiogenesis. Hence, TAM can 
stimulate tumor-cell proliferation, promote angiogenesis, and favor invasion and metastasis, 
which gives them a dual role in cancer biology [201, 205]. However, our results demonstrate 
a decreased angiogenesis and proliferation of tumor cells, which rules out a contribution of 
TAMs to tumor growth. The presence of these phagocytic effector cells inside the tumors 
could potentially contribute to the anti-tumor effect of TRAIL-L in combination with 
EpCAMxCD3 in both xenograft models. 
4.6 Summary 
 
In conclusion, this is the first study, which shows the effective lentiviral transduction of 
human lymphocytes with the death ligand TRAIL. The vector pV3TP2A effectively 
transduced human lymphocytes to over-express TRAIL. The majority of these TRAIL-over-
expressing lymphocytes were CD8+ T cells and retained their cytotoxic functions, their 
migratory and proliferative properties after the transduction. Furthermore, this study showed 
that EpCAMxCD3 possesses a potent anti-tumor activity in vivo. In NOD/SCID mice, 
EpCAMxCD3 had a long serum half-life (t1/2 ∼ 7 days). In two mouse models the 
combination of EpCAMxCD3 with lymphocytes significantly retarded the growth of BxPc-3 
pancreatic and PC-3 prostate cancer xenografts. For mimicking a pancreatic cancer 
microenvironment in vitro a 3D tumor reconstruct system was used, in which lymphocytes 
were co-cultured with EpCAM-expressing tumor cells and fibroblasts in a collagen matrix. In 
this in vivo-like system EpCAMxCD3 potently stimulated the production of the effector 
cytokines IFN-γ and TNF-α by extracorporally pre-activated lymphocytes. Moreover, 
compared with a bivalent anti-CD3 antibody, EpCAMxCD3 more efficiently activated 
production of TNF-α and IFN-γ by non-stimulated PBMCs. We demonstrate for the first time 
that EpCAMxCD3 induces prolonged contacts between lymphocytes and tumor cells, which 
may be one of the main reason for the observed anti-tumor effects. The combination with 
lymphocytes over-expressing the death ligand TRAIL could effectively enhance the anti-
tumor effects of bsAb EpCAMxCD3. The combination with TRAIL-L enabled us to strongly 
reduce the dose of EpCAMxCD3 necessary for an anti-tumor effect. This is a great advantage, 
which could minimize potential side effects of bsAb treatment. EpCAMxCD3 did not alter 
lymphocyte migration as measured by time-lapse video microscopy, which is an important 
prerequisite for future use in patients. Apoptosis induction in tumor cells by TRAIL-L was 
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confirmed in vitro in 3D tumor reconstructs. In cytotoxic killing assays, the anti-tumor effect 
of TRAIL-L was significantly enhanced by EpCAMxCD3. In 3D gels, lymphocytes were 
effective producers of IFN-γ, TNF-α and chemokines, which could also be detected in vivo 
from tumor lysates. An increased infiltration of the tumor islets with macrophages and 
granulocytes was observed upon treatment with TRAIL-L and EpCAMxCD3. A potential 
explanation for the demonstrated anti-tumor effect of EpCAMxCD3 and TRAIL-L 
combination therapy, is an enhancement of the observed effects of single treatment, namely 
the reduced proliferation in tumor cells, decreased blood vessels formation, local production 
of cytokines and chemokines, apoptosis and an increased infiltration of tumor tissue with 
macrophages. Conclusively, the combination of TRAIL-transduced lymphocytes and the 
bispecific antibody EpCAMxCD3 was very efficient in pancreatic and prostate xenograft 
models in vivo. This combination of gene therapy with immunotherapy could potentially be a 
possible therapeutic option for the clinical application in the future.  
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